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I. Abstract 
Skeletal muscle is a direct target for the group of seco-steroids collectively termed Vitamin 
D. Skeletal muscle expresses both CYP27A1 and CYP27B1 encoding for the hydroxylases 
required to convert Vitamin D to 25[OH]D and subsequently the bioactive 1α-25-
dihydroxyvitamin D3 (1α-25[OH]2D3) (Girgis et al., 2014b). Crucially, the Vitamin D 
receptor (VDR) is also present in skeletal muscle (Srikuea, Zhang, Park-Sarge, & Esser, 
2012) and upon exposure, binds to its ligand 1α-25[OH]2D3 and initiates genomic and non-
genomic rapid signalling responses. At present there is a global prevalence of low serum 
Vitamin D (25[OH]D) concentrations due to a lack of sun exposure (the primary route for 
Vitamin D synthesis) as a function of latitude and/or an indoor lifestyle coupled with few 
dietary sources of Vitamin D (Chen et al., 2007). Accumulating data are now suggestive that 
low 25[OH]D may be associated with perturbations in contractile activity and the 
regeneration of human skeletal muscle (Owens, Fraser, & Close, 2014), although a definitive 
causal relationship is yet to be established. Therefore, this thesis aimed to establish a more 
precise role for Vitamin D in human skeletal muscle function and regeneration. There were 
four overarching aims: 
 
1. Explore the role of Vitamin D in human skeletal muscle contractile properties in humans 
in vivo. 
2. Identify the role of Vitamin D in human skeletal muscle contractile properties ex vivo. 
3. Investigate the role of Vitamin D in skeletal muscle regeneration following eccentric 
exercise induced muscle damage in vivo. 
4. Elucidate cellular mechanisms of the muscle regeneration process that are responsive to 
Vitamin D in vitro. 
 
The main findings from this work imply that serum 25[OH]D concentrations across a broad 
range from 18->100 nmol.L-1 do not affect skeletal muscle contractile properties. Conversely 
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elevating serum 25[OH]D from <50 nmol.L-1 to >75 nmol.L-1 resulted in significant 
improvements in the recovery of maximal voluntary contraction force following a bout of 
eccentric exercise. Implementing an in vitro model of muscle regeneration also identified 
potential cellular mechanisms for these observations: Muscle derived cells treated with a 
total amount of 10 nmol 1α-25[OH]2D3 following a mechanical scrape improved migration 
dynamics and fusion capability of skeletal muscle derived cells. 
 
Taken together, low Vitamin D concentrations are highly prevalent but can be easily 
corrected with supplementation of Vitamin D3. This may have the advantage of optimising 
the regenerative capacity of skeletal muscle amongst other health benefits previously 
characterised by others.  
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Chapter 1 
General Introduction 
  
This chapter gives a broad background into the environmental challenges that account for the 
prevalence of Vitamin D deficiency and introduces the field of Vitamin D research. 
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2.1 General Introduction 
The monogenesis model of human evolution dictates that early modern man (Homo sapiens) 
emerged from sub-Saharan Africa and thus developed its biochemical mechanisms for 
maintaining life on the rich organic molecules available in its immediate milieu. Macro- and 
micronutrients could be obtained from animal and plant life and as such, mechanisms to 
digest and metabolize them evolved. Since sunlight was also in abundance, a photosynthetic 
reaction in the dermal layer of skin developed to make use of solar radiation (ultraviolet), 
which is now understood to be the main pathway for the synthesis of Vitamin D, a group of 
pleiotropic seco-steroid hormones. The evolution of these efficient phenotypic adaptations 
allowed man to flourish as an intelligent species. 
However, fossil evidence implies that at some point around 35-40,000 years ago, Homo 
sapiens migrated away from Africa and colonized areas of Europe (Stringer, 2003), a 
dramatic change to the sun-rich climate of sub-equatorial Africa. Consequentially, new 
environmental challenges to homeostasis were placed on man. One such challenge was a 
drastic difference in the annual pattern of sunlight exposure. Phenotypic changes have 
emerged to account for this altered exposure. Indeed, a degree of skin depigmentation 
occurred in migrants that can be readily observed today between the races of northern 
Europe and Africa. A simple explanation for this is that as man’s exposure to solar radiation 
lessened, so did the need for melanin, which absorbs ultraviolet radiation competing with the 
steroid precursor that converts to pre-Vitamin D under thermal isomerization. However, the 
significance of this phenotypic change in skin pigmentation is further reaching than photo-
protection. It is probably an evolutionary attempt to redefine the balance between protection 
against ultraviolet (UV) radiation and to increase the UV-B dependent photosynthetic 
production of Vitamin D from 7-dehydrocholesterol in the skins dermis. This environmental 
challenge has however, occurred too recently in evolutionary history and as such, 
depigmentation has not been an effective mechanism to compensate. This is evidenced by 
population-based data from Northerly latitudes that describe a high prevalence of Vitamin D 
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deficiency. Moreover, even in sun rich climates close to the equator there is a high 
prevalence of Vitamin D deficiency due to a predominantly indoor lifestyle, the covering of 
large amounts of skin with clothing and sunscreen application. 
Until the identification of the fat soluble Vitamin D by Elmer McCollum in 1913 our 
understanding of the physiological significance of Vitamin D was undefined. Since then, 
particularly in the past 20 years, the scientific literature has witnessed a renaissance in 
Vitamin D research and our knowledge base has increased exponentially (Figure 1.1). It is 
now understood that Vitamin D regulates numerous biological processes in man. 
 
 
 
 
 
 
 
 
 
Figure 1.1 Research interest in Vitamin D based on articles published per annum as reported by PubMed 
(National Centre for Biotechnology Information). 
 
Consequently, there has been a search for the ‘optimal’ Vitamin D concentration for all 
health outcomes. Unfortunately, as with other steroids, different tissues respond differently 
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to the same stimulus, thus it is unlikely that there is an optimal Vitamin D concentration for 
global health benefits. 
Forming the basis of this thesis is the research interest in Vitamin D and skeletal muscle. As 
will be discussed there are preliminary data that support a role for Vitamin D in skeletal 
muscle function and regeneration, however definitive causal relationships are yet to be 
established. Understanding how Vitamin D may impact upon skeletal muscle will 
undoubtedly provide insights into the potential of manipulating Vitamin D status to promote 
muscle health throughout the lifespan, which is of interest from developmental, athletic and 
ageing perspectives. This thesis aims to examine in more detail the role of Vitamin D in 
skeletal muscle function and regeneration by employing a systems biology approach to the 
primary research question. 
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Chapter 2 
Review of the Literature 
  
This chapter gives a synthesis of research findings that describe human skeletal muscle 
function and repair with reference to factors that mediate both processes. A review of the 
literature on Vitamin D in relation to muscle function and repair is then provided culminating 
in the scientific rationale for this thesis. 
Publications resulted from this chapter; Owens, D.J., Fraser, W.D. and Close, G.L. (2014). 
Vitamin D and the Athlete: Emerging Insights. European Journal of Sport Science, 18:1-12. 
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2.1 Human Skeletal Muscle Form and Function 
2.1.1 Background: In humans, skeletal muscle provides a mechanism of locomotion, 
comprises ~40% of body mass and plays a critical role in metabolic homeostasis accounting 
for ~30% of the resting metabolic rate (RMR), is the predominant storage tissue for 
glycogen in addition to being the predominant site of insulin stimulated glucose disposal 
(Thiebaud et al., 1982). Physical inactivity is therefore unsurprisingly a major risk factor for 
a host of chronic disease states including type II diabetes mellitus, heart disease, obesity and 
age related loss of muscle or sarcopenia (Booth, Roberts, & Laye, 2012). Exercise training 
however partially reverses such disease processes and is in fact the most effective medicine 
in the treatment and prevention of type II diabetes and sarcopenia (Borst, 2004; Colberg et 
al., 2010). Further, the type of exercise training may be manipulated in terms of modality, 
duration, frequency and intensity such that subsequent local and systemic factors produce 
differential transcriptional responses ultimately remodelling the muscle proteome to suit the 
profile of innervation that it repeatedly experiences. This highlights the extraordinary 
plasticity of skeletal muscle, demonstrating its ability to respond positively and negatively to 
different stimuli and signifies the importance of maintaining skeletal muscle health to 
promote global health benefits, prevent disease and optimize physical performance. 
However, skeletal muscle is also prone to perturbations in form and function as a 
consequence of dietary deficiencies, disease and injury. Understanding the aetiology of 
skeletal muscle dysfunction in these contexts will undoubtedly lead to the development of 
strategies to maintain muscle and optimize musculoskeletal performance. 
 
2.1.2 Overview of Skeletal Muscle Structure: The structure of skeletal muscle is organised 
at a number of levels making it highly adapted to its primary function: the generation and 
transmission of force. Whole muscle structures are enveloped by the epimysium, connective 
tissue that contains bundles of skeletal muscle fibres. These fibre bundles are encased by 
perimysium and within consist of myofibres, which are surrounded by connective tissue 
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termed endomysium. The units of skeletal muscle that contain the necessary components for 
force production are myofibres. These	  syncytial tubes range in length based on anatomical 
location and in cross sectional area (CSA) based on fibre type (Rivero, Talmadge, & 
Edgerton, 1998). There are several fibre types in mammalian skeletal muscle, however 
human skeletal muscle is comprised of the pure type I, type IIa and type IIx (Harridge et al., 
1996) with some hybrid fibres also reported (Sant'ana Pereira, Wessels, Nijtmans, Moorman, 
& Sargeant, 1995). The classification of fibres has developed considerably on the basis of 
correlated histochemical and physiological studies of individual motor units, electron 
microscopy of fast and slow skeletal muscles, novel procedures for myosin ATPase 
histochemistry and biochemical studies on oxidative and glycolytic enzymes in different 
muscles (Schiaffino & Reggiani, 2011). Table 2.1 provides a succinct overview of human 
fibre type properties. 
Table 2.1 Human skeletal muscle fibre contractile, metabolic and morphological properties. 
 Type I Type IIa Type IIx 
General Properties    
Myosin heavy chain isoform MHC1 MHC2A MHC2X 
bRelative myosin heavy chain % 33.9 ± 11.4 46.3 ± 3 19.8 ± 11.5 
Metabolic Characteristics Highly oxidative Oxidative/glycolytic Glycolytic 
Power output Weak Intermediate Strong 
Endurance capacity High Moderate Low 
Recruitment threshold Low Moderate High 
Morphological Properties    
Capillaries per fibre (density) 4.2 4.0 3.2 
Mitochondrial Density High Intermediate Low 
bFibre Size (CSA - µm2)  4844 ± 1286 6174 ± 1587 5160 ± 1324	  
cMyonuclear domain size (µm3) 24.9± 1.1 32.9 ± 2.1 42.7 ±4.9 
 
Table adapted from Saltin and Gollnick (1983). 
bData from Staron et al. (2000); Ninety-five young healthy males aged 21.5 ± 2.4 yrs. Fibres isolated from Vastus Lateralis. 
cData from Liu et al. (2009); values from 460 µm sections of single muscle fibres from Vastus Lateralis expressing different 
MHC isoforms. Data expressed as mean and s.e.m. 
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2.1.3 Skeletal Muscle Microstructure: Each myofibre contains the contractile filaments 
that allow movement, the proteins actin and myosin, in a highly organised array to allow 
both longitudinal and lateral force transduction within and between fibres (Bloch et al., 
2004). This arrangement forms the contractile element termed a myofibril. Within each 
myofibril exist a number of sarcomeres in series and parallel, which can be identified in an 
electron micrograph as the unit between Z-lines (where actin is held in a square array). 
Figure 2.1 provides simplistic schema and micrograph images of the arrangement of the 
contractile apparatus. 
 
 
 
 
 
 
 
 
 
Figure 2.1. Schema that describe the arrangement of actin and myosin filaments.a) Each myosin filament is surrounded by six 
actin filaments such that the myosin filament may interact with any of the six actin filaments. Each actin filament is also 
capable of binding to any of three myosin filaments b) A fragment of an electron micrograph of a transverse section of a fibre 
from rabbit psoas muscle in the low temperature, relaxed state. Thick and thin spots correspond to myosin and actin filaments, 
respectively (Bershitsky et al., 2010) c) This assembly allows actin filaments to ‘slide’ between myosin filaments. This unit 
from Z-line to Z-line is termed a sarcomere d) An electron micrograph of a sarcomere typically 2-2.5µm in length in 
mammalian muscle (obtained from sacromere.org on 10/09/2014). 
a b 
c d 
Actin 
Myosin 
Actin 
Myosin 
Sarcomere (2-2.5 µm) 
Z-line Z-line 
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2.1.4 Skeletal Muscle Function: The purpose of skeletal muscle in all animals including 
humans is to generate tension. The generation of tension occurs in the myofibre by 
interaction of the contractile filaments achieved via electrochemical signalling. This is 
brought about by sarcolemmal depolarization accomplished by a nerve impulse derived from 
the motor cortex of the brain and transmitted by branched terminal axons of motor neurons 
innervating the fibre. When a nerve impulse reaches the neuromuscular junction (NMJ), the 
neurotransmitter acetylcholine (ACh) is released from intracellular vesicles into the synaptic 
junction. The amount of ACh released from a single synaptic vesicle is termed a quantum. 
On the post-synaptic membrane of the muscle fibre, ACh can bind to its receptor (AChR) 
and produce a miniature membrane potential or MEPP. A single MEPP depolarizes the 
sarcolemma but only when sufficient quanta are released into the synaptic junction at the 
same time are enough MEPP’s generated to produce an action potential (AP). The AP 
generated at the NMJ is brought about through an influx of Na+ and efflux of K+ resulting in 
a change in membrane potential. 
The AP is propagated along the sarcolemma and travels down invaginations into the fibre 
termed T-tubules. As the T-tubules are depolarized, the surface membrane near the NMJ is 
repolarized by active transport of Na+ out of the cell and K+ into the cell via Na+K+ ATPase 
pumps. It is the depolarization of the T-tubular system that allows the electrical signal 
generated at the sarcolemma to be transmitted to the interior of the fibre by converting the 
electrical signal into a chemical signal. This phenomenon occurs through voltage dependent 
Ca2+ channel (or L-type) release and dihydropyridine (DHPR) and ryanodine receptor (RyR) 
interaction. In the latter the two receptors are not linked with contact but lie in close 
proximity to allow efficient interaction. This arrangement permits a signal coupling 
mechanism for calcium release from the sarcoplasmic reticulum (SR) into the sarcoplasm of 
the fibre. The SR surrounds groups of approximately 200 actin and myosin filaments and 
lies close to the T-tubular system. These areas of close contact known as terminal cisternae 
provide an intimate and efficient mechanism of calcium signalling. Intracellular Ca2+ 
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concentrations differ between fibre types as slow fibres have resting concentrations of 40-50 
nmol whereas fast twitch fibres are lower at 30 nmol (Fraysse et al., 2003; Fraysse et al., 
2006). It is due to fluxes in intracellular Ca2+ concentration that cross bridge formation is 
permitted, subsequently allowing myosin heads to exert force on actin monomers through a 
change in myosin head angle powered by adenosine triphosphate (ATP) hydrolysis. 
Ca+2 is released from the SR when the voltage change in the DHPR causes opening of the 
ryanodine channel on the SR membrane. The calcium released can stimulate further calcium 
release from adjacent sites but most importantly binds to the troponin isoform C (TnC) 
causing a conformational change to the protein tropomyosin that surrounds actin, thus 
allowing myosin to interact with actin. Once the myosin head has bound an actin monomer, 
the myosin head rotates and stretches a compliant portion of the myosin filament and 
generates force that is exerted onto the actin filament allowing actin to ‘slide’ between 
myosin filaments. Once contraction has occurred, calcium is sequestered in the SR via 
calcium ATPase. This process requires Mg2+ and transports two Ca2+ ions in exchange for 
one H+ ion at the expense of an ATP molecule. Calcium is then sequestered in the terminal 
cisternae of the SR by the calcium binding protein calsequestrin at a concentration of ~1 
mmol.L-1. A number of factors can however affect the release and re-uptake of calcium in 
skeletal muscle, ultimately modulating the ability to generate force. Examples of such 
factors include exercise-induced fatigue (Li et al., 2002; Westerblad, Dahlstedt, & 
Lannergren, 1998) generation of reactive oxygen species (Andersson et al., 2011) and 
dietary factors such as caffeine (Allen & Westerblad, 1995). 
As each sarcomere is linked in series at the Z line of actin filaments, the force produced 
during actin-myosin cross bridge cycling is transmitted through the length of the muscle 
permitting a whole muscle contraction. Importantly, costameric proteins that are arranged in 
a rectilinear manner, parallel the underlying contractile apparatus allowing force to be 
transmitted laterally to the extracellular matrix (ECM) and provide a two way signalling 
pathway between Z-line and ECM transducing mechanical stress signals from the outer cell 
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to intracellular signalling pathways (Bloch et al., 2002; Peter, Cheng, Ross, Knowlton, & 
Chen, 2011).  
As eluded to in the previous section, different skeletal muscle fibre types exhibit differences 
in their contractile properties. There are a number of features that characterize the term 
‘contractile properties’, including the shape of the twitch, relaxation time from an isometric 
tetanus, fusion frequency and fatigability. A summary of the twitch and fatigue profiles of 
the major human motor unit types is found in Figure 2.2.  
 
 
 
 
 
 
 
 
Figure 2.2. Contractile characteristics of the main human motor units. Upper curves are forces generated from a 
single 1Hz twitch. Lower traces represent force fatigue curves during tetanic stimulation (e,g. 100Hz).  
 
Investigation of these profiles allows for the detection of subtle changes in muscle plasticity. 
Indeed, force profiles for single twitches, force frequency profiles and fatigue profiles at 
both the whole muscle and single fibre level have demonstrated that changes can be detected 
as a consequence of physiological stress such as hypoxia (Degens et al., 2010), disuse 
(D'Antona et al., 2003), muscular dystrophies (Williams, Head, Lynch, & Stephenson, 1993) 
Type IIx Type IIa Type I 
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and exercise training (Harber, Gallagher, Creer, Minchev, & Trappe, 2004; Malisoux, 
Francaux, Nielens, & Theisen, 2006; Trappe et al., 2000). Coupling single fibre studies with 
whole muscle measures therefore provides a powerful translational tool for investigating the 
functional characteristics of striated muscle. 
2.2 Skeletal Muscle Damage and Repair 
2.2.1 Background: As a consequence of episodic bouts of the differential muscle 
contractions described in the previous section, skeletal muscle undergoes functional 
adaptation and remodelling. Minor day-to-day damage caused by such contractions is 
effectively repaired by simple recruitment of intracellular vesicles (Steinhardt, Bi, & 
Alderton, 1994). However, since mature myofibres are terminally differentiated, severe 
damage requiring degeneration of damaged necrotic tissue and subsequent regeneration is 
reliant on the timely activation, proliferation and differentiation of the resident muscle stem 
cell population termed ‘satellite cells’ (SCs). 
 
2.2.2 Mechanisms and Nature of Muscle Damage:  Skeletal muscle damage may be 
defined as the loss of muscle function caused by physical disruption of muscle structures 
involved in producing or transmitting force. Injury may be caused by a physical insult such 
as a contusion or tear, may be drug induced or more commonly, as a consequence of 
unaccustomed or eccentric exercise. For the purpose of this thesis, only the latter will be 
discussed. It is noteworthy however that following the primary damaging event, the process 
of degeneration and regeneration is similar between drug and exercise induced muscle 
damage (Ciciliot & Schiaffino, 2010). 
Prior to considering events subsequent to damaging contractions, it is appropriate to explore 
the type of contraction that most commonly induces injury and mechanical factors that can 
explain this. Early research utilised mouse models in which muscle was stimulated to 
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contract whilst length and shortening velocity were controlled for. Using such a model, it 
was feasible to induce concentric, eccentric and isometric contractions in the mice, take 
maximal force measures following the bout of contractions and then isolate the muscle to 
assess histological changes in muscle architecture. This pioneering work demonstrated that 
only after a bout of eccentric contractions was there a significant loss in force and substantial 
histological damage (McCully & Faulkner, 1985). Such findings have been replicated in 
other animal studies and indeed in humans using different eccentric exercise modalities such 
as downhill running and isokinetic dynamometry (Close et al., 2006; Paulsen et al., 2007). 
Following this early work, investigations have sought to understand the mechanical factors 
associated with different contractions to elucidate mechanisms for the observed damage. 
Muscle tension, lengthening and lengthening velocity were initially investigated in rodents 
(Warren, Hayes, Lowe, & Armstrong, 1993). The investigators determined that force loss 
following eccentric contractions was most strongly correlated to peak tension. Similarly 
Brooks, Zerba, and Faulkner (1995) demonstrated that peak tension and work done both 
strongly correlated to the degree of damage but importantly also showed that lengthening 
velocity and tension during lengthening were important determinants of the degree of 
damage. The latter findings have been supported by further data on the length-tension-
damage relationship (Talbot & Morgan, 1998) and in summary state that slow velocity high 
tension eccentric contractions result in greatest muscle damage. 
Logically, it is important to also ask what the morphological consequences of skeletal 
muscle damage are. A hallmark of eccentric contraction induced injury is focal damage to 
the sarcomere. Newham, McPhail, Mills, and Edwards (1983) first demonstrated this with 
the use of electron microscopy, providing evidence of single and half disrupted sarcomeres 
and Z-line streaming, all evident immediately post damage and persisting and increasing up 
to three days post damage (see Figure 2.3).  
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Figure 2.3. An area of extensive focal sarcomere damage resulting from eccentric contraction induced muscle 
damage (Newham et al., 1983). 
Aside from sarcomeric disruption, cytoskeletal integrity is compromised and may be a cause 
of force loss following eccentric contraction induced injury. Identifying changes in 
cytoskeletal integrity is achieved by examining localization and abundance of cytoskeletal 
proteins, first eloquently demonstrated by Lieber, Schmitz, Mishra, and Friden (1994). The 
authors confirmed a 20% loss of the cytoskeletal protein Desmin 1-day post eccentric 
induced damage by immunohistochemistry. Further studies have observed similar 
cytoskeletal protein changes in Titin and Dystrophin (Lieber, Thornell, & Friden, 1996; 
Lovering & De Deyne, 2004). It is likely that this loss of protein content is due to the 
increased activity of Ca2+ dependent, cysteine protease Calpain following eccentric 
contractions (Zhang et al., 2012). 
Numerous findings have supported the notion that in order to effectively repair focal damage 
to the myofibre, the resident muscle satellite cell (SC) is vitally important. Hyldahl, Olson, 
Welling, Groscost, and Parcell (2014) employed eccentric contractions to cause muscle 
33 
	  
injury in humans showing that there is a significant expansion of the SC pool which 
correlates with histological signs of damage and this SC expansion is needed to proceed to 
regenerate the damaged fibre.  
2.2.3 Satellite Cells: SCs are so termed due to their sublaminal residence, lying intimately to 
the myofibre sarcolemma (see Figure 2.4). Upon discovery SCs were thus immediately 
postulated as a cell pool for muscle hypertrophy and repair, owed to the post mitotically 
quiescent nature of mature myofibres (Mauro, 1961). Indeed, data later confirmed an 
absolute requirement for SCs in the regeneration process, as muscle does not regenerate 
when SCs are ablated (Reviewed by Relaix & Zammit, 2012). 
 
 
 
 
 
 
Figure 2.4. Left: A satellite cell on an isolated muscle fibre. The fibre has been stained with an antibody to M-
cadherin (red) and desmin (green) and counterstained with DAPI (blue) to show the nuclei. M-cadherin is present 
on the satellite cell. Desmin is present in the striations of the muscle fibre and in the satellite cell (image from 
Morgan & Partridge, 2003). Right: a graphical representation of the location of satellite cells in relation to the 
single muscle fibre.  
 
2.2.4 Overview of Factors Controlling SC Activation & Function: In intact muscle, SCs 
like other somatic stem cells are highly reliant on their microenvironment, termed a stem cell 
niche (Jones & Wagers, 2008). This niche allows SCs to remain in G0 (quiescence) phase 
until exposure to appropriate stimuli that signal exit from quiescence and entry to the cell 
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cycle (Scadden, 2006). Myogenic commitment of SCs in postnatal muscle remodelling is 
determined by the activity of myogenic regulatory factors (MRFs), which act with 
pleiotropic transcription factors to control muscle gene expression patterns that initiate 
differentiation (Braun & Gautel, 2011). The committed muscle progenitor is termed an adult 
myoblast. The behaviour of SCs is dictated by multiple structural and biochemical factors 
within their immediate niche, from the local milieu and from the systemic milieu as depicted 
in Figure 2.5 (adapted from Yin, Price, & Rudnicki, 2013).  
Within the SC niche, there are a number of factors that are reported to be vital to the 
activation of SCs following muscle damage. Regulatory signalling pathways that appear to 
be important in this process include Wnt/Notch signalling pathways and sphingolipid 
signalling.  
 
• Wnt signalling is implicated in numerous processes involved in the muscle regeneration 
process such as cell adhesion, cell polarity, cell proliferation and cell morphology. Wnt 
glycoproteins bind to Frizzled receptors and low density lipoprotein receptor related 
proteins (LRP) to initiate intracellular effects. These downstream effects appear to be 
mediated by either β-catenin or planar cell polarization (PCP) pathways. The exact 
function of the Wnt/β-catenin pathway in muscle regeneration remains a topic of debate, 
however it is likely that different activating and inhibitory Wnt ligands function to 
control β-catenin localization and thus quiescence and proliferation in the muscle 
regeneration process (Otto et al., 2008). As for the Wnt/PCP pathway, signalling through 
Frizzled and LRP receptors activates Rho/Rac small GTPase and Jun NH2-terminal 
kinase (JNK) to regulate cytoskeleton organization and gene expression. Of interest, 
Wnt7a has been demonstrated to act through this pathway and mediate symmetric 
division of SCs but also stimulate the migration of SCs resulting in improved muscle 
regeneration and strength (Bentzinger et al., 2014). 
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• Notch signalling is an important effector of proliferation, differentiation and cell fate 
determination. The Notch transmembrane receptor is activated by its ligands, Delta and 
Jagged, following which the receptor undergoes enzymatic cleavage to form an active 
shortened form of Notch. Activated Notch may then interact with the suppressor of 
Hairless and Lag-1 (CBF1) leading to transcriptional activity of target genes. In muscle 
injury, Delta is up regulated in SCs and myofibres leading to a consequential increase in 
the notch intracellular domain (NICD; cleaved form of Notch). This allows for the 
expansion of SCs and their progenitors. Importantly, blunting this pathway inhibits SC 
activation and attenuates muscle regeneration (Conboy & Rando, 2002). 
• Sphingolipid signalling is implicated in cell proliferation, migration, death and 
senescence. Of prime importance in regenerating skeletal muscle appears to be 
sphingomyelin which is an important mediator of mitogenic S1P synthesis. It is the 
synthesis of S1P that signals SC entry to the cell cycle and permits normal muscle 
regeneration (Nagata, Partridge, Matsuda, & Zammit, 2006). Inversely, when the 
sphingomyelin to S1P synthetic pathway is inhibited, there is a marked decrease in 
activated SC number and overall impairment in muscle regeneration (Calise et al., 
2012). These observations are likely due to the proliferative, pro-inflammatory and anti-
apoptotic functions of the S1P pathway. 
 
Aside from these key intracellular pathways are extracellular matrix interactions and other 
related factors that control SC activation and function. As previously discussed, SCs reside 
between the apical surface of the myofibre and the basal lamina. As a result, there is 
considerable binding between the SC and the ECM through integrins (specifically α7β1). 
This is crucial for the anchoring of SCs and for the transduction of mechanical force that 
stimulates intracellular signalling responses within the SC (Boppart, Burkin, & Kaufman, 
2006). Such binding also exists with the myofibre, whereby integrins on the SC membrane 
associate with muscle specific laminin. This intricate architecture not only allows SCs to be 
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anchored at a given site and respond to mechanical stimuli, but also allows a mechanism of 
migration through integrin binding and recycling at polarized edges of the activated 
SC/myogenic progenitor (Huttenlocher & Horwitz, 2011). In addition, SCs also display 
surface receptors that allow interaction with growth factor precursors that are vitally 
important to their activation and function.  
• Hepatocyte Growth Factor (HGF or Scatter Factor) is one such precursor that is 
released following muscle damage (Tatsumi, Anderson, Nevoret, Halevy, & Allen, 
1998). This is brought about by the synthesis of nitric oxide (NO) by NO synthase 
(NOS) in response to muscle damage. NO stimulates the release of HGF that interacts 
with its receptor, c-MET, on the surface of SC’s to control various downstream 
processes. Indeed, Tatsumi et al. (2006) and Tatsumi, Sheehan, Iwasaki, Hattori, and 
Allen (2001) have provided both in vivo and in vitro evidence for the important role of 
NO-HGF signalling in satellite cell activation, demonstrating that stretching muscle 
liberates HGF in a NO dependent fashion leading to SC activation to remodel the 
stretched muscle. 
• Insulin-like Growth Factors (IGF) 1 and 2 demonstrate important roles in SC 
activation and function. IGF1 mediates cell migration, proliferation and differentiation 
whilst IGF2 has a more dedicated role in signalling myoblast differentiation (Coolican, 
Samuel, Ewton, McWade, & Florini, 1997). The pleiotropic functions of IGF1 are 
achieved through its binding protein, IGF1R, which functions as a tyrosine kinase to 
initiate signal transduction pathways that include the phosphatidinositol-3-kinase 
(PI3K)/Akt/mTOR and PI3K/Akt/P38-MAPK, key effectors of myoblast differentiation 
and hypertrophy. Importantly, IGF1R signalling also activates the Ras/Raf/ERK 
pathway, which is crucial for SC expansion (Coolican et al., 1997). The importance of 
IGF signalling in myogenesis has been evidenced through the generation of mice 
carrying null mutations of components of either the IGF1 or IGF2 pathway. IGF1R-/- 
mutants are born with a dystrophic phenotype and typically die shortly after birth (Liu, 
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Baker, Perkins, Robertson, & Efstratiadis, 1993) and IGF2-/- mutants are born lighter 
(~40%) than WT mice (DeChiara, Efstratiadis, & Robertson, 1990).  
• Fibroblast Growth Factors (FGFs) are comprised of a family of mitogenic factors that 
are implicated in SC function. FGFs function through dimerization with their receptors 
(FGFR), which display tyrosine kinase activity and activate the Ras/MAPK pathway. 
Activation of this pathway by FGF/FGFR leads to pro-proliferative and anti-
differentiation effects allowing normal skeletal muscle regeneration. In addition, FGF 
displays pro-angiogenic properties that enable muscle regeneration (Lefaucheur, Gjata, 
Lafont, & Sebille, 1996). 
• Matrix Metalloproteinases (MMPs) in skeletal muscle play an important role in the 
homeostasis and maintenance of myofibre integrity by breaking down ECM components 
and regulating skeletal muscle cell migration, differentiation and regeneration (Chen & 
Li, 2009). Relating to migration, it is important that myogenic progenitors can degrade 
the ECM to migrate efficiently toward the site of damage to fuse to and repair the 
Myofibre. Investigations have demonstrated that MMPs are important to this process in 
vitro and in vivo (El Fahime, Torrente, Caron, Bresolin, & Tremblay, 2000; Zimowska, 
Brzoska, Swierczynska, Streminska, & Moraczewski, 2008). Indeed, the inhibition of 
MMPs results in markedly impaired migration capacity causing attenuated repair 
(Nishimura et al., 2008), whilst overexpression increases migration speed (Allen, 
Teitelbaum, & Kurachi, 2003). Consequently MMPs are crucial for successful migration 
of skeletal muscle progenitors and thus an important factor in efficient muscle 
regeneration. MMPs also act as important regulatory molecules in the activation of SCs. 
Yamada et al. (2006) isolated SCs from 9-month-old male Sprague-Dawley rats and 
subjected them to mechanical stretch. The authors report that MMPs released as a result 
of mechanical stretch are involved in the NO dependent release of HGF which, as 
previously discussed, is a key regulator of SC activation. 
Outside of the immediate niche, within the muscle fascicle lie a number of factors that have 
the ability to mediate SC function and ultimately muscle regeneration. 
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• Neurons play a crucial role in maintaining muscle health through electrical activity 
permitting contraction and remodelling. Thus, when denervation of muscle occurs there 
is a marked atrophy of the muscle and a significant reduction in SC number (Rodrigues 
Ade & Schmalbruch, 1995). The reduction in SC content is likely due to the absence of 
neurotrophic factors such as nerve growth factor (NGF) and brain derived neurotrophic 
factor (BDNF), although mechanisms involved are far from being established. 
• Interstitial cells such as fibroblasts secrete growth factors (such as FGF) and ECM 
remodelling factors (collagen, laminin, fibronectin, tenascin and heparin sulphate 
protoeglycans) that are crucial for SC homeostasis. Recent data also propose that 
fibroblasts influence muscle progenitor differentiation and alignment in contact 
dependent and independent manners in vitro (Rao et al., 2013). 
• Microvasculature provides an important pathway for the delivery and removal of 
substances to skeletal muscle. Interestingly, genetically engineered mice allowing direct 
muscle SC visualization indicate that, in addition to being located beneath myofibre 
basal laminae, SCs are patently close to capillaries (Christov et al., 2007). Indeed,	  
endothelial cell cultures enhanced SC growth, through IGF-1, HGF, bFGF, PDGF-BB, 
and VEGF. Satellite cells and myoblasts also produce vascular endothelial growth factor 
(VEGF) promoting angiogenesis in muscle repair. Thus, SCs, myoblasts and endothelial 
cells interact and cooperate to facilitate angiogenesis and myogenesis. 
A final point of discussion around factors implicated in SC function is the systemic milieu. 
Circulating factors are important both in the stimulation of SC activation but also indirectly 
in the muscle degeneration/regeneration process. 
• Immune cells are key players in the muscle regeneration process and have a dual role in 
dissolution of the damaged fibre and in the activation of SCs. Following an initial 
infiltration of neutrophils, two macrophage populations namely CD68+/CD163- and 
CD68-/CD163+, are implicated in pro and anti-inflammatory signalling. The CD68-
/CD163+ population have been reported to activate SC, which is in keeping with the 
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highly orchestrated nature of muscle regeneration since this population of macrophages 
are implicated in the last phase of fibre degeneration prior to regeneration by SCs 
(Tidball & Villalta, 2010). Recent evidence implies that the two macrophage 
populations may not in fact be distinct but undergo a phenotypic switch from a pro to 
anti-inflammatory phenotype (Arnold et al., 2007). 
• Androgens such as testosterone bind to the androgen receptor (AR) present in SCs, 
which are responsive to androgen signalling (Doumit, Cook, & Merkel, 1996). 
Testosterone has been demonstrated to activate rat SCs to proliferate (Joubert & Tobin, 
1995) and increase myonuclear number (Sinha-Hikim, Cornford, Gaytan, Lee, & 
Bhasin, 2006) and myofibre/whole muscle size in human adult males (Sinha-Hikim et 
al., 2002).  
• Nitric oxide (NO) can be produced by numerous cells types by NO synthases (NOS) 
and has a strong function in both healthy and regenerating muscle. Macrophage and 
myofibrillar production of NO during muscle regenerating aids the lysis of the damaged 
fibre and reduces other inflammatory induced damage suggestive of facilitative and 
protective role of NO in muscle regeneration. The inhibition of NO production has 
demonstrated impaired SC activation during regeneration as a consequence of reduced 
HGF-c-Met interaction. Furthermore, NO may stimulate SC migration permitting fast 
regeneration of the focal damage site (Otto, Collins-Hooper, Patel, Dash, & Patel, 2011) 
and facilitate long-term regeneration by regulating SC fate (Buono et al., 2012). 
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  a 
Figure 2.5. a) Niche and b) fasicle factors that influence satellite cell behaviour. Abbreviations: bFGF – 
fibroblast growth factor. SDF-1 – stromal cell derived factor 1. Wnt 7a – integration/Wingless 1. IGF – insulin like growth 
factor. HGF – hepatocyte growth factor. EGF – epidermal growth factor 
b 
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2.2.5 Skeletal Muscle Regeneration Steps: The skeletal muscle regeneration process 
occurs in three well-orchestrated, sequential but overlapping stages: 1) the inflammatory 
response; 2) the activation, migration, differentiation, and fusion of SCs; and 3) the 
maturation and remodelling of newly formed myofibres (Yin et al., 2013). Preceding the 
regeneration process however, is an important phase of degeneration, driven by calcium-
dependent proteolysis, a consequence of increased calcium influx due to sarcolemma 
dissolution and calcium release from the sarcoplasmic reticulum (Armstrong, 1990). The 
necrosis of the myofibre importantly activates the complement cascade and subsequently 
inflammatory responses, the first process in muscle regeneration. Firstly, a population of 
neutrophils infiltrate the damaged muscle followed by two populations of macrophages 
(CD68+/CD163- and CD68-/CD163+) that secrete pro-inflammatory cytokines in the early 
stages of inflammation and anti-inflammatory cytokines in later stages preceding the 
termination of the inflammatory response. Recent data are suggestive that injured skeletal 
muscle recruits monocytes exhibiting inflammatory profiles that operate phagocytosis and 
rapidly convert to anti-inflammatory macrophages that stimulate myogenesis and fiber 
growth (Arnold et al., 2007). Indeed, the importance of the inflammatory response has been 
demonstrated by selectively depleting monocytes/macrophages by dipethria toxin injection 
in mice, which completely impairs regeneration following muscle damage (Arnold et al., 
2007). Importantly, the CD68-/CD163+ sub population are known to aid in the activation of 
SCs (Tidball & Villalta, 2010). 
Upon appropriate cues discussed in section 2.2.3, SCs will be activated and undergo 
stochastic or asymmetric division as represented below in Figure 2.6. This allows for 
replenishment of the SC pool whilst also providing a myogenic progeny for muscle repair 
and remodelling. 
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Figure 2.6. Fates of the activated satellite cell. Stochastic division involves the generation of two daughter SCs 
or two myogenic progenitor cells whereas asymmetric division involves the generation of one daughter cell and 
one myogenic progenitor. 
 
The commitment of satellite cells to a myogenic fate is orchestrated by the temporal 
expression of myogenic regulatory factors (MRFs), a group of transcription factors that 
target myogenic loci. This expression profile is characterized by an early increase of Myf5 
and MyoD, which precedes increases in Myogenin and Mrf4 expression and a decrease in 
the early differentiation MRFs, Myf5 and MyoD.  
2.2.6 Myoblast Migration: In order to efficiently repair damaged tissue following activation 
myoblasts must migrate toward the site of damage to fuse to the area of focal injury to 
complete the resolution of the myofibre. Myoblasts are capable of migration between 
myofibres, muscles, across basal lamina and connective tissue during development and 
regeneration (Hughes & Blau, 1990; Jockusch & Voigt, 2003). Briefly, this process involves 
key steps that include: polarisation of the cell (establishing a front and rear), formation of 
stable adhesions with the extracellular substrate, formation of cell protrusions at the leading 
cell edge, cytoskeletal contraction and rear edge detachment. Recent insights also point to 
alternative mechanisms of SC movement in vivo via cytoplasmic changes in hydrostatic 
pressure and membrane blebbing (Charras & Paluch, 2008). 
• Cell polarisation is poorly understood but is vitally important to allow the cell to have a 
‘sense’ of direction. Migration will only be effective if the cell moves towards the target 
Stochastic	  Division	   Asymmetric	  Division	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area, in the case of muscle damage this is the focal injury site. Polarisation is 
characterised by asymmetric localization or activation of specific signalling proteins, 
creating a morphological asymmetry. This can be conceptualised by the formation of 
lamelipodia (broad, flat structures) and filapodia (thin, long strictures) at the leading 
edge of the cell. The establishment of these structures is brought about by localized actin 
polymerization at the leading edge of the cell (Mogilner & Oster, 1996). 
• Creation of tension through focal adhesion formation is necessary to create traction 
between the cell and the substratum and to organize signalling networks that regulate 
migration. Via integrin-mediated linkages with the ECM a link is formed between the 
cell and the substratum. Upon binding to the substratum, integrin clusters are formed 
creating multi-protein complexes that create intracellular signalling pathways and 
coupling to the actin cytoskeleton. The process of integrin binding dynamically forming 
and ‘recycling’ coupled with the polarized assembly and disassembly of adhesions are 
essential for peak migration velocity and directionality (Bridgewater, Norman, & 
Caswell, 2012) 
• Cytoskeletal contraction is achieved through traction signals transmitted via integrin 
adhesion complexes and provides a feedback loop between extracellular tension and 
cytoskeletal tension to mediate cytoskeletal organization and migration (Yamaguchi & 
Condeelis, 2007). 
• Rear edge detachment is equally as important as the events at the cells anterior because 
in the absence of co-ordinated disassembly of adhesion complexes, cells do not move 
(Palecek, Schmidt, Lauffenburger, & Horwitz, 1996). The process of rear edge 
detachment appears to be strongly mediated by the function of the proteolytic enzyme 
Calpain. A number of studies provide evidence of a necessity for Calpain in attachment 
and migration (Dedieu et al., 2004; Mazeres, Leloup, Daury, Cottin, & Brustis, 2006; 
Van Ba & Inho, 2013). 
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• Blebbing or ameboid-based movement has been demonstrated to be an important 
mechanism of SC movement in vivo, functionally distinct from canonical lamellipodial 
migration and involves the creation of membrane blebs via hydrostatic pressure created 
by the sarcoplasm under the control of the actomyosin cortex (Charras & Paluch, 2008). 
• Cell-cell signalling is known to occur between many cells through secreting and 
releasing proteins and vesicles. However, until a recent investigation by Ma et al. (2015) 
mechanistic understanding as to how this occurs during migration was limited. The 
authors provide evidence of ‘migrasomes’ – exosome like organelles secreted by leading 
migrating cells through retraction fibres, that can be taken up by trailing cells and may 
potentially provide guidance cues between cells.  
 
Many regulatory molecules have been implicated in myoblast migration such as MAPKs, 
phoshpholipases, Ser/Thr & Tyr kinases. However, key regulatory proteins in myoblast 
migration believed to be most influential are the Rho family of GTPases that link cell 
surface receptors to a variety of intracellular responses connected to cell migration (Nobes & 
Hall, 1999). Three Rho GTPases are implicated in cell migration; Rho, Rac and Cdc42. Rho 
regulates the assembly of contractile filaments whilst Rac and Cdc42 regulate actin 
polymerization to form lamelipodia and filapodia, respectively. All three Rho GTPases can 
regulate the assembly of integrin based adhesion complexes and can affect the microtubule 
cytoskeleton and gene transcription.  
During cell migration, important upstream signalling of the Rho GTPases are the PI3-K and 
P130Cas/CrkII/Dock180 pathways. Dimchev, Al-Shanti, and Stewart (2013) demonstrate 
that inhibition of the natural PI3-K inhibitor phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase (PTEN) results in improved myoblast motility. Additionally, when PI3-K/Akt 
are inhibited this improved migration returns to control levels. Similarly, the receptor 
tyrosine kinase c-MET is also required for normal myoblast migration. Mutant c-MET null 
mice do not regenerate muscle efficiently following acute injury as a consequence of 
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defective lamellipodia formation, shorter progenitor migration distances and slower 
migration compared to control myoblasts (Webster & Fan, 2013). 
2.2.7 Myoblast Fusion: To successfully finish the regeneration process, myoblasts fuse with 
the damaged myofibre contributing new myonuclei. This process is highly orchestrated and 
crucial for regeneration, for which the underpinning molecular mechanisms are still largely 
undefined. At present it is understood that cell-cell recognition, adhesion and membrane 
merging are three mechanistically linked phases of myoblast fusion.  
More protracted efforts have been made to study these processes and their regulators in 
Drosphilia, however only recently has research efforts focussed on mammalian models. 
Przewozniak et al. (2013) denervated and crushed the soleus muscle of 3-month-old mice to 
identify the role of adhesion proteins in skeletal muscle fusion following injury. The authors 
first demonstrate that integrin α3, integrin β1, ADAM12, CD9, CD81, M-cadherin and 
VCAM-1 all increase their expression profile during fusion and myotube formation 
following injury in vivo. Subsequently, the researchers show the complexity and importance 
of individual members of multi-protein adhesion complexes by silencing the integrin α3 
subunit via RNA interference. This in vitro experiment provided evidence that under 
expression of integrin α3 leads to an impaired fusion capability of myoblasts, an observation 
that was not related to modifications in expression of other proteins (those previously 
mentioned). This highlights that the under expression of a single member of a multi-protein 
adhesion complex can impair the capability of the complex to orchestrate cell-cell adherence 
and fusion. Recently a novel membrane protein termed Myomaker, required for the 
activation and fusion of myoblasts was identified (Millay et al., 2013). Over expression of 
the protein significantly enhances fusion capability and abolition results in perinatal death 
due to a failure to form myotubes. Similarly, but to a lesser extent than Myomaker, normal 
myoblast fusion requires Myoferlin (Doherty et al., 2005). As described earlier, myoblast 
fusion requires the alignment and fusion of two phospholipid bilayers (sarcolemma) and 
Myoferlin appears important for binding phospholipids in a calcium-sensitive manner. 
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Myoferlin -/- mice still form myotubes however show an impaired regenerative capacity and 
develop smaller myotubes than WT controls, instead displaying a dystrophic phenotype. 
Taken together, a number of interacting systems control myoblast fusion and impairments 
even in single proteins can significantly alter normal myoblast fusion. 
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2.3 Vitamin D 
2.3.1 Background: Vitamin D was first discovered, like other vitamins, through 
investigation into diseases attributable to dietary deficiencies (McCollum, 1914). Since then, 
there has been a considerable increase in research attention toward Vitamin D. This is in part 
due to the re-emergence of the preventable bone disorder rickets and a well-documented 
prevalence of worldwide Vitamin D deficiency (discussed in further detail section 2.3.9). 
There have been a number of key research findings which have advanced the field 
considerably, particularly the identification of the Vitamin D receptor (VDR) in many 
tissues through which Vitamin D exerts the majority of its effects (Demay, 2006). Moreover, 
the generation of the VDR knock out mouse (Li et al., 1997) has provided great insight into 
the multiplicity of biological actions of Vitamin D. It is now understood that aspects of 
innate and acquired immunity (Chun, Liu, Modlin, Adams, & Hewison, 2014), bone health 
(Ebeling, 2014), cardiovascular health (Lavie, Dinicolantonio, Milani, & O'Keefe, 2013) and 
processes within skeletal muscle are just some of the physiological features thought to be 
regulated by Vitamin D.  
 
2.3.2 Forms of Vitamin D: There are a number of biological forms of Vitamin D that occur 
in dietary sources and that are synthesized endogenously in the human body. Vitamin D2 
(also termed ergocalciferol) and D3 (also termed cholecalciferol, both graphically presented 
in Figure 2.7) are the major sources of Vitamin D contributing to Vitamin D status and are 
both found in food sources with only the D3 form synthesized in the body following 
appropriate exposure to UV irradiation. 
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Figure 2.7. Nutritional forms of Vitamin D. Left; Vitamin D2 and Right; Vitamin D3. Note the broken 9,10 
carbon bond of the B ring giving the Vitamin D compounds their seco-steroid classification. The structural 
difference between vitamin D2 and vitamin D3 is in their side chains. The side chain of D2 contains a double bond 
between carbons 22 and 23, and a methyl group on carbon 24. 
 
2.3.3 Vitamin D Synthesis: The human genome developed the mechanism for Vitamin D 
synthesis in the skins dermis that is activated by sunlight, or more specifically ultraviolet B 
irradiation (UVB) at a wavelength of approximately 290-315 nm (Holick, 1995). During this 
photosynthetic reaction, the B ring of 7-dehydrocholesterol (precursor to cholesterol and pre 
Vitamin D3) is cleaved and resultantly the thermodynamically unstable pre-Vitamin D3 (pre-
cholecalciferol) is formed. Thermal isomerization following this cleavage yields Vitamin D3, 
a seco-steroid hormone. In human skin, the thermal isomerisation process converts ~80 % of 
pre-Vitamin D3 to Vitamin D3 within 8 hours of exposure to UVB (Tian, Chen, Matsuoka, 
Wortsman, & Holick, 1993). When a sufficient quantity of Vitamin D has been synthesized 
in the skin (at approximately 7-10% of the original 7-dehydrocholesterol content), pre-
49 
	  
Vitamin D3 is converted to the biologically inactive photoproducts tachysterol and lumisterol 
(Holick, MacLaughlin, & Doppelt, 1981), serving as an endogenous toxicity regulator. 
There are many factors that can affect the dermal synthesis of Vitamin D. For example, the 
amount of radiation that actually reaches the biosphere (thus available for cutaneous Vitamin 
D photosynthesis) is a product of wavelength and the amount of ozone that solar radiation 
must pass, which itself is a function of the solar zenith angle dependent on latitude, season 
and time of day (Chen et al., 2007). If UVB reaches the skin, another influential factor 
impacting the subsequent photosynthetic reaction is skin pigmentation as melanin competes 
with 7-dehydrocholesterol for absorption of UVB radiation. Resultantly, those with darker 
skin require exposure to a stronger source of UVB or more prolonged exposure time to elicit 
comparable changes in circulating Vitamin D concentration seen in lighter skinned persons 
(Chen et al., 2007; Clemens, Adams, Henderson, & Holick, 1982). 
 
2.3.4 Dietary Sources of Vitamin D: An obvious alternative route for obtaining vital 
nutrients not naturally synthesized (such as the other vitamins) is through dietary intake. 
Indeed there are some, but very few, dietary sources of Vitamin D although it is unlikely that 
humans obtain enough Vitamin D from such sources to compensate for a lack of sun 
exposure. Unlike dermal synthesis that solely produces Vitamin D3, dietary intake provides 
both Vitamin D2 and D3. Dietary sources of Vitamin D include oily fish, eggs, fortified 
breakfast cereals, shitake mushrooms and powdered milk. However, intake of these foods 
appears to be limited in developed countries (Hill, O'Brien, Cashman, Flynn, & Kiely, 2004; 
Moore, Murphy, Keast, & Holick, 2004; Survey, 2011; Tylavsky, Cheng, Lyytikainen, 
Viljakainen, & Lamberg-Allardt, 2006). Large scale investigations have identified that < 2% 
of individuals studied met the recommended daily allowance (RDA = 600 IU.day-1 or 15 
µg.day-1 for adults; 100 IU =2.5 µg) for Vitamin D intake from foods (Hill, Jonnalagadda, 
Albertson, Joshi, & Weaver, 2012). Adding further complexity to obtaining sufficient 
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Vitamin D in the diet, Chen et al. (2007) provide evidence that many foods stating 
fortification with Vitamin D may in fact contain < 80% of the Vitamin D claimed on the 
label whilst 14% of samples tested contained no detectable Vitamin D. Thus, when UVB 
exposure is lacking, it may be difficult to obtain sufficient Vitamin D from the diet. 
 
2.3.5 Vitamin D Metabolism: Regardless of how Vitamin D is obtained (through dermal 
synthesis or from dietary sources), both forms will travel in the circulation bound to the 
Vitamin D binding protein (DBP; Cooke & Haddad, 1989). It is of importance to note at this 
stage that Vitamin D2 (ergocalciferol) which enters systemic circulation from dietary food 
sources undergoes the same metabolic steps as Vitamin D3, however D3 has a relative 
potency to Vitamin D2 of 9.5:1 for increasing serum 25[OH]D (Armas, Hollis, & Heaney, 
2004).  
Once circulating bound to DBP, Vitamin D will undergo two important hydroxylation steps 
occurring in the liver (via 25-hydroxylase) and in the kidney (via 1α-hydroxylase) or tissues 
directly expressing 1α-hydroxylase such as skin, pancreas, brain, colon (Zehnder et al., 
2001), immune system cells (Moran-Auth, Penna-Martinez, Shoghi, Ramos-Lopez, & 
Badenhoop, 2013) and skeletal muscle (Girgis et al., 2014b; Srikuea et al., 2012). The 
resultant 1α,25-dihydroxyvitamin D (1α,25[OH]2D3), is metabolically active and it is this 
form of Vitamin D that exerts its biological effects. The efficacy of tissues expressing 1α-
hydroxylase to convert DBP bound 25[OH]D will be dependent upon the ability of the cell 
to internalize the 25[OH]D-DBP complex. In skeletal muscle, this is likely to be achieved by 
the expression of membrane bound Megalin that has recently been identified (Abboud et al., 
2013). Following the final activating hydroxylation step, 1α,25[OH]2D will bind to the 
Vitamin D receptor (VDR) and exert genomic and non-genomic effects or may also interact 
with protein disulphide isomerase, family A, member 3 (Pdia3) to exert rapid cell signalling 
effects. 
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2.3.6 The Vitamin D Receptor: A significant advancement in the understanding of the 
VDR has developed since its cloning and recognition as a member of the nuclear receptors 
that regulate gene expression (McDonnell, Mangelsdorf, Pike, Haussler, & O'Malley, 1987). 
The receptor is constituted of 427 amino acids with its two major functional units being the 
N-terminal zinc finger DNA-binding domain and the C-terminal ligand-binding domain. The 
intricacies of the VDR structure are not in the scope of this literature review and have been 
eloquently discussed elsewhere (Haussler et al., 1998). 
Of relevance to this thesis are the functional characteristics of the receptor. In its basal state, 
the VDR has been identified by fractionation and immunocytochemical localization as un-
liganded in the nucleus of many cells including skeletal muscle cells (Berger et al., 1988; 
Buitrago & Boland, 2010; Clemens et al., 1988; Milde, Merke, Ritz, Haussler, & Rauterberg, 
1989; Walters, Hunziker, & Norman, 1980; Zanello, Collins, Marinissen, Norman, & 
Boland, 1997). Upon exposure to 1α,25[OH]2D there is evidence of nuclear-sarcoplasmic 
translocation, with the VDR localizing in close proximity to caveolae within the sarcolemma 
(Buitrago & Boland, 2010). Ligand binding of 1α,25[OH]2D to the VDR may induce 
translocation of the complex to the cell nucleus where it tightly binds with 9-cis-retinoic acid 
receptor (RXR) to form a heterodimer (MacDonald et al., 1993). This VDR:RXR complex is 
capable of penetrating the deep groove of DNA and recognizing Vitamin D response 
elements (VDREs) in the sequence of Vitamin D regulated genes. In a series of 
immunoprecipitation experiments, Chiba, Suldan, Freedman, and Parvin (2000) first 
demonstrated that the liganded VDR:RXR complex binding to the Vitamin D receptor 
activating protein (DRIP) co-activator complex induces interaction with RNA polymerase II 
to activate transcription. Data have subsequently established that upon binding to VDREs 
the complex can recruit other transcriptional co-activators such as steroid co-activators 
(SRC-1, -2 and -3) and Smad proteins that possess histone acetyl transferase (HAT) activity 
(MacDonald, Baudino, Tokumaru, Dowd, & Zhang, 2001). The VDR:RXR heterodimer 
binding to DNA appears to alter the receptor dynamics including the co-activator binding 
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surfaces and the sequence of the DNA response element can determine these dynamics. 
Further, agonist binding results in changes in the stability of the VDR binding domains 
(DBD), indicating that the ligand itself may play a role in DNA recognition. These data 
imply a mechanism by which the VDR:RXR complex expresses promoter specificity 
permitting differential effects on numerous Vitamin D related target genes (Zhang et al., 
2011).  
It is also important to recognise the established non-genomic functions of the VDR. A 
number of investigations have demonstrated that treatment of C2C12 skeletal myoblasts and 
isolated primary chick myoblasts with Vitamin D stimulates tyrosine phosphorylation 
cascades within seconds to minutes of exposure (Nemere et al., 1998). Importantly, the use 
of anti-VDR antisense oligonucleotides inhibits such rapid responses lending support to a 
genomic role (Santillan, Baldi, Katz, Vazquez, & Boland, 2004). Further backing for this 
non-genomic function has been provided in an investigation in which the suppression of 
protein translation with cycloheximide did not inhibit the rapid effects of 1α,25[OH]2D-
VDR signalling (de Boland & Boland, 1987).  
There is some conjecture as to whether the classical VDR is involved in all of the apparent 
rapid signalling responses that occur upon exposure to 1α,25[OH]2D3. Some authors have 
suggested that the VDR involved in the rapid activation of signal transduction pathways is a 
non-nuclear form of the receptor distinct from the nuclear isoform and some suggest a 
receptor distinct to the VDR (termed 1,25-dihydroxyvitamin D-membrane-associated, rapid 
response steroid-binding receptor or MARRS) with 1α,25[OH]2D binding potential and 
exerting cellular effects in skeletal muscle (Nemere, Garbi, & Winger, 2015).	  Protracted 
efforts to investigate the roles of these two apparently distinct receptors have revealed that 
Pdia3 is located in caveolae of bone and cartilage cells and is also implicated in rapid VDR 
signalling. Binding of 1α,25[OH]2D to Pdia3 establishes interaction with phospholipase A2 
(PLA2) activating protein (PLAA) and caveolin-1 (Cav1) to initiate rapid signalling via Ca2-
calmodulin-dependent protein kinase II (CaMKII), phospholipase C (PLC), protein kinase C 
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(PKC), and in turn, the extracellular receptor mediated protein kinases (ERK) 1/2 family of 
the MAPKs (Boyan, Chen, & Schwartz, 2012). In some cases VDR is reported to be 
separate from such function and present on the sarcolemma where it is required for 
1α,25[OH]2D induced rapid activation of Src signalling. Although yet to be confirmed in 
skeletal muscle, crosstalk of signalling pathways has recently been implicated as Chen et al. 
(2013) demonstrate an interaction between Pdia3 and VDR in MC3T3-E1 osteoblasts, 
initiating rapid intracellular signalling through PLA2 and c-Src in response to1α,25[OH]2D3 
exposure. 
It is also interesting to consider that there are three known transcript variants of the VDR. 
Variants 1 and 2 encode the same protein and differ only in 92 base pairs. Variants 1 and 2 
differ in the 5' UTR and coding sequence compared to variant 3 (VDRB1). The resulting 
isoform (VDRA) is shorter at the N-terminus compared to isoform VDRB1. As the N-
terminal of the VDR is responsible for DNA binding, it is possible that isoforms 1 and 2 
initiate rapid signalling whilst VDRB1 is responsible for the genomic actions of Vitamin D. 
Data to support this notion are not currently available and the functional differences (if any) 
of the two VDR isoforms remains to be established. 
Supporting the role of the classical VDR in Vitamin D/skeletal muscle signalling are recent 
data that provide evidence for differential expression of the VDR in response to ligand 
availability (Garcia, King, Ferrini, Norris, & Artaza, 2011; Girgis et al., 2014b; Srikuea et al., 
2012). This is in line with previous findings in other tissues such as bone and intestine, 
where VDR content is positively associated with an increase in biological activity following 
exposure to 1α,25[OH]2D (Dokoh, Donaldson, & Haussler, 1984; Halloran & DeLuca, 
1981). These findings strongly suggest that the VDR is important for the biological function 
of Vitamin D in skeletal muscle. 
Although the described evidence provides potential mechanisms by which Vitamin D may 
exert biological effects in skeletal muscle, the presence of the VDR in skeletal muscle has in 
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itself recently been called into question. Many reports spanning from 1985 utilising sucrose 
density gradients through to 2011 where more advanced immunostaining methods have been 
employed have supported the presence of the VDR (summarized in Table 2.2). However, 
Wang, Zhu, and DeLuca (2012) recently reported that the VDR is not present in skeletal 
muscle as determined by immunoblotting and immunohistochemistry and suggest that 
antibodies previously used to detect the VDR where not specific to VDR protein. They 
report that the Santa Cruz VDR 9A antibody is most specific to the VDR and failed to detect 
the presence of the receptor in skeletal muscle, also detecting only very small levels of VDR 
transcripts by PCR. Conversely, Srikuea et al. (2012) provide robust evidence for the 
presence of the VDR in C2C12 myoblasts by employing a number of techniques including 
immunoblotting, immunocytochemistry, PCR-based cloning and DNA sequencing, all of 
which successfully detected the presence of the VDR in skeletal muscle. Similar findings are 
described by Girgis et al. (2014b). The investigators successfully demonstrate the presence 
of the VDR in skeletal muscle of two in vitro models (C2C12 cell line and primary mouse 
myotubes) using PCR, immunoblot and immunohistochemistry. Interestingly, Kislinger et al. 
(2005) implemented large-scale gel-free tandem mass spectrometry to detect proteome 
alterations throughout the myogenic differentiation programme in C2C12 myoblasts and 
observed an up regulation of the VDR during early myoblast differentiation. Similar 
observations have been made demonstrating transient changes in VDR expression as 
discussed earlier. It is plausible that the time point at which the VDR protein is probed in 
skeletal muscle may affect the ability to identify it, as its expression appears to fluctuate 
based on ligand exposure and cell cycle stage. 
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Table 2.2. Summary of investigations directly assessing the presence of the VDR in skeletal muscle. 
Authors Model Methodology VDR Detected (+/-) 
Simpson, Thomas, and 
Arnold (1985) 
G8, H9c2 myoblasts Sucrose density gradient, 
chromatography. 
+ 
Costa, Blau, and 
Feldman (1986) 
Cloned human muscle [3H]1α,25-[OH]2D3 binding assay 
(sucrose density gradient). 
+ 
Boland, Norman, Ritz, 
and Hasselbach (1985) 
Primary chick embryo 
myoblasts 
Sucrose density gradient + 
Sandgren, Bronnegard, 
and DeLuca (1991) 
Rat skeletal muscle Immunoradiometric assay - 
Buitrago, Vazquez, De 
Boland, and Boland 
(2000) 
Primary chick 
myoblasts 
SDS-PAGE Western Blot + 
Bischoff et al. (2001) Human skeletal 
muscle tissue 
Immunohistochemistry + 
Boland et al. (2002) Primary chick 
myoblasts 
SDS-PAGE Western Blot + 
Capiati, Benassati, and 
Boland (2002) 
Primary chick 
myoblasts 
SDS-PAGE Western Blot + 
Endo et al. (2003) VDR -/- mice and 
C2C12 cell line 
Immunohistochemistry, RT-qPCR, 
Northern Blot 
+ 
Wang and DeLuca 
(2011) 
Six- to 7-wk-old 
C57BL/6 mice 
Immunohistochemistry, RT-qPCR - 
 
Taken together, recent findings lend support to the notion that the majority of actions of 
Vitamin D in skeletal muscle are mediated through the classical VDR, which evidently is 
necessary for both the genomic and rapid non-genomic actions of the hormone. Furthermore, 
exposure to Vitamin D appears to be an important determinant of VDR signalling although 
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as will be discussed, many individuals lack adequate Vitamin D, compromising tissue 
exposure. 
2.3.7 Measuring Vitamin D Concentration: Prior to discussion of worldwide Vitamin D 
status is the necessity to consider how and what to measure. Over 40 metabolites of Vitamin 
D have been identified (Bouillon, Okamura, & Norman, 1995), but most of these have a very 
short half-life in the circulation and so are currently of minimal interest. Although the parent 
sterol Vitamin D has a half-life close to 24 hours (Clemens, Adams, Nolan, & Holick, 1982) 
this is relatively short compared to 25[OH]D with a half–life of 21-30 days (Zehnder et al., 
2001). The measurement of circulating 25[OH]D is a better indicator of Vitamin D exposure 
whether obtained from UVB exposure (contributing 80-90% of 25[OH]D) or dietary sources 
(contributing 10-20%). The most potent physiologically active circulating metabolite 
produced by humans is 1α,25[OH]2D which has a half-life of 4-15 hours and while 25[OH]D 
circulates in nmol.L-1 concentrations, 1α,25[OH]2D is present in much lower concentrations 
(pmol.L-1). 
Supplementation of foods and health products or supplemental treatment with either Vitamin 
D2 or D3 can increase the percentage derived from exogenous sources and so assay 
technology needs to be able to measure both D2 and D3 metabolites. The main rate limiting 
step in the pathway of Vitamin D metabolism is the 25-hydroxylation that takes place in the 
liver. This step is primarily dependent on the substrate concentration (Vitamin D) and is the 
reason why seasonal variability exists related to UVB exposure. 1α-hydroxylation mainly 
takes place in the kidney but can also happen in bone, skin, placenta, granuloma tissue and 
indeed skeletal muscle (Srikuea et al., 2012; Zehnder et al., 2001) and requires 25[OH]D2/D3 
as the substrate. The rate of 1α,25[OH]2D production by the kidney can be influenced by the 
prevailing calcium and parathyroid hormone (PTH) concentration. For these reasons, as well 
as the short half-life, measurement of total 1α,25[OH]2D is a poor indicator of overall 
Vitamin D status as total 25[OH]D needs to decrease to around 10 nmol.L-1 for total 
1α,25[OH]2D to decrease significantly (Need et al., 2008). 
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Isotope dilution LC-MS/MS is considered the gold standard method for measuring serum 
total 25[OH]D and can simultaneously quantify 25[OH]D2 and 25[OH]D3 with summation 
of the two values resulting in an accurate and precise measure of total 25[OH]D. All 
immunoassays evaluated appropriately have a problem with the recognition of 25[OH]D2 
and under-recover this molecule whether added in the natural/synthetic form or estimated in 
the circulation following ingestion. Detailed comparison of the performance of 
commercially available assays inclusive of assay data can be found in Snellman et al. (2010). 
 
2.3.8 Categorization of Vitamin D Status: The categorization of Vitamin D status has been 
the subject of intense debate in the past decade. Conflicting views as to what constitutes 
deficiency and what is optimal are at the centre of this dispute. The present guidelines put 
forward by the US Institute of Medicine are generally adhered in worldwide medical 
practice (Table 2.3).  
Table 2.3. US Institute of Medicine (2011) Vitamin D concentration classification and suggested optimal 
(Zittermann, 2003). 
Serum 25[OH]D Classification 
< 12 nmol.L-1 Severely deficient 
12 – <30 nmol.L-1 Deficient 
30 – 50 nmol.L-1 Inadequate 
> 50 nmol.L-1 Adequate 
 
However, many have called for revision of these guidelines, claiming that they are too 
conservative. As examples, it has been suggested that only when serum 25[OH]D is >75 
nmol.L-1 should this be considered adequate since perturbations to calcium and phosphate 
homeostasis occur below this level with intact parathyroid hormone concentrations being 
elevated (Heaney, 2013). Some authors have suggested that >100 nmol.L-1 should be 
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considered optimal as those living and working outdoors in sun rich environments present 
with concentrations in this range (Zittermann, 2003). The debate over what constitutes 
classification of Vitamin D limits its usefulness and therefore investigation into the role of 
Vitamin D in skeletal muscle function should be discussed in relation to absolute circulating 
concentration of serum 25[OH]D. 
2.3.9 Worldwide Vitamin D Status: Vitamin D deficiency and insufficiency as classed by 
the US IoM is common with estimates of 1 billion people worldwide into the category, even 
in areas with ample sunlight exposure for dermal synthesis throughout the year. In the 
United States, it is reported that approximately 40% of the population has vitamin D 
concentrations < 50 nmol.L-1 (Forrest & Stuhldreher, 2011). A similar prevalence has been 
observed in Australia (Daly et al., 2012) and also areas in the Middle East (Elsammak, Al-
Wossaibi, Al-Howeish, & Alsaeed, 2011; Hoteit et al., 2014). At Northerly latitude’s (> 35o 
N) in Europe, deficiency is also common. Large population-based studies from Ireland 
(Cashman et al., 2012) Denmark (Thuesen et al., 2012) France (Chapuy et al., 1997), 
Germany (Hintzpeter, Mensink, Thierfelder, Muller, & Scheidt-Nave, 2008) and the UK 
(Bates et al., 2003) report high frequency of serum 25[OH]D levels < 50 nmol.L-1. In sub 
populations such as professional athletes, Vitamin D deficiency is also common. Our 
research group has previously established this in a cohort of 64 professional UK based 
athletes. These data are in line with other reports in Europe and the rest of the world (See 
table 2.4). 
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Table 2.4. Summary of trials assessing Vitamin D status in athletic populations. 
Authors Elite Sample Population Test Month 
(Season) 
Serum 25[OH]D 
Concentrations 
Hamilton, 
Grantham, 
Racinais, and 
Chalabi (2010) 
93 middle eastern professional and 
semi-professional athletes from sports 
including; football, athletics, squash, 
handball, cycling, martial arts and 
body building. 
Apr-Oct (random 
testing) 
91% <50 nmol.L-1 
Morton et al. 
(2012b) 
20 FA Premier League soccer players Aug and Dec 
(Summer vs 
Winter) 
65% <50 nmol.L-1 
Close et al. (2013b) 64 Professional UK based athletes from 
sports including; football, rugby horse 
racing 
Nov-Jan (Winter) 62% <50 nmol.L-1 
Wolman et al. 
(2013) 
19 elite classical ballet dancers Winter vs 
summer 
74% 25–75 
nmol.L-1 
26% <25 nmol.L-1 
Valtuena, 
Dominguez, Til, 
Gonzalez-Gross, 
and Drobnic (2014) 
408 elite Spanish athletes across more 
than 30 different sports. 
Winter (Jan) vs 
Spring (Apr) vs 
Summer (Ju)l vs 
Autumn (Oct) 
82% <75-50 
nmol.L-1 
45% <50-27.5 
nmol.L-1 
6% <27.5 nmol.L-1 
Wilson et al. (2013) 37 elite professional jockeys Jan-Apr (Winter) 31% 30-50 nmol.L-
1 
42% 12.5-30 
nmol.L-1 
5% <12.5 nmol.L-1 
 
As discussed previously, there are many factors that limit the cutaneous synthesis of Vitamin 
D and few dietary sources can provide sufficient quantity to compensate for a lack of sun 
exposure. These factors explain the epidemiological data above as all of the geographical 
locations described fall into the category of developed countries where a sun-shy lifestyle 
due to indoor work, excessive sun-screening and government guidance to avoid sun 
exposure is commonplace.  
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Although the data are striking, they do not describe the consequence of Vitamin D 
deficiency, which ultimately influences the relevance of such statistics. Indeed there are a 
number of physiological roles for Vitamin D and known consequences of deficiency. 
Classically, severe Vitamin D deficiency is understood to cause rickets in children and 
osteomalacia in adults, as the Vitamin D-parathyroid hormone (PTH) axis is a crucial 
regulator of bone resorption and turnover. Consequentially, it is reported that markers of 
bone resorption and turnover are elevated above the normal reference ranges in individuals 
with insufficient serum 25[OH]D concentrations (Dawson-Hughes et al., 1991; Sahota, 
Masud, San, & Hosking, 1999; Sahota et al., 2004). It is also now well established that 
Vitamin D is a potent regulator of aspects of innate and acquired immunity (Chun et al., 
2014) and regulates cell cycle progression, potentially protecting against the development 
and advancement of fatal diseases such as cancer (Pilz, Gaksch, Hartaigh, Tomaschitz, & 
Marz, 2015). 
Emerging insights from human trials suggest severe Vitamin D deficiency correlates with 
smaller heart size (Allison et al., 2014), impaired energy metabolism (Sinha, Hollingsworth, 
Ball, & Cheetham, 2013), diabetes (Dalgard, Petersen, Weihe, & Grandjean, 2011), 
oxidative stress (Uberti et al., 2014) and Alzheimer’s diseases (Littlejohns et al., 2014). The 
focus of this thesis however pertains specifically to skeletal muscle for which scientific data 
are lacking in the context of Vitamin D. 
2.3.10 Vitamin D and Skeletal Muscle: Observational Studies:  Early interest in vitamin 
D and skeletal muscle health was stimulated by numerous observational findings. It has 
repeatedly been reported that severe Vitamin D deficiency is accompanied by skeletal 
muscle myopathy that is reversible with supplemental Vitamin D (Mingrone, Greco, 
Castagneto, & Gasbarrini, 1999; Prabhala, Garg, & Dandona, 2000; Rimaniol, Authier, & 
Chariot, 1994; Russell, 1994; Ziambaras & Dagogo-Jack, 1997). In a large meta-analysis of 
randomised controlled trials (Bischoff-Ferrari et al., 2009), it was reported that Vitamin D 
reduced the corrected odds ratio of falls by 20% (corrected OR, 0.78; 95% confidence 
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interval [CI], 0.64-0.92) compared with patients receiving calcium or placebo. One 
observational study described a two-fold greater risk in the development of sarcopenia in 
individuals with baseline serum 25[OH]D <25 nmol.L-1 (Visser, Deeg, Lips, & Longitudinal 
Aging Study, 2003). In another report, baseline 25[OH]D <50 nmol.L-1 correlated with a 
greater 3-year risk of physical performance decline than individuals with concentrations >50 
nmol.L-1 (Wicherts et al., 2007). 
These data are limited to clinical cohorts, however in non-clinical populations similar 
observations have been made. Barker et al. (2013a) provide correlative evidence that higher 
serum 25[OH]D associates with a faster recovery of force from eccentric exercise and 
subsequently have demonstrated that young individuals receiving a Vitamin D supplement 
recover quicker than those receiving placebo (Barker, Schneider, Dixon, Henriksen, & 
Weaver, 2013b), unfortunately no participants started the trial with Vitamin D 
concentrations <50 nmol.L-1 raising to question the validity of these data. The same authors 
also describe a quicker recovery of peak quadriceps force in individuals with higher serum 
25[OH]D following anterior cruciate ligament injury (Barker, Henriksen, Rogers, & Trawick, 
2015). 
These findings are limited by their design. Observational data cannot describe a causal 
relationship between Vitamin D and muscle function/regeneration. These data may be 
explained by secondary problems caused by Vitamin D deficiency such as systemically 
altered calcium/phosphate homeostasis. Furthermore, a major confounding variable for some 
of these studies is the pre-existing frailty that may be present in elderly populations 
preventing outdoor activity thereby causing a decline in serum 25[OH]D as a function of a 
lack of UVB exposure. As such, randomised controlled trials (RCTs) and mechanistic 
investigations are needed to confirm a cause-effect role for Vitamin D and muscle health. 
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2.3.11 Vitamin D and Skeletal Muscle - RCT’s: Very few RCT’s have been conducted 
into the potential role of Vitamin D in muscle function and those that exist have provided 
conflicting results. In the elderly, pooled data analysis from 5 RCTs suggests that Vitamin D 
supplementation may reduce falls risk by 22% versus elderly individuals prescribed placebo 
(Bischoff-Ferrari et al., 2004a). As with observational studies on Vitamin D and muscle 
function, these data are hampered by the selectivity of the sample population being elderly 
(age range 70-85 years old), predominantly institutionalized individuals. It is therefore 
difficult to generalize such findings across a wider age range since institutionalized persons 
are likely to have habitually lower physical activity levels contributing to loss of muscle 
mass and function. 
In young, otherwise healthy individuals data are scarce. In a cohort of young active males 
with Vitamin D concentrations <25 nmol.L-1 improvements in vertical jump height and 10m 
sprint times were observed when participants were supplemented for eight weeks with 5,000 
IU.day-1 Vitamin D3 resulting in significant serum 25[OH]D increases to >100 nmol.L-1 
(Close et al., 2012). However, the placebo group in this trial also showed improvements in 
most of the performance measures, although not statistically significant. Since the sample 
population was also small, whether an actual physiological effect of the Vitamin D 
supplement was observed in this trial may be debated. In a similar study by the same authors, 
findings did not correlate to the first trial. Young males with mean serum 25[OH]D of 51 ± 
24 nmol.L-1  performed 1-RM bench press and leg press and vertical jump height prior to 
and following supplementation for twelve weeks with 20,000 or 40,000 IU.week-1 Vitamin 
D3 or placebo (Close et al., 2013a). Although serum concentrations significantly improved in 
the Vitamin D treatment group, no changes in musculoskeletal performance were detected.  
Studies from other research groups report similarly disparate results. Wyon, Koutedakis, 
Wolman, Nevill, and Allen (2014) assessed Vitamin D status in professional ballet dancers 
demonstrating high prevalence of Vitamin D deficiency. Following randomized 
supplementation for four months with 2,000 IU.day-1 Vitamin D3 or placebo, the 
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supplemental Vitamin D group improved isometric strength and vertical jump height and 
experienced significantly fewer soft tissue injuries in comparison to the placebo control 
cohort. However, Barker et al. (2012) observed no strength changes in individuals 
supplemented with 400 or 2,000 IU.day-1 Vitamin D3 for 28 days despite significant 
increases in serum 25[OH]D in the 2,000 IU.day-1 group. 
The investigations described have generally examined muscle contractile function in the 
context of whole muscle physiology and insights for potential mechanisms are still sparse. 
However, in a recent investigation Sinha et al. (2013) explored the possibility that 
mitochondrial oxidative function may be a potential mechanism by which Vitamin D 
deficiency could impair muscle function. Phosphocreatine and ADP recovery kinetics 
following exercise were measured via 31P magnetic resonance spectroscopy in individuals 
(age range = 18-54 years) with severe Vitamin D deficiency (< 15 nmol.L-1) prior to- and 
following supplementation with Vitamin D (20,000 IU on alternate days for 10-12 weeks) or 
placebo. Despite no changes in phosphate metabolites at rest, recovery kinetics were 
significantly improved in the supplemental Vitamin D group indicating an improvement in 
mitochondrial oxidative metabolism. 
A likely explanation for inconsistency in findings has been proposed by Lappe and Heaney 
(2012). The authors postulate that RCTs on Vitamin D sometimes fail due to heterogeneity 
in baseline serum 25[OH]D concentration which leads to a failure to detect functional 
improvements of the tissue being investigated i.e. if the participant in question is already on 
the ascending limb of an improvement curve then it is difficult to detect change as the curve 
plateaus. Furthermore, heterogeneity in outcome measures, supplemental Vitamin D doses 
and a lack of sensitivity in chosen muscle function tests further complicates available data. 
 
2.3.12 Vitamin D Receptor Polymorphisms and Muscle Function: A number of studies 
have aimed to identify an association between VDR single nucleotide polymorphisms (SNP) 
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and parameters of musculoskeletal performance. The outcomes of these association studies 
have produced conflicting results. Windelinckx et al. (2007) explored the presence of 
common Vitamin D receptor polymorphisms and their apparent correlation to muscle 
strength in men and women. Based on the notion that the VDR is a candidate gene for inter-
individual muscle strength variability, the authors’ genotyped BsmI, TaqI and FokI VDR 
polymorphisms in 253 men and 240 women and report an association for quadriceps 
strength with FokI SNP in women and with BsmI-TaqI haplotype in men. Although these 
data are widely cited and generally accepted amongst the literature, there are a number of 
criticisms that limit the usefulness of these findings. First, although the authors aimed to 
establish an association between genotype and max strength, they failed to detect any 
association at the slower dynamic movement velocity (60 deg.sec-1), which would be more 
appropriate to elicit peak torque (Baltzopoulos & Brodie, 1989). In addition, the translational 
potential of these data are limited by a lack of information as to how such polymorphisms 
may influence muscle contractile properties. Notably, the VDR polymorphisms reported to 
correlate with muscle strength are located at the 3’ end of the VDR gene and do not 
influence protein structure. Thus, functional changes in the VDR are unlikely. However, 
SNPs in the 3’ region of the gene are associated with mRNA stability and thus could 
influence VDR protein expression. Since it is unknown whether VDR SNPs associate with 
differential responses to exogenous Vitamin D, it is currently unknown how VDR SNPs 
could have any influence on Vitamin D signalling. 
Other data provide contrasting evidence: Allelic variants of the VDR in 271 older 
community dwelling men were investigated for associations with bone mineral density 
(BMD) and biochemical markers of bone accretion and also muscle strength (Van 
Pottelbergh, Goemaere, De Bacquer, De Paepe, & Kaufman, 2002). Although genotype 
demonstrated a trend with BMD, no association with muscle strength was detected. These 
data are also subject to critique since muscle function in the cohort assessed may be 
compromised by the already underlying age related loss of function and mass (sarcopenia). 
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In summary, allelic variation in VDR gene and its role in muscle function and regeneration 
is an area of research to be approached with caution as definitive answers are yet to be 
provided by well-powered, mechanistic investigations that employ sensitive investigative 
techniques. Additionally, genetic variation in other aspects of the Vitamin D metabolic 
pathway such as binding protein genotype (Malik et al., 2013) should also be investigated in 
conjunction with VDR genotyping to provide a more complete understanding of genetic 
variation of the Vitamin D pathway and its influence on downstream outcomes. In contrast, 
a number of animal, human, cellular and molecular investigations have provided various 
fragments of evidence suggestive of a functional role for Vitamin D in skeletal muscle 
contraction and growth signalling, regardless of VDR genotype. 
 
2.3.13 Vitamin D and Skeletal Muscle: Animal Models: Early work on rabbits with 
experimental uremia and consequentially impaired Ca2+ transport were found to show 
marked improvements in calcium flux and storage following treatment with Vitamin D 
however exact mechanisms remained to be determined and the significance of the role for 
Vitamin D to be explored (Matthews et al., 1977). Protracted efforts to better understand the 
global role of Vitamin D led to the generation of the VDR knockout (VDR -/-) mouse (Li et 
al., 1997). Subsequent investigations sought to isolate skeletal muscle from the VDR -/- 
mouse to study morphological differences when compared with wild type (WT) mice (Endo 
et al., 2003). Histological sections demonstrated distinct morphological changes with all 
fibres observed displaying a smaller and more variable phenotype than WT. Furthermore, 
abnormally high and persistent expression of immature muscle genes, Myf5, E2A, and early 
myosin heavy chain isoforms were observed. Importantly, these factors are down regulated 
in WT isolated myoblasts treated with 1α,25-[OH]2D in vitro suggestive of a crucial role for 
Vitamin D in muscle development. This work has stimulated much of the later work 
undertaken in animal and cell models in the context of Vitamin D. 
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Indeed, mice with congenital absence of the VDR show an impaired motor ability (Burne, 
Johnston, McGrath, & Mackay-Sim, 2006). In a series of swimming tests, VDR -/- mice had 
more sinking episodes and reduced post swimming activity versus WT mice. Although these 
data infer a role for Vitamin D in motor function, they do not confirm a causal relationship 
and thus whether these abnormalities are secondary to impairments in other tissue systems is 
unanswered. However, in a recent study some answers have been provided for the previous 
observations made by Burne and are suggestive of an interactive role between the muscle 
and nerve. Vitamin D3 treated mice showed improved locomotive ability (Rotarod exercise 
treadmill running) whereas VDR -/- and untreated mice showed an inability and impaired 
ability to adapt to the exercise, respectively. The data demonstrate that Vitamin D acts 
directly on the skeletal muscle, enhancing myogenic differentiation and also provide novel 
evidence that Schwann cells in peripheral nerves express VDR and respond to Vitamin D3 
exposure. Furthermore, Vitamin D treated mice up regulate IGF-1 production in the 
Schwann cells to regulate neuromuscular maintenance (Sakai et al., 2015). These data 
provide a novel insight that Vitamin D may influence muscle health through direct and 
indirect mechanisms. 
Aside from motor function, Vitamin D may be implicated in skeletal muscle wound healing. 
In order to investigate this potential relationship, Stratos et al. (2013) induced a crush injury 
to the soleus muscle of male rats that had undergone Vitamin D depletion or Vitamin D 
supplemented diets from birth. The rats were then also fed diets supplemented with Vitamin 
D or placebo during the regeneration process over 42 days post insult. Muscle force 
measures and tissue samples were obtained periodically during the 42 days post injury to 
assess the recovery of the soleus functionally and morphologically. The authors report a 
significant increase in cell proliferation and a significant inhibition of apoptosis at day 4 
after injury compared to control animals. SC number was not influenced by the vitamin D 
application, but there was an increase in prolyl-4-hydroxylase-β (P4Hβ) expression, 
suggestive of up regulated extracellular matrix proteins that could potentially improve ECM 
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stability. As a possible consequence of rapid cell proliferation and dampened apoptosis, the 
researchers found a significant improvement in muscle force recovery at day 48 when 
compared with vehicle treated rats. Deficiency may also lead to atrophy and impair the 
ability of muscle to hypertrophy following damage. In order for skeletal muscle to 
regenerate, hypertrophy of the repaired fibres is necessary which is brought about by 
decreased catabolic signalling and increased anabolic signalling. Intriguingly Bhat, Kalam, 
Qadri, Madabushi, and Ismail (2013) have provided evidence that Vitamin D deficient rats 
show muscle atrophy that is driven by up regulation of the ubiquitin proteasome degradation 
pathway in skeletal muscle highlighting the importance of maintaining Vitamin D 
sufficiency during muscle regeneration. 
The described data provide rich evidence for a role for Vitamin D in animals, however there 
is a paucity of information in humans. Despite this, a number of investigations have taken to 
cellular and molecular based investigations to study the bioactivity of Vitamin D on various 
processes in skeletal muscle in order to exploit its therapeutic potential. 
 
2.3.14 Vitamin D and Skeletal Muscle: Cell Models: The primary focus of early in vitro 
investigations into Vitamin D and skeletal muscle was centred on calcium homeostasis. 
Studies on sarcolemma vesicles isolated from Vitamin D-treated chicks show significant 
improvements in Ca2+ and phosphate uptake, greater activity of Ca2+-ATPase and an 
improved ability of mitochondria to accumulate Ca2+ in comparison to those derived from 
deficient chicks. Importantly these effects are not diminished by inhibitors of protein or 
RNA synthesis but are however inhibited by voltage dependent calcium channel (CaV 1.1) 
blockers (de Boland & Boland, 1987). In subsequent spectrofluorometric studies that utilise 
Fura-2-loaded muscle cells, additional information related to the regulation of muscle 
intracellular Ca2+ homeostasis by 1α,25[OH]2D3 was obtained. The data demonstrated that 
the cytosolic Ca2+ response to Vitamin D was mediated by an initial rapid sterol-induced 
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Ca2+ mobilization from IP3 sensitive stores followed by cation influx from the extracellular 
milieu, accounting for a sustained Ca2+ phase, which does not return to basal concentrations 
as long as the cells are exposed to 1α,25[OH]2D3. This Ca2+ influx is mediated not only by 
the well-established VDCC controlled Ca2+ entry but also by a store-operated Ca2+ (SOC) 
channels (Vazquez, de Boland, & Boland, 1997; Vazquez, de Boland, & Boland, 1998). In 
later work, the involvement of protein kinase C (PKC) in upstream Vitamin D signalling was 
established (Massheimer & de Boland, 1992) and also the involvement of G-protein coupled 
receptors and the proto-oncogene tyrosine-protein kinase Src (Buitrago et al., 2000) are 
necessary for these rapid changes in Ca2+[i]. However, 1α,25[OH]2D3 may also indirectly 
modulate Ca2+ homeostasis through stimulation of protein synthesis for a number of 
different proteins related to Ca2+ binding and transport (Drittanti, Boland, & de Boland, 
1989). Recent data suggest that the effects on protein synthesis may not be limited to Ca 
related proteins by showing that treatment of C2C12 murine myoblasts with 1α,25[OH]2D3 
enhances the growth stimulatory effect of insulin and leucine through the Akt/mTOR 
signalling network (Salles et al., 2013). Taken together these findings establish a strong role 
for Vitamin D in calcium homeostasis and a link to growth signalling that may converge to 
regulate many downstream cellular actions. 
Indeed in vitro treatment with 1α,25[OH]2D3 regulates growth, differentiation and survival of 
skeletal myoblasts from both animal and human muscle through similar operational 
networks as in the regulation of Ca2+. Likewise these responses are non-genomic in nature 
occurring within minutes to hours of exposure. In a series of investigations, myoblasts 
treated with varying concentrations 1α,25[OH]2D3 showed dose dependent stimulation of 
mitogenic signalling pathway members ERK1/2, p38 MAPK and JNK and upstream 
involvement of Src kinase and Akt (Buitrago, Arango, & Boland, 2012; Buitrago & Boland, 
2010; Buitrago, Pardo, & Boland, 2013; Buitrago, Pardo, de Boland, & Boland, 2003; 
Buitrago, Ronda, de Boland, & Boland, 2006; Buitrago et al., 2000). 
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The biological significance of these data is contextualised by experiments that have 
investigated cell behaviour in the presence of Vitamin D. Buitrago et al. (2012) effectively 
show that treatment of C2C12 myoblasts with 1α,25[OH]2D3 induces myoblast proliferation 
through a PI3K dependent mechanism and increases Src activity and Akt activation during 
differentiation. However, Srikuea et al. (2012) provide conflicting data suggestive of a 
suppressive effect on proliferation of 1α,25[OH]2D3 treated C2C12 myoblasts but an up 
regulation of the VDR during muscle regeneration. Girgis, Clifton-Bligh, Mokbel, Cheng, 
and Gunton (2014a) demonstrate similar findings in C2C12’s and report a suppression of 
myotube formation but an increase in cross sectional area of myotubes (1.8 fold change). 
The contrasting findings between trials may be attributable to the 1α,25[OH]2D3 doses used; 
Buitrago et al. (2012) utilised a 1 nmol dose whereas Srikuea et al. (2012) and Girgis (2014) 
utilised 20 nmol and 100 nmol, respectively. As Vitamin D possesses great tissue specificity 
and large variation in response between tissues, in some cases opposing effects, it is difficult 
to cross compare in vitro data from other cell models. 
Taken together, exogenous treatment of skeletal muscle progenitor cells and mature 
myotubes in culture results in clear effects on implemented are often supra-physiological 
and thus the translation to whole tissue physiology requires in depth study of the whole 
tissue. As yet, this link between whole muscle and cellular data has not been firmly 
established when considering Vitamin D in the context of muscle function and regeneration 
and thus the physiological significance of the data available are still open to question.  
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2.4 Perspective 
In summary, muscle contraction and regeneration are highly orchestrated processes 
involving input from numerous intracellular and extracellular stimuli, thus there are many 
potential areas for disruption to the normal functioning of skeletal muscle. Exercise plays a 
large role in optimizing these processes, however a number of disease states, heritable 
disorders and modifiable dietary deficiencies may impair contractile activity and muscle 
regenerative capacity. Accumulating data are suggestive that Vitamin D deficiency impairs 
fundamental processes related to muscle contraction such as calcium flux and the expression 
of calcium handling proteins. Further, the sterol may also activate intracellular signalling 
networks that function to stimulate satellite cell proliferation and growth, differentiation and 
survival of skeletal myoblasts. Research interest into Vitamin D and muscle health is 
therefore growing, however is still in its infancy. 
The development of appropriate strategies to correct Vitamin D deficiency will depend on a 
greater understanding of the influence that it plays in skeletal muscle homeostasis. Therefore, 
the overall aim of this thesis is to investigate the role of Vitamin D in non-pathological 
skeletal muscle in the context of muscle contraction and regeneration to identify strategies 
for optimizing Vitamin D status and muscle health. To realise this aim, the following 
objectives will be addressed: 
1. Explore the role of Vitamin D in human skeletal muscle contractile properties in vivo. 
2. Identify the role of Vitamin D in human skeletal muscle contractile properties ex vivo. 
3. Investigate the role of Vitamin D in skeletal muscle regeneration following eccentric 
exercise induced muscle damage in vivo. 
4. Elucidate cellular mechanisms of the muscle regeneration process that are responsive to 
Vitamin D in vitro. 
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Chapter 3 
General Methodology 
  
This chapter describes general methodologies and theory of methodologies adopted in the 
investigations undertaken for this thesis. Assays specific to a methodology adopted in one 
chapter are described within that chapter.  
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3.1 Ethical Approval 
Ethical approval for muscle function analyses and blood sampling procedures was granted 
by the Liverpool John Moores University local research ethics committee. For muscle 
biopsy procedures and tissue analysis, ethical approval was granted by the West Midlands 
National Research Ethics Committee (NREC approval number: WM/09/13). All samples 
and data were treated and stored in line with the Declaration of Helsinki and according to 
Human Tissue Act specifications. 
	  
	  
3.2 General Screening & Inclusion Criteria 
Participants who volunteered to take part in the investigations described in this thesis were 
first screened with a medical history questionnaire and a physical activity readiness 
questionnaire (PAR-Q). Inclusion criteria for all studies were: 
• Male volunteers (to avoid changes in muscle function as a consequence of menstrual 
cycle (Sarwar, Niclos, & Rutherford, 1996) and known sex differences in Vitamin D 
storage (Correale, Ysrraelit, & Gaitan, 2010)) 
• Aged 18-30 
• Free from known medical conditions 
• Not taking prescribed medications 
• Not taking supplemental Vitamin D2 or D3, fish oils or multi vitamins 
• Not sun bed users 
• No planned travel abroad during the study  
• At the standard of readiness to exercise as indicated by PAR-Q 
	  
	  
3.3 Blood Sampling 
For the analysis of Vitamin D metabolites (D2 and D3) and intact parathyroid hormone 
(iPTH), participants provided a fasted venous blood sample collected from the antecubital 
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vein into two K2EDTA plasma (10 ml) vacutainers and two serum separator ((SST) 8.5 ml) 
vacutainers (Beckton Dickinson. Oxford, UK). Serum samples were allowed to clot for 1 
hour at room temperature whilst K2EDTA samples were immediately stored on ice, 
following which all samples were centrifuged for 15 minutes at 1500 RCF at 4oC. Serum and 
plasma were manually extracted and stored at -80oC until required for analysis. 
 
3.4 Quantification of Vitamin D Metabolites 
For the analysis of total serum 25[OH]D concentration high-pressure liquid chromatography 
tandem mass spectrometry (LC-MS/MS) was implemented. The LC-MS/MS method of 
analysis has been validated against other commercially available assays and is regarded as 
the most valid and reliable technique for the assessment of Vitamin D metabolites (Snellman 
et al., 2010). Assays were performed in a Vitamin D External Quality Assurance Scheme 
(DEQAS) accredited laboratory.  
 
3.4.1 LC-MS/MS Principle – LC-MS/MS combines the resolving capability of liquid 
chromatography with the mass analysis ability of mass spectrometry. Therefore, the process 
can be generally categorized into the separation step (step 1), ionization step (step 2) and the 
mass analysis section (step 3). In step 1 the sample (i.e. vitamins purified from serum) is 
forced at high pressure by a liquid (mobile phase) into a column (solid phase) to allow 
separation. In step 2, the sample is charged via atmospheric pressure chemical ionisation 
(APCI), during which a solvent reagent (to allow detection in the final step) ionizes the 
analyte. In step 3, the ions are separated according to their mass-to-charge ratio in an 
analyser by electromagnetic fields. The ions are detected by a quantitative method and the 
signal is then processed into mass spectra  
 
3.4.2 LC-MS/MS Method – For the studies within this thesis, 25[OH]D2, 25[OH]D3 and 
deuterated internal standard were extracted from serum samples following zinc sulphate 
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protein precipitation, using Isolute C18 solid phase extraction cartridges. Potential 
interfering compounds were removed by initial elution with 50% methanol followed by 
elution of the vitamins using 10% tetrahydrofuran in acetonitrile. Dried extracts were 
reconstituted prior to injection into an LC-MS/MS in the multiple reaction mode. The 
multiple reaction mode transitions (m/z) used were 413.2 > 395.3, 401.1 > 383.3 and, 407.5 
> 107.2 for 25[OH]D2, 25[OH]D3, and hexa-deuterated [OH]D3 respectively. The assay was 
validated against published acceptance criteria (FDA, 2001). Assay sensitivity was 
determined by the lower limit of quantification (LLOQ):  25[OH]D3 = 2.5nmol.L-1 and 
25[OH]D2 = 2.5nmol.L-1. Coefficients of variation for the assay were 10% across a working 
range of 2.5 nmol.L-1 to 625 nmol.L-1 for both 25[OH]D2 and 25[OH]D3.  Data validating 
the precision, detection and recovery of the assay are provided in Table 3.1. The assay was 
calibrated using a 3PLUS1 Multilevel Serum Calibrator Set and MassCheck by 
Chromsystems (Chromsystems Instruments and chemicals. Gräfelfing, Germany) control 
standards (lyophilised human serum) were used to monitor accuracy and precision of the 
LC-MS/MS assay. MassCheck calibration materials and controls are traceable against NIST 
972 reference material.  
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Table 3.1. Table A) Imprecision of the LC-MS/MS assay and B) Recovery efficiency of the assay. Intra 
precision was assessed by running quality control materials (Chromsystems) and commercially bought material 
(calf serum) ten times (n=10) within a single run, and separately over 15 runs (n=15) for inter-assay assessment. 
Variation is expressed as standard deviation (SD) and percentage of coefficient of variation (%CV).  
 
A 
Intra-assay 
precision 
Chromsystem 1 Chromsystem 2 Calf serum 
 
nmol.L-1 
Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2 
Mean 42.9 43.4 80.2 81.1 6.9 7.8 
SD 4.1 3.4 7.8 8.6 0.7 0.8 
%CV 9.5 7.8 9.7 10.6 10.1 10.2 
Inter-assay 
precision 
Chromsystem 1 Chromsystem 2 Calf serum 
nmol.L-1 Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2 
Mean 40.4 32.4 76.8 95.3 7.7 7.8 
SD 2.4 3.3 7.2 8.3 0.7 0.9 
%CV 6 10 9.3 8.7 9.1 10.8 
 
 
 
B 
  
 Endogenous 25[OH]D3 
nmol.L-1 
Spiked (nmol.L-1) Measured value 
(nmol.L-1) 
%Recovery 
Sample 1 5.5 50 53.7 96.4 
Sample 2 10.2 100 103.4 93.8 
Blank 0 500 491 98.2 
 Endogenous 25[OH]D2 
nmol.L-1 
Spiked (nmol.L-1) Measured value 
(nmol.L-1) 
%Recovery 
Sample 1 37.0 50 84 96.5 
Sample 2 80.2 100 171.3 95 
Blank 0 500 479 95.8 
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3.5 Muscle Biopsy Procedure 
Participants were instructed to avoid exercise training 48 hours preceding the biopsy 
procedure. On arrival at the muscle biopsy suite at Liverpool John Moores University, 
participants were asked to relax on a hospital bed whilst the biopsy site was prepared. 
Briefly, the incision site (Vastus Lateralis) was shaved to maximise sterility and washed 
with an alcohol swab and Hydrex surgical scrub (ECOLAB Ltd. Leeds, UK) following 
which a sterile sheet was placed around the sterile site. To anaesthetise the biopsy site, 
bupivacaine hydrochloride (Astra Zenica. Luton, UK) was administered at a concentration of 
5 mg.ml-1 (approximately 1.5 ml administered). A sterile single use scalpel was then used to 
penetrate the skin and deep muscle fascia. A Bard disposable core biopsy instrument (12 g x 
10cm. CR Bard Ltd. Crawley, UK) was then used to retrieve three passes of muscle tissue 
from within the incision site (Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Anatomical location of the muscle biopsy procedure (Vastus Lateralis), Bard biopsy needle 
instrument and a muscle biopsy procedure from an investigation within this thesis with an example muscle 
biopsy sample. 
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3.6 Gene Expression Analysis 
For the analysis of gene expression, reverse transcriptase quantitative polymerase chain 
reaction (RT-qPCR) was employed.  
3.6.1 Polymerase Chain Reaction Principle - The method relies on the following principle 
to amply mRNA isolated from a biological sample. Isolated mRNA is first synthesized into 
complementary DNA (cDNA) by reverse transcription using reverse transcriptase and 
nucleoside triphosphates (dNTPs). Complimentary DNA is then heated to denature into two 
single stranded DNA molecules (ssDNA). An optimal temperature for the annealing of 
sequence specific primers (SSPs) and transcription of the target by RNA polymerase is then 
achieved. The detection of amplified product is performed by labelling the cDNA with 
molecules emitting fluorescence, which is proportionally increased with the amplification of 
the cDNA molecules with each cycle of the reaction and is detected in real time (See Figure 
3.2). 
 
 
 
 
 
 
 
 
 
Figure 3.2. Schematic representation of the principle steps in real time quantitative polymerase chain reaction. 
 
80 
	  
3.6.2 RNA Isolation Method - Single step liquid phase separation with guanidinium 
thiocyanate-phenol-chloroform was implemented for the isolation of RNA from cell lysates. 
TRI reagent contains phenol and guanidine thiocyanate that are capable of lysing cells and 
denaturing proteins, therefore TRI reagent also inhibits the activity of DNAse and RNAse 
enzymes thus maintaining RNA integrity in addition to its lysing capability. One ml of TRI 
reagent is ample to isolate RNA from 5-106 cells or 10 cm2 of a cell culture dish of cells 
grown in monolayer. Since monolayers of muscle derived cells are typically seeded at a 
density of 8x105 and grown to confluence on six well plates, a volume of 300 µl per well is 
sufficient to isolate total RNA. The addition of chloroform and the process of centrifugation 
of the lysates result in 3 phases: aqueous phase containing RNA, interphase containing DNA 
and a lower red/pink organic phase containing proteins (see Figure 3.3). The aqueous phase 
is isolated and RNA precipitated from the phase with isopropanol. The precipitated RNA is 
then washed with ethanol to remove residual impurities and then re-suspended in RNA 
storage solution for downstream application of RT-qPCR. 
 
 
 
 
 
Figure 3.3. Example phase separation with TRI reagent. 
To isolate RNA in the studies described in this thesis, cell monolayers were first washed 
twice with PBS to remove any residual media. Three hundred µl of TRI reagent was then 
added to each well of a 6-well plate to lyse the monolayers and isolate total RNA. The TRI 
reagent was left to lyse the monolayers for 5 minutes and then lysates were collected via 
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scraping into RNA free microfuge tubes, briefly vortexed and stored at -80oC until required 
for analysis.  
When analysis was required, 200 µl of chloroform per ml of TRI reagent was added to the 
sample. The mixture was then inverted 2-3 times, shaken vigorously by hand and left to 
stand for 5 minutes on ice before centrifugation at 12,000 RCF for 15 minutes at 4oC. The 
RNA containing aqueous phase was then transferred to a new RNA free microfuge tube for 
RNA precipitation into which 500 µl of ice cold 100% isopropanol per ml of TRI reagent 
used was added. The sample was mixed by hand and left to stand for 10 minutes at RT 
before centrifugation at 12,000 RCF for 10 minutes at 4oC. 
Supernatant was discarded and the RNA pellet was washed with 1 ml of 75% ethanol per ml 
of TRI reagent used. The sample was then vortexed briefly to wash the RNA pellet and 
centrifuged for 5 minutes at 7,500 RCF at 4oC. The wash was discarded and the wash 
processes repeated again. Following the second centrifugation step, the ethanol wash was 
discarded and the sample was left to air dry for 10-15 mins. When the sample was almost 
completely dry, 50 µl RNA storage solution containing 1 mM sodium citrate, pH 6.4 ± 0.2 
(Ambion, Life Technologies. Waltham, MA. USA) was added and mixed by passing the 
solution up and down several times with the pipette tip. Samples were then heated on a 
heating block pre-heated to 60oC for 10 minutes prior to RNA quality and quantity 
measurements. 
3.6.3 Method for Assessment of RNA Quality - RNA purity and concentration were 
assessed by UV spectroscopy, using a Nanodrop UV-vis spectrophotometer (Thermo Fisher 
Scientific. Waltham, MA. USA). The absorbance of the diluted RNA sample was measured 
at 260/280 nm and 260/230 nm, known as RNA purity ratios. 
• A 260/280 ratio of ~2.0 is generally accepted pure for RNA. 
• The 260/230 ratio for pure nucleic acid is typically higher than that of 260/280 with 
common values in the range of 1.8-2.2. 
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An initial cleaning of the measurement surfaces of the spectrophotometer was performed 
with RNA free dH2O. Following cleaning, a blank sample measurement was made by 
pipetting 1 µl of RNA storage solution onto the spectrophotometer for analysis. One µl of 
diluted sample was pipetted directly onto the measurement pedestal to allow good liquid 
column formation and accurate RNA assessment.  
 
 
 
 
 
 
 
Figure 3.4. Example nucleic acid spectral image used to assess RNA sample quality. 
3.6.4 Method of RNA quantification - Absorbance at 260 nm was used to determine the 
RNA concentration, as it is known that a 260 reading of 1.0 is equivalent of 40 µg.ml-1 of 
RNA. For the quantification of nucleic acids, a modified version of the Beer-Lambert 
equation was used by the Nanodrop software. 
 
C =    A×εb  
 
Equation 3.1. The modified Beer-Lambert equation used in the current work to determine RNA concentration 
via spectrophotometric analysis. 
Where: 
• C is the nucleic acid concentration (ng.µl-1). 
• A is the absorbance in AU. 
• ε is the wavelength-dependent extinction coefficient (ng-cm.µl-1). For RNA 
the wavelength-dependent extinction constant is 40 ng-cm.µl-1. 
• b is the path length in cm. 
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3.6.5 Polymerase Chain Reaction Method – For the experiments described in this thesis, 
purified RNA was diluted to 7.3 ng.ml-1 in DNase RNase free H2O (Sigma-Aldrich 
Company Ltd. Dorset, UK) and amplified with specific primer sequences in a rotor-gene Q 
(Qiagen) PCR machine using a one-step SYBR Green I RT-qPCR kit (Qiagen). Briefly, 
double stranded cDNA was first synthesized at 50oC for 10 minutes with the use of dTP 
oligonucleotides and reverse transcriptase. Complimentary DNA was then denatured to 
ssDNA at 95oC for 10 seconds and combined primer annealing and extension was initiated at 
60oC for 30 seconds. The cycle of denaturation and annealing/extension was repeated for 40 
cycles. SYBR Green mix contains a green fluorescent dye (SYBR green) that binds all 
double stranded DNA molecules, emitting fluorescence on binding. The excitation and 
emission maxima for SYBR Green are 494 and 521 nm, respectively. With the use of rotor 
gene Q software, amplification curves for fluorescence were detected in real time throughout 
the PCR run (see Figure 3.5 for example). Primers sequences were designed using National 
Centre of Biotechnology Primer-BLAST software and highly purified salt free primer for 
each sequence was purchased from Sigma-Aldrich.  
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Figure 3.5. a) Design of the polymerase chain reaction protocol used in the experiments described in this thesis. 
b) examples of real time fluorescence detection curves. Cycle threshold is determined from this curve by locating 
the lower third of the curve below the exponential phase of amplification.  
3.6.6 Quantification Method - A method of relative quantification was used to assess 
changes in mRNA expression. Relative quantification determines the changes in steady state 
mRNA levels of a target gene across multiple samples and expresses it relative to the levels 
of a reference gene. To determine the level of expression, the differences (∆) between the 
threshold cycle (Ct) are measured. This method is known as the ∆Ct method (Livak & 
Schmittgen, 2001). In a further step a second relative parameter termed a calibrator sample 
can be added such as an untreated control or a zero hour time point. The latter more complex 
relative quantification method is summarized as the ∆∆Ct method (Livak & Schmittgen, 
2001). 
a 
b 
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For the ΔΔCt calculation to be valid, the amplification efficiencies of the target and the 
endogenous reference must be approximately equal. Therefore, in the investigations within 
this thesis, samples were excluded from analysis if PCR efficiency between target and 
reference gene was not comparable within a CV of 10%. 
 
3.6.7 Method for Assessment of PCR products – Specificity of each PCR was first 
assessed by melt curve analysis. As described earlier, the RT-qPCR protocol was designed 
to include a melting profile once all amplification cycles were complete. During the melt 
cycle, PCR products are reheated at a 1oC every 5 minutes from 50oC to 99oC to produce a 
melt profile that determines whether a specific product was amplified and whether non-
specific RNA has been amplified or if primer dimers have formed. A single sharp peak 
indicates specificity of the primers (see Figure 3.6). 
 
 
 
Figure 3.6. Example melt curve for the reference gene ribosomal protein L13a (RPL13a). 
 
Although melt curve analysis provides an indication of primer specificity, the method cannot 
confirm that the product amplified is the gene of interest since information relating to 
amplicon size is not provided. Such information can be derived by running the PCR products 
through an agarose gel against a DNA ladder to determine amplicon size. In the current 
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work 8 µl of Norgen FullRanger 100 bp DNA ladder was loaded and 8 µl of sample was 
loaded after preparation with a DNA loading dye (Geneflow Ltd. Staffordshire, UK.) into an 
agarose gel (2% Agarose (Bioline Reagents Ltd. London,UK) in 1X Tris-acetate-EDTA 
buffer (Invitrogen, Life Technologies Ltd. Paisley, UK)) prepared with Midori Green 
nucleic acid stain (Nippon Genetics Europe GmbH. Düren, Germany) at a concentration of 
1:200. Samples were electrophoretically separated by passing a 50V current through the gel 
for 20 minutes and a 70V current through the gel for a further 20 minutes. Samples were left 
to run for longer if the loading dye had not migrated ~80% through the lanes by 40 minutes. 
Following electrophoretic separation, gels were placed on a UV transilluminator for 
visualization and analysis. All PCR primer sequences and related information as well as 
agarose gel products can be found in Table 3.2 and Figure 3.7, respectively. 
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Table 3.2. Gene primer sequences for human MDC samples and amplicon lengths. All primers were used in the 
same PCR cycling conditions. 
Gene Accession No. Primer Sequence Amplicon Length (bp) 
Exon 
Junction 
Vitamin D Receptor 
(VDR) NM_001017536 
F GACCTGTGGCAACCAAGACT 174 Reverse 1575/1576 R GGACGATCTGGGGAGACGA 
Myogenin (MYOG) NM_002479.5 
F TCCCAGATGAAACCATGCCC 103 None R AGGCCCCTGCTACAGAAGTA 
Myogenic Regulatory 
Factor 4 (MRF4) NM_002469.2 
F ACCCTTCCTGGCCTAATCCT 
198 None R ACCCTTCCTGGCCTAATCCT 
Ribosomal Protein L13a 
(RPL13A) NM_012423 
F GGCTAAACAGGTACTGCTGGG 
105 Reverse: 230/231 R AGGAAAGCCAGGTACTTCAACTT 
 
 
 
  
VDR	  RPL13A	  
MRF4	   MYOG	  
Figure 3.7. a) Melt curves for all genes assessed in this thesis. b) Electrophoretically separated PCR products used to 
determine primer specificity. Product lengths are; RPL13a = 105bp; VDR = 174 bp; MYOG = 103 bp; MRF4 = 198 bp. 
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3.7 Protein Quantification  
In order to detect changes in enzyme activity (i.e. creatine kinase enzyme activity) via 
enzyme linked immunosorbence assays, total protein concentration was first quantified.  
3.7.1 BCA assay principle - The bicinchoninic acid (BCA) assay is a colorimetric method 
for the quantification of total protein in a sample. The method works on the following 
principle: First in the presence of peptides, a Cu2+ ion is reduced to form Cu1+. The Curprous 
ion is then chelated by BCA resulting in a purple coloured reaction product. The reaction 
product shows strong absorbance at 520 nm that is nearly linear with increasing protein 
concentrations across a broad working range of 20-4000 µg.ml-1 
 
 
 
 
3.7.2 BCA Assay Method - Standards made with bovine serum albumin (BSA) were used 
to determine the concentration of protein (mg.ml-1) based on a standard curve generated 
using a Thermo Multiskan Spectrum plate reader (Thermo Fisher Scientific. Waltham, MA. 
USA). Bovine serum albumin protein standards were prepared at 4, 2, 1, 0.5, 0.25, 0.125, 
0.0625 and 0 mg.ml-1 initially by diluting 4 mg BSA (in 0.9% sodium chloride and sodium 
azide as a preservative; Sigma) with 4.8 ml tris-mes triton (TMT; 50 µM tris-mes, 1% triton-
X 100, pH 7.8) and serially 50 µl of standard with 50 µl of TMT apart from the 0 mg.ml-1 
standard which was TMT alone. 
The BCA reaction materials were purchased as part of a Pierce BCA protein assay kit 
(Rockford, IL, USA). The kit contains two reagents; A & B. Reagent B was made up of 4% 
cupric sulphate and was mixed thoroughly in a multichannel trough with reagent A (sodium 
Protein 
(Cysteine,Tyrosine and 
Tryptophan residues) 
+ Cu2+ 
2 BCA OH- 
Cu1+ BCA-Cu1+ complex 
Colour change à  Purple 
Increased absorbance at 520nm 
Temp dependent 
89 
	  
carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.1 M of sodium hydroxide) at a 
ratio of 1:50. Ten µl of standard, sample and a blank (TMT) were pipetted in duplicate into a 
96 well plate. Two hundred µl of the working reagent was added to all wells using a 
multichannel pipette (excluding the blank), and the plate was incubated at 37oC for 60 mins. 
Following background subtraction, the absorbance was recorded at 30 and 60 minutes at 595 
nM using a Thermo Multiskan Spectrum plate reader. The standard curve was generated by 
plotting the average blank-corrected 595 nM measurement of each BSA standard against its 
pre-programmed known concentration in mg.ml-1. Sample concentrations were calculated 
from the standard curve. 
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3.8 Creatine Kinase Activity 
3.8.1 CK Assay Principle - Creatine kinase activity was used as a marker of myogenic 
differentiation in 2D muscle cell cultures as it is accepted that CK increases correlate with 
increases in fusion (Al-Shanti & Stewart, 2008; Foulstone, Huser, Crown, Holly, & Stewart, 
2004; Foulstone, Meadows, Holly, & Stewart, 2001; Saini, Al-Shanti, Sharples, & Stewart, 
2012; Sharples, Al-Shanti, Hughes, Lewis, & Stewart, 2013). The principle of the method is 
based upon the conversion of PCr and adenosine diphosphate to creatine and adenosine 
triphosphate. The resultant ATP is quantitatively determined by coupling a hexokinase 
reaction and glucose-6-phosphate reaction to 6-phosphogluconic acid and a concomitant 
reduction of NAD to NADH. The reduction of NAD results in an increased absorbency of 
NADH at 340 nm and is directly proportionate to CK activity: 
 
(1) PCr + ADP à Cr + ATP 
(2) ATP + Glucose à ADP + G-6-P 
(3) G-6-P + NAD à 6-PG + NADH 
 
Figure 3.8. Reactions involved in the CK assay. Reaction 1 is catalysed by creatine kinase (CK). Reaction 2 is 
catalysed by hexokinase (HK) and reaction 3 is catalysed by glucose-6-phosphate dehydrogenase (G-6-PDH). 
Abbreviations: PCr = creatine phosphate, ADP = adenosine diphosphate, Cr = creatine, ATP = adenosine 
triphosphate, G-6-P = glucose-6-phosphate, NAD = nicotinamide adenine dinucleotide, 6-PG = 6-
phosphogluconate, NADH = reduced NAD. 
 
3.8.2 CK Assay Method – The assay method is based on that described by the Scandinavian 
Committee on Enzymes and the German Society for Clinical Chemistry (Ljungdahl & 
Gerhardt, 1978; Oliver, 1955; Szasz, Gerhardt, & Gruber, 1977). In the current work, 10 µl 
of TMT cell lysate was loaded in duplicate wells on a 96 well UV plate and used for 
quantification of CK. The creatine kinase reaction reagent and diluent (Catachem Inc. 
Connecticut, US) were prepared as per the manufacturer’s instructions and heated for 2 
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minutes at 37oC. When reconstituted, the reagent contained the following active ingredients: 
30 mmol.L-1 PCr, 2 mmol.L-1 ADP, 5 mmol.L-1 AMP, 2 mmol.L-1 NAD, 20 mmol.L-1 N-
Acetyl-L-Cystine, 3000 U.L-1 HK, 2000 U.L-1 G-6-PDH, 10 mmol.L-1 Mg2+, 20 mmol.L-1 D-
Glucose, 10 µmol.L-1 di(adenosine 5’) pentaphosphate and 2 mmol.L-1 EDTA. The reagent 
mixture was then added to the samples and the change in absorbance monitored 
continuously over 10 minutes in a temperature controlled (37oC) spectrophotometer at a 
wavelength of 340 nm. Calculation of CK concentration was determined by the following 
equation: 
 
 
CK (U.L-1) = 
∆  OD.!"#!! x  0.21  ml  x  10006.22  x  0.01ml  
 
 
Equation 3.2. Equation for the calculation of CK concentration via spectrophotometric analysis. Once 
normalised to total protein the unit of measurement is mU.mg.ml-1 
 
  
Where: 
• Δ OD.min-1 = change in absorbance per minute 
• 0.21 ml = total reaction volume in ml 
• 1000 = conversion of U/ml to U/L 
• 6.22 = extinction coefficient 
• 0.01 ml = serum sample used in assay 
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3.9 Isolation and Characterization of Human Derived Muscle Cells 
3.9.1 Isolation Procedure 
Cells were retrieved from biopsy specimens by implementing a modified method of that 
previously described by Blau and Webster (1981): Biopsy samples were obtained from the 
vastus lateralis via the method described in the section 3.5 of this chapter and samples were 
transferred in pre-cooled transfer media (TM; containing Hams F-10, 2% hiFBS, 1% pen-
strep and 1% amphotericin-B) to the laboratory. This process is unlikely to have affected the 
yield and variability of myoblasts retrieved as previous work has demonstrated that postnatal 
muscle samples can be stored at 4oC in Hams F-10 culture media for up to 24 hours 
following sample isolation with no adverse effects on yield and variability (Blau & Webster, 
1981). To dissociate the tissue, biopsy samples were carefully dissected with a sterile scalpel 
in petri dishes to remove connective tissue whilst still in Hams F-10 TM. Following three 
washes with ice cold PBS + antibiotics (1% pen-strep and 1% amphotericin-B), 5ml Trypsin 
EDTA was added and the samples were scissor minced to fragments <1 mm3. The dissected 
sample was then triturated on a magnetic stirring platform at 37oC. The trypsinization 
process was repeated 2 times in succession and supernatant derived following each treatment 
was collected and pooled with HS at a concentration of 10% of the total volume to inhibit 
further protease activity. Once Trypsin treatments were complete, pooled cell supernatant 
was centrifuged at 1300 rpm for 5 minutes to produce a cell pellet. The supernatant was then 
discarded and the cell pellet re-suspended in GM and plated on a T25 cm2 culture flask for 
cell population expansion.  
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Figure 3.9. Left: fresh biopsy specimen immediately following biopsy procedure. Right: biopsy specimen in 
Tyrpsin EDTA following initial removal of fat and connective tissue, prior to mechanical dissociation to 1mm3 
fragments. 
 
3.9.2. Cell Population Expansion 
Following approximately 10 days in culture, T25 cm2 culture flasks reached ~80% 
confluence and were passaged via trypsinization. Cells were then counted by Trypan Blue 
exclusion and frozen in GM with 10% dimethyl sulfoxide (DMSO) as a cryopreservant or 
re-plated to expand the population. For expansion, cells were grown in GM, which was 
changed every 48 hours following 2 washes with PBS + antibiotics. 
 
3.9.3. Immunocytochemistry 
Immunocytochemistry (ICC) Principle: ICC is a technique that allows the detection of a 
specific antigen (i.e. a protein such as desmin, expressed only in skeletal muscle cells) via 
the use of an antibody. An antibody is a protein complex produced by B cells of the immune 
system. The organization of an antibody includes two functional domains that, resemble the 
letter Y. The antigen binding fragment (Fab) domain makes up the arms of the Y, and at the 
end of each arm is a variable region responsible for antigen binding, called the antigen-
binding site. The Fc domain comprises the tail of the Y, which other antibodies recognize 
primarily. This structure allows direct detection of antigens using a single fluorophore-
labelled antibody or indirect detection through binding of a fluorophore labelled secondary 
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antibody raised against the Fc domain of an unlabelled primary antibody (see Figure 3.10). 
Because the Fc domain is conserved within a species, the labelled secondary antibody can be 
used to detect any primary antibody raised from a single species (Odell & Cook, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When exposed to specific light wavelengths, the secondary antibody containing a 
fluorochrome will emit fluorescence. Fluorescence is a member of the luminescence family 
of processes in which susceptible molecules emit light from electronically excited states 
created by the absorption of light. Briefly, in fluorescence microscopy a wavelength of light 
is focus on the antibody labelled specimen to excite the electrons of the fluorochrome 
molecules to a higher energy state (excitation), known as Stokes shift. Subsequently, the 
excited electron relaxes to a lower energy level and emits light in the form of a lower-energy 
photon in the visible light region. The fluorescence light is then filtered through a dichroic 
mirror and visualised through a microscope (Figure 3.12). 
Figure 3.10. Schematic representation of the principle of immunolabelling. a) the basic components needed for 
immunolabelling including the primary antibody (1o) which is an immunoglobulin specific to a particular antigen  
depicted as a triangle with the abbreviation Ag and the secondary antibody (2o) which is raised against the Fc 
domain of the primary antibody. b) The primary antibody is first bound to the antigen following which the 
secondary antibody will bind to the primary antibody. The fluoroschrome molecule bound to the secondary 
antibody will be excited by specific wavelengths of light that excite the fluorschrome causing it to excite in its 
energy state and emit a light of a different wavelength. 
a b 
95 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fixation: Cell monolayers were fixed at passage 1 for determination of myogenicity (% 
Desmin+ cells). For the fixation of cell monolayers, methanol was used in a graded fashion 
i.e. 25%, 50%, 100% (v/v) in 1x tris buffered saline (TBS) to reduce the morphological 
distortion of nuclear detail and cytoplasm shrinkage that occurs with using absolute alcohol. 
Briefly, GM was aspirated from cell monolayers and the cells were washed twice with PBS 
following which 500µl of 25% methanol solution was added to each well of a six well plate 
for 5 minutes at room temperature. Following the first incubation, methanol solution was 
removed and the process repeated for 50 and 100 %. After the final incubation in 100% 
methanol, 1ml of 1x TBS solution was added to each well until immunocytochemical 
staining was performed. 
 
Figure 3.11. Schematic representation depicting the path of excitation and emission light in a fluorescence 
microscope. Excitation light (blue) is directed onto the sample via the objective. The fluorophore is then excited 
and emits fluorescence (green). The green light is passed through a prism filtering out light of other wavelengths 
and produces an image that can be seen through the eyepiece of camera of the microscope. 
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Staining Procedure: Following fixation, monolayers were stained for Desmin, an 
intermediate filament protein specific to skeletal muscle, to quantify the percentage of 
myogenic cells in the population. Monolayers were first blocked and permeabilized for one 
hour with 500µl of 0.2% Triton-X, 5% Goat Serum in 1x TBS. Following three washes with 
1x TBS, monolayers were incubated overnight at 5oC with 1o Desmin antibody (1:200). 
After overnight incubation, 1o antibody was removed and monolayers washed three times 
with 1x TBS. Secondary antibody TRITC antibody (1:200) was then applied and left for two 
hours at 5oC. Finally, following removal of 2o antibody and three 1x TBS washes, a nuclear 
counterstain (Sytox-Green; 1:5000) was applied and monolayers incubated for 1 hour before 
a final three 1x TBS washes. Monolayers were stored wet in 1x TBS for fluorescent 
imaging.  
 
Cell Counting: Desmin+ cells and total nuclei were counted using ImageJ (NIH) cell 
counter plug-in. Six images were taken per well with an average of 107 (± 46) nuclei 
counted per image. All counting procedures were conducted in duplicate over two wells of a 
6 well plate. The percentage of myogenic cells retrieved from each biopsy specimen can be 
observed in Figure 3.12. 
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Figure 3.12. Representative images showing high (>60%) and low (<25%) Desmin+ cell populations retrieved 
from two different human muscle biopsies. Desmin stained red (TRITC) and nuclear counterstain is green (Sytox 
Green). Images taken with a 10x objective and scale bar is 100 µm. 
 
3.10. Cell Culture 
All cell culture experiments were performed under a Kojair Biowizard Silverline class II 
hood (Kojair. Vippula, Finland). Cells were incubated in a HERAcell 150i CO2 Incubator 
(Thermo Scientific Inc. Cheshire, UK). All liquids, waste media and supernatant were 
discarded via an extraction pump (Charles Austen Pumps Ltd. Surrey, UK). Solutions were 
prepared using dH2O from a MilliQ water purification system (Merck KGaA. Darmstadt, 
Germany). Cell populations were cultured on T75 cm2 (Nunc. Roskilde, Denmark) and T25 
cm2 (Corning Inc., Life Sciences. Massachusetts, US) culture flasks and experiments were 
performed on cell monolayers seeded on sterile six well plates (Nunc. Roskilde, Denmark). 
Culture flasks and six well plates were coated with a 2 mg.L-1 porcine gelatin solution (~90-
110 g Bloom; Sigma-Aldrich Company Ltd. Dorset, UK) to allow cell adhesion via integrin 
binding.  
Participant No. % Desmin+ Cells 
 1 45 
2 43 
3 23 
4 23 
5 51 
6 60 
7 63 
8 44 
9 51 
10 53 
11 20 
12 22 
13 34 
14 56 
Low	  Desmin+	  
High	  Desmin+	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3.11. Reagents 
Dulbecco’s modified eagles medium (DMEM) with added L-Glutamine (2.5 mM) and high 
glucose (4,500 mg.L-1) was purchased from Sigma-Aldrich (Sigma-Aldrich Co. Dorset, 
UK). Sera (goat (GS), horse (HS), heat inactivated fetal bovine (hiFBS) and heat inactivated 
new born calf serum (NBCS)) were purchased from Gibco (Life Technologies. California, 
US). Hams F-10 and MEM-alpha for primary human cell culture were purchased from 
Lonza (Lonza, Basel, Switzerland). Antibiotics (penicillin-streptomycin (PS) and 
amphotericin-B) were purchased from Gibco. Phosphate buffered saline (PBS) for cell 
monolayer washes was purchased in tablet form from Sigma-Aldrich and reconstituted to 
give a working concentration of 0.01 M phosphate buffer, 0.0027 M KCl, and 0.137 M 
NaCl, pH 7.4 in dH2O. We also purchased 1α,25-dihydroxyvitamin D3 from Sigma-Aldrich 
and reconstituted as per the manufacturers guidelines in 100% ethanol. 
 
Myoblast growth media (MGM) for murine C2C12 cells (used in pilot studies for 
optimization of an in vitro model of muscle regeneration, see Chapter 6) consisted of 
DMEM, 10% FBS, 10% NBCS and 1% penicillin streptomycin (50 units penicillin/50 µg 
streptomycin). C2C12 differentiation media (MDM) consisted of DMEM, 1% FBS, 1% 
NBCS and 1% penicillin streptomycin. 
 
Human growth media (GM) used for the expansion of human muscle derived cell 
populations consisted of Hams F-10 growth media with added L-Glutamine (2.5 mM), 10% 
hiFBS, 10% NBCS, 1% PS (50 units penicillin/50 µg streptomycin) and 1% amphotericin B 
(2.5 µg.ml-1). Human differentiation media (DM) consisted of MEM-alpha, 1% hiFBS, 1% 
NBCS, 1% PS (50 units penicillin/50 µg streptomycin) and 1% amphotericin B (2.5 µg.ml-1). 
A quiescent media (QM) used in human MDC pre-treatments consisted of the same 
components as DM however hiFBS and NBCS were added at a concentration of 0.1% each 
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(0.2% serum total). The QM was also used as a transfer media (TM) to transport freshly 
collected biopsy specimens from the biopsy site to the cell culture facility. 
 
3.12. Chemicals and Solvents 
All chemicals and solvents were purchased from Sigma Aldrich and Fisher Scientific. 
Desmin polyclonal rabbit anti-human antibody (Ab 15200) was purchased from Abcam 
(Abcam Plc. Cambridge, UK) and anti-fibroblast monoclonal mouse anti-human antibody 
(clone TE) from Merck Millipore (Merck KGaA. Darmstadt, Germany). Secondary 
fluorophores (Alexa Fluor-488 and TRITC) and nuclear counterstains (DAPI and Sytox-
Green) were purchased from Life Technologies and Sigma-Aldrich. 
 
3.13. Microscopy and Live Imaging 
All cell imaging and photography was performed on a Leica DMI 6000B inverted research 
microscope (Leica Biosystems GmbH. Nussloch, Germany) with recording capability (Leica 
DCF365 FX). For live cell imaging, the microscope was equipped with a heat controller and 
Pecon incubator and CO2 controller (PeCon GmbH. Erbach, Germany) to permit a 
humidified environment of 37oC, 5% CO2 (Figure 3.13). Images were captured with a 10x 
objective and 0.5 magnification c-mount fitted to a camera. 
 
 
 
 
 
 
 
 
Gas	  Control	  
Humidifier	  
Fluorescence	  Control	  
Light	  Control	  
Temperature	  Control	  
Incubated	  Microscope	  
Camera	  
Automated	  Stage	  with	  6	  well	  Plate	  Casing	  
Figure 3.13. Annotated image of live imaging hardware used to perform live imaging experiments and fluorescence 
microscopy. Images are visualized via Leica Application Suite linked to the microscope. 
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3.14. Cell Migration Analysis 
To assess the number of cells migrating into the wound space of the model described in 
Chapter 6, images were split into three equal segments (two outer segments termed segment 
1 and the inner wound area termed segment 2) in the 0 hours wound area as shown in Figure 
3.14 and counted at 48 hours post damage in the experiments described in Chapters 6 & 7. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Representative image of a wound inflicted with a 1ml pipette tip. The wound area is 900 µm in 
width and split into 3 x 300 µm segments. Magnification is 10.5x and scale bar is 100 µm. The out most 
segments are referred to as segment 1 and thr single inner segment is referred to as segment 2.  
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3.15. Statistical Analysis and Graphical Representations 
All statistical analyses were performed using SPSS Predictive Analytics Software (v.20, 
IBM Corporation. New York, US). For the comparison of two group means, a t-test was 
used and where comparison of multiple groups of means was required an analysis of 
variance (ANOVA) was used. Data sets were first checked for normal distribution and 
where data violated the assumption of normality, an appropriate correction factor was used. 
If data violated the assumption of sphericity Greenhouse-Geiser or Huyn-Feldt correction 
factors were used. Where significant main effect and interactions were present, the 
Bonferroni post-hoc pairwise comparisons test was used to detect where significances lay 
between paired comparisons, an analysis that includes correction for an ANOVA’s multiple 
comparisons. Significance was assumed when α reached ≤0.05. All data are presented as 
mean ± standard deviation (SD). All figures were designed in Microsoft Excel v.2011. 
  
102 
	  
Chapter 4 
 
Vitamin D Status and Skeletal Muscle Contractile 
Properties in vivo and ex vivo 
  
This chapter explores the influence of Vitamin D concentration on muscle function in vivo and 
ex vivo. Findings suggest that mild Vitamin D deficiency does not impair skeletal muscle 
performance and opens up further questions as to what degree of deficiency is a threat to 
muscle function. 
Publications resulted from this chapter; Owens D.J., Webber D., Impey S.G., Tang J., Donovan T.F., Fraser 
W.D., Morton J.P. and Close G.L. (2014). Vitamin D supplementation does not improve human skeletal 
muscle contractile properties in insufficient young males. European Journal of Applied Physiology. 
114(6):1309-20. 
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4.1 Abstract 
Purpose – Vitamin D may be a regulator of skeletal muscle function although human trials 
investigating this notion are limited to predominantly elderly populations. The aim of the 
current study was to assess the effect of oral Vitamin D3 in healthy young males upon 
skeletal muscle function. 
Methods - Participants (n = 29) received either an oral dose of 10,000 IU.day-1 vitamin D3 
(VITD) or a visually identical placebo (PLB) for three months. Serum 25[OH]D and intact 
parathyroid hormone (iPTH) were measured at baseline and then at week 4, 8 and 12. 
Muscle function was assessed in n = 22 participants by isokinetic dynamometry and 
percutaneous isometric electromyostimulation at baseline and then at week 6 and 12.  
Results - Baseline mean total serum 25[OH]D was 40.4 ± 16.6 nmol.L-1 and 41 ± 21 
nmol.L-1 for PLB and VITD, respectively. VITD showed a significant improvement in total 
25[OH]D at week 4 (150 ± 31 nmol.L-1) that remained elevated throughout the trial (P < 
0.005). Contrastingly, PLB showed a significant fall in 25[OH]D at week 12 (25 ± 15 
nmol.L-1) compared with baseline. Despite marked increases in total serum 25[OH]D in 
VITD and a fall in PLB, there were no significant changes in any of the muscle function 
outcome measures at week 6 or 12 for either group (P > 0.05).  
Conclusions - Elevating total serum 25[OH]D to concentrations > 120 nmol.L-1 has no 
effect on skeletal muscle function. It is postulated that skeletal muscle function is only 
perturbed in conditions of severe deficiency (<12.5 nmol.L-1). 
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4.2 Introduction 
Vitamin D is classically regarded as a vital endocrine regulator of bone health via its role in 
calcium and phosphate homeostasis (Anderson, Turner, & Morris, 2012). However, a 
myriad of non-skeletal effects of the steroid hormone are now known and are predominantly 
attributable to the identification of the VDR in virtually all tissues (Rosen et al., 2012) 
including skeletal muscle (Srikuea et al., 2012). Genome wide analyses suggest that any 
improvement in vitamin D status significantly affects the expression of a large number of 
genes that have many biological functions (Hossein-nezhad, Spira, & Holick, 2013). 
Specifically regarding skeletal muscle, it has long been understood that patients with 
osteomalacia resultant from inadequate dietary Vitamin D intake often display an 
accompanying skeletal muscle myopathy presenting as a proximal muscle weakness, that is 
responsive to Vitamin D supplementation (Al-Said, Al-Rached, Al-Qahtani, & Jan, 2009; 
Irani, 1976; Smith & Stern, 1967; Ziambaras & Dagogo-Jack, 1997). Emerging data now 
suggest at a cellular level that skeletal muscle is indeed a tissue that responds functionally to 
Vitamin D. Recent data have demonstrated in vivo, improvements in mitochondrial oxidative 
function when severe Vitamin D deficiency is corrected in humans (Sinha et al., 2013). 
Moreover, studies in chick embryo myoblast cultures have provided robust evidence that 
Vitamin D is a regulator of intracellular Ca2+ concentration (Capiati, Vazquez, Tellez Inon, 
& Boland, 2000; Morelli, de Boland, & Boland, 1993), which has also been observed in vivo 
in chicks (Vazquez, Boland, & de Boland, 1995) and in vitro in fully differentiated soleus 
muscle (de Boland, Massheimer, & Fernandez, 1988). Vitamin D may therefore be 
implicated in skeletal muscle contractility, which early reports from Vitamin D depleted rats 
have alluded to (Rodman & Baker, 1978). Aside from these observations, reports suggest a 
role for the bioactive 1α,25[OH]D in signalling pathways involved in myoblast proliferation 
and differentiation indicating a key role for Vitamin D in muscle cell development and 
survival (Garcia, Ferrini, Norris, & Artaza, 2013; Srikuea et al., 2012; Stratos et al., 2013). 
Despite such evidence, Vitamin D deficiency is still widespread around the globe (van 
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Schoor & Lips, 2011). This observation is consistent in sub-populations of professional 
athletes and otherwise-healthy, young athletic cohorts (Close et al., 2013a; Close et al., 
2013b; Morton et al., 2012a) 
A number of trials have sought to assess the effect of Vitamin D status on muscle function at 
a macroscopic scale. Insights from these investigations have established a link between 
Vitamin D concentration and falls and various other physical performance measures such as 
handgrip, lower limb strength, balance and gait speed (Bischoff-Ferrari et al., 2004b; 
Gerdhem, Ringsberg, Obrant, & Akesson, 2005; Houston et al., 2007; Marantes et al., 2011). 
However, such trials are limited to predominantly geriatric or clinical populations and it is 
difficult to generalise such findings to young otherwise healthy populations, due to age-
related skeletal muscle disease (i.e. sarcopenia). The few trials that have been conducted in 
young otherwise healthy cohorts have resulted in equivocal findings, with some 
investigations reporting beneficial effects of Vitamin D supplementation in muscle (Close et 
al., 2013b; Sinha et al., 2013) and others observing no perceptible changes following 
supplementation (Close et al., 2013a). Hampering such findings further is the large 
heterogeneity in outcome measures implemented to assess muscle function, low participant 
numbers, heterogeneity in supplementation protocols and varying baseline Vitamin D status 
of the sample population making cross comparison between findings difficult.  
Adding further complexity to this issue is that the daily requirement for vitamin D needed to 
elevate total serum Vitamin D concentrations to a level necessary for optimal physiological 
function is a point of debate. With regard to dose, the United States Institute of Medicine 
(US IoM) has set the RDI for Vitamin D at 600 IU.day-1 for young adults and tolerable upper 
intake at 4,000 IU.day-1 (IoM, 2011), although the US IoM set the ‘no observed adverse 
effect limit’ (NOAEL) at 10,000 IU·day-1 (IoM, 2011). In relation to total serum 25-
hydroxyvitamin D (or 25[OH]D) concentration, the US IoM suggest > 50 nmol.L-1 as 
adequate whilst suggesting that concentrations exceeding 125 nmol·L-1 may be detrimental 
to health. Others have suggested these guidelines are too conservative and claim values 
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exhibited in those living outdoors in sun-rich climates (~100 nmol.L-1) to be adequate, since 
they reflect the values present when the human genome evolved in such rich environments 
around equatorial Africa (Heaney, 2011; Vieth, 2011). An ‘optimal’ 25[OH]D concentration 
for muscle function is currently still elusive and no study to date has tested the hypothesis 
that elevating serum 25[OH]D concentrations to >120 nmol.L-1 is optimal for muscle 
function in healthy recreationally active individuals, as previously suggested (Heaney, 2011). 
Our group has previously implemented doses of 20,000 IU.week-1 and 40,000 IU.week-1 oral 
Vitamin D3, but failed to elevate serum concentrations > 100 nmo.L-1 (Close et al., 2013a). 
Thus higher doses may be necessary to achieve a total serum 25[OH]D concentration > 100 
nmol.L-1. 
Given the available evidence and a clear lack of data in the area, the main objective of the 
current investigation was to explore the impact of Vitamin D concentration on lower limb 
muscle function using valid macroscopic techniques including percutaneous isometric 
electromyostimulation (EMS) and isokinetic dynamometry (IKD) in otherwise healthy, 
recreationally active young men. It was hypothesized that supplementing with high dose oral 
Vitamin D3 (cholecalciferol) to elevate total serum 25[OH]D concentrations > 100 nmol.L-1 
(suggested optimal Heaney, 2011; Vieth, 2011; Zittermann, 2003) would have a beneficial 
effect on our chosen outcome measures of muscle function. 
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Vitamin D and Skeletal Muscle Contractile Properties In Vivo 
4.3 Aims and Hypotheses 
The primary aim of this investigation was to examine whether improving Vitamin D 
concentration (serum 25[OH]D) with supplemental Vitamin D3 improves parameters of 
muscle function in healthy young males. It was hypothesized that improving Vitamin D 
concentration will result in a positive change in skeletal muscle function. 
 
4.4 Methodology 
4.4.1 Participants 
Twenty-nine male participants (age = 22.7 ± 3 years; height = 179.3 ± 5.9 cm; weight = 76.1 
± 16.2 kg) volunteered to partake in the current trial. Participants were screened for inclusion 
as described in the General Methods chapter of this thesis. After meeting this initial 
inclusion criteria, participants provided a venous blood sample that was analysed for total 
25[OH]D via LC-MS/MS as described in detail in section 3.4 of the General Methods 
chapter of this thesis. Those presenting with total serum 25[OH]D concentrations ≥ 100 
nmol.L-1 were excluded from the trial. This was based on suggestions that > 100 nmol.L-1 is 
necessary for optimal health and associated with serum concentrations of individuals 
regularly exposed to sunlight near the equator (Zittermann, 2003). Ethical approval was 
granted by the local ethics committee of Liverpool John Moores University and all data were 
collected in accordance with the Declaration of Helsinki. 
Participants were initially block randomized on their baseline 25[OH]D concentration and 
electrically evoked 20 Hz isometric knee extensor force into two experimental groups. Of 
the 29 initial participants, 22 completed all test procedures whilst the remaining 6 only took 
part in supplementation and blood sampling and one dropped out completely. This was due 
to an inability on the participants’ behalf to commit sufficient time for each testing point. 
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Fourteen participants were assigned to an oral Vitamin D treatment group (VITD) and 15 
participants were initially assigned to a visually identical placebo control group (PLB (see 
Table 4.1. below).  
Table 4.1. Block randomization data including mean total serum 25[OH]D concentration presented as nmol.L-1 
and mean isometric force from a single stimulation at a frequency of 20 Hz and stimulation intensity of 130 mA.  
 PLB (n = 11) VITD (n = 11) 
Mean total 25[OH]D (nmol.L-1) 40 41 
±SD 17 21 
t-test t = 0.867, P = 0.876 
Mean Isometric Force (N) 267 306 
±SD 69 67 
t-test t = -1.086, P = 0.303 
 
4.4.2 Vitamin D Supplementation 
 
Participants allocated to VITD received 10,000 IU·day-1 of vitamin D3 (Bio-Tech Pharmacal. 
Arkansas, US) taken as two 5,000 IU gelatin capsules. Those allocated to PLB received two 
visually identical placebo capsules each containing 90 mg cellulose (Bio-Tech Pharmacal. 
Arkansas, US). The supplementation period lasted 12 weeks between the months of January 
and April in order to achieve a plateau in serum 25[OH]D response, as previously shown in 
a dose response trial with 10,000 IU.day-1 vitamin D3 cholecalciferol (Heaney, Davies, Chen, 
Holick, & Barger-Lux, 2003). Both researcher and participant were blinded until completion 
of the study procedures. 
4.4.3 Whole Muscle Force Measurements 
A number of outcome measures were employed to validly assess muscle function of the 
lower limb. Participants completed both an isokinetic dynamometry (IKD) protocol and 
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electromyostimulation (EMS) protocol. All tests were completed at baseline, week 6 and 
week 12 of supplementation apart from IKD, which was only completed at baseline and 
week 12. 
 Isokinetic Dynamometry (IKD) 
Isokinetic torque was assessed on a Biodex isokinetic dynamometer (Biodex Medical 
Systems Inc. Shirley, NY), previously validated for its use in reliable assessment of muscle 
function variables related to force production (Drouin et al. 2004). Participants were seated 
as per the manufacturer’s guidelines with a 90-degree flexion of the hip and non-extendable 
straps crossing the chest and abdomen and across the quadriceps to maximise isolation of the 
target muscle group (Figure 4.1). The test protocol consisted of four consecutive maximal 
extension and flexion movements of the right quadriceps and hamstrings at two different 
fixed movement velocities, 1.05 rad.sec-1 (60 deg.sec-1) and 3.14 rad·sec-1 (180 deg.sec-1) 
from which peak torque (Nm) was generated, separated by a five minute rest to allow full 
recovery of the high energy phosphate pool (Soderlund and Hultman 1991). All participants 
were familiarized with the protocol until the co-efficient of variation for each participant was 
< 10% (Atkinson and Nevill 1998). See Table 4.2. 
 
 
 
 
 
 
 
Figure 4.1. IKD experimental set up. Left: participant at full extension. Right: participant at full flexion. 
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Table 4.2 Co-efficient of variation for each isokinetic dynamometry variable. Data are presented as group means. 
1.05 rad·sec-1 = 60 deg·sec-1; 3.14 rad·sec-1 = 180 deg·sec-1. Based on n = 22. 
Measurement 
Variable 
Flexion  
1.05 rad·sec-1  
Extension  
1.05 rad·sec-1  
Flexion  
3.14 rad·sec-1  
Extension  
3.14 rad·sec-1  
CV% 3.9 3.7 4.9 4.1 
 
Electromyostimulation (EMS) 
Stimulation was applied through surface electrodes, delivered via a BIOPAC systems 
MP100 stimulator (BIOPAC systems inc, Santa Barbara, CA) and knee extension forces 
were recorded with a tension compression load cell (Tedea-Huntleigh, Vishay Precision 
Group Inc. Malvern, PA) connected to a non-extendable strap attached to the participant’s 
lower leg approximately 5-8 cm from the malleolus. Information collected from the force 
transducer was visualized and analysed using AcqKnowledge v.3.7.2 software (BIOPAC 
systems inc. Santa Barbara, CA). Muscles were stimulated at an intensity of 130 mA for 
each test procedure as described previously (Gerrits et al. 2002).  For the determination of 
muscle contractile properties, contraction was evoked by a 1 Hz twitch. For the 
determination of fatigue resistance, contractions were evoked by 20 Hz, 0.2 sec square wave 
pulses, previously defined to be representative of normal voluntary human motor neurone 
firing rates (Bigland-Ritchie et al. 1979) and thus physiologically valid when used to assess 
the fatigue resistance of human skeletal muscle.  
For every session, the position of the participant in the isometric chair (Lido Active, Loredan, 
Davis, CA, USA) was standardized in accordance with guidelines previously published 
(Morton et al. 2005). Two 3 x 5 inch (8 x 13 cm) oval self-adhesive stimulating electrodes 
(Chattanooga, DJO Global, CA, USA) were placed approximately 5 cm above the knee joint 
across the vastus medialis (VM) and proximal to the acetabulofemoral joint across the vastus 
lateralis (VL), as shown in Figure 4.1. Participants were required to fully extend and 
contract the quadriceps to make the muscle body more apparent prior to electrode placement 
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to minimise antagonist co-activation, although this was not monitored with 
electromyography during stimulation.  
 
 
 
 
 
 
 
 
 
Figure 4.2. EMS experimental set up. Left: participant fully secured in the isometric chair. Right: placement of 
the electrodes used to deliver electrical stimuli. 
 
To determine time to peak twitch and half relaxation time, a 1 Hz, 0.2 sec square wave pulse 
was administered. Time to peak twitch was measured as the time taken to reach peak 
isometric force from the onset of stimulation. Half relaxation time was determined as the 
time from peak stimulated force to reach half peak stimulated force (see Figure 4.3 a). 
Fatigue resistance was determined from two minutes repeated stimulation with 20 Hz, 200 
msec square wave pulses every 750 msec (total of 160 evoked contractions equating to 32 
secs of total stimulation). Fatigue index was calculated as the percentage force loss from the 
highest recorded contraction to the lowest recorded contraction (see Figure 4.3 b). Test retest 
reliability data revealed that the CV% for time to peak twitch and for ½ relaxation time as 
determined by a 1 Hz twitch at 130 mA was 4.5% and 5.7%, respectively. 
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Figure 4.3. a) Example twitch feedback curve obtained from a 200 ms square wave pulse of 130 mA at a 
frequency of 1 Hz. b) Example fatigue data from two minutes repeated stimulation with 20 Hz, 200 msec square 
wave pulses every 750 msec. Representative output taken from AcqKnowledge software.  
  
a 
b 
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4.4.4 Statistical Methods 
Statistical analyses were performed as described in the Chapter 3 of this thesis. In addition, a 
power calculation was performed a priori using Minitab software (v.16) to allow for any 
dropouts based on detecting a significant change in serum 25[OH]D and increased peak 
torque in response to Vitamin D supplementation. Pilot work from our laboratories during 
the winter months suggested that the standard deviation for test–retest serum 25[OH]D 
concentrations (taken 6 weeks apart) in young athletes is ∼12 nmol.L-1. Furthermore, 
previous work from our laboratory demonstrated that standard deviation in isokinetic torque 
at 1.04 rad·sec-1 (60 deg·sec-1) is ~35 Nm. To enable the detection of a 50 nmol.L-1 increase 
in total serum 25[OH]D concentration  between pre-supplementation and post-
supplementation with 80% power and a 10% (21 Nm) increase in peak torque between pre-
supplementation and post-supplementation with 80% power, n = 12 per experimental group 
was required. Therefore, initially 30 participants were recruited to allow for dropouts and 
maintain statistical power. Finally, a linear regression was plotted using Pearsons correlation 
to assess whether baseline 25[OH]D concentration was a predictor of Δ serum 25[OH]D in 
response to supplementation.  
 
 
 
 
 
Figure 4.4. Sample size calculation based on detecting a meaningful change in a) total serum 25[OH]D and b) 
peak isokinetic torque. 
 
 
a b 
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4.5 Results 
Baseline Total Serum 25[OH]D is a Predictor of Response to Supplementation 
	  
Regression analysis determined that pre-treatment Vitamin D concentration was a strong 
predictor of 25[OH]D response to supplementation in VITD, where 83% of the variation in 
response to supplementation was attributable to baseline concentration (Figure 4.5.).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Linear regression describing the relationship between baseline Vitamin D status and response to 
supplementation. Baseline total 25[OH]D concentration is the predictor variable whilst change in total 25[OH]D 
at 12 weeks is the response variable.  
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Response of Total Serum 25[OH]D and iPTH to Supplemental Vitamin D3 
There was a significant interaction between treatment group and time for total serum 
25[OH]D (P < 0.005) where there was a significant main effect for both time (P < 0.005) 
and treatment group (P < 0.005); Participants in VITD demonstrated significantly elevated 
total serum 25[OH]D concentrations at week 4 compared with baseline (pre = 41 ± 21 vs 
week four = 150 ± 31 nmol.L-1) , that remained elevated throughout the trial (week twelve = 
127 ± 31 nmol.L-1). Contrastingly, participants in PLB displayed total serum 25[OH]D 
concentrations significantly lower at week 12 compared with baseline ((pre 40 ± 17 vs week 
twelve = 25 ± 14 nmol.L-1) see Figure 4.6 a). VITD showed no significant change in iPTH 
concentration throughout the trial (P = 0.322) whereas PLB showed a significant increase in 
iPTH concentration at week 4 ((pre = 2.45 ± 0.61 vs week four = 5.01 ± 1.09 pmol.L-1) P < 
0.005), which remained elevated throughout the trial (see Figure 4.6 b.) showing an inverse 
relationship with serum 25[OH]D. 
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Figure 4.6. a) Response of total serum 25[OH]D to 12 weeks supplementation with 10,000 IU·day-1 vitamin D3 
or placebo. b) Response of intact parathyroid hormone to 12 weeks supplementation with 10,000 IU·day-1 
vitamin D3 or placebo. * denotes significance to baseline (P < 0.05). 
	    
a 
b 
*	  
*	  
*	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Maximum Voluntary Contraction 
 
There was no significant interaction between experimental groups for peak torque 
production at prior to and following the supplementation protocol at 60 deg.sec-1 extension 
(P = 0.163) and flexion (P = 0.807) or 180 deg.sec-1 extension (P = 0.269) or flexion (P = 
0.940  (Figure 4.7)), indicating that increasing serum 25[OH]D did not affect the maximal 
force producing capacity of the lower limb at two dynamic movement velocities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.  Peak torque from maximal extension (ext) and flexion (flex) of the right lower limb at two fixed 
velocities of 1.05 rad·sec-1 (60o·sec-1) and 3.14 rad·sec-1 (180o·sec-1) prior to and following 12 weeks 
supplementation with 10,000 IU·day-1 Vitamin D3 (grey bars) or placebo (black bars). 
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Fatigue Resistance 
The effects of Vitamin D supplementation on fatigue resistance of the VL & VM muscles 
can be seen in Figure 4.6. Data are presented as absolute maximal force (Figure 4.8 a) and 
percentage of maximal force (Figure 4.8 b) although statistical analysis was performed on 
the fatigue ratio of absolute data only. No significant interaction was detected between 
treatment group and time i.e. baseline, week 6 and week 12 (P = 0.134). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. a) Absolute isometric force and b) percentage force loss during 120 sec of repeated unilateral lower 
limb stimulation from an electrically evoked square wave pulse of 0.2 msec, 20 Hz and a stimulation intensity of 
130 mA, every 750 ms. Data presented prior to supplementation (baseline) and then at week 6 and 12 of 
supplementation. 
a 
b 
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Time to Peak Twitch and Half Relaxation Time 
No significant interaction was detected between treatment group and time (baseline, week 6 
and week 12) for time to peak isometric twitch force (P = 0.968) or half relaxation time (P = 
0.924; Figure 4.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Muscle contractile properties from an electrically evoked 1 Hz twitch and a stimulation intensity of 
130 mA. Data are displayed from baseline, 6 weeks and 12 weeks of supplementation with 10,000 IU.day-1 
Vitamin D3 or placebo. 
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4.6 Discussion 
The aim of the current study was to investigate the impact of Vitamin D concentration on 
muscle function in otherwise healthy, recreationally active young men. It was hypothesized 
that supplementing with oral Vitamin D3 (cholecalciferol) to elevate total serum 25[OH]D 
concentrations would have a beneficial effect on muscle function. However, although it was 
demonstrated that in a population of predominantly Vitamin D inadequate young men, 
supplementation with 10,000 IU.day-1 effectively elevated total serum 25[OH]D 
concentration to values > 100 nmol.L-1, this had no effect (positive or negative) on muscle 
force, muscle fatigue or muscle contractile properties. 
The primary findings are in agreement with other RCTs assessing the impact of Vitamin D 
supplementation on skeletal muscle function. Previous data have demonstrated in a sample 
of 30 club level athletes with a mean 25[OH]D concentration of 51 nmol.L-1 (SD ± 24 
nmol.L-1) that neither 20,000 or 40,000 IU.week-1 of Vitamin D3 for 12 weeks were effective 
in improving 1-RM bench press, leg press or vertical jump height although both doses 
achieved a significant elevation of total serum 25[OH]D (20,000 & 40,000 IU.day-1 Vitamin 
D3  = 85±10 nmol.L-1 & 91±24 nmol.L-1, respectively) after 12 weeks (Close et al., 2013a). 
Similarly, others studies predominantly undertaken in elderly cohorts have failed to detect 
improvements in parameters of muscle strength following supplementation (Kenny, Biskup, 
Robbins, Marcella, & Burleson, 2003; Kukuljan et al., 2011).  
The current study also found that elevating serum 25[OH]D >100 nmol.L-1 does not reduce 
the force producing capacity, fatigue resistance or contractile properties of skeletal muscle in 
humans, an idea that has previously been suggested. One randomized controlled trial has 
previously reported that annual high dose Vitamin D3 (500,000 IU) effectively elevated 
serum concentrations of 25[OH]D to approximately 120 nmol.L-1 in community dwelling 
older women (Sanders et al., 2010). However, this resulted in an increased risk of falls and 
fractures compared with a placebo control group. This observation could be attributable to 
the dosing strategy implemented, as smaller but more frequent doses in other RCTs do not 
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show comparable findings. Furthermore, although Sanders et al. state that baseline 
prevalence of risk factors for falls and fractures were similar in both the supplemented and 
placebo groups, the physical activity profile of the two experimental groups is not reported. 
This is a confounding factor given that physical activity is a valuable counter measure for 
sarcopenia (Forbes, Little, & Candow, 2012), thus disparity in the physical activity profile of 
the two experimental groups is of importance when interpreting this data.  
Intact parathyroid hormone concentration was also assessed in the current study and 
displayed an inverse relationship with serum 25[OH]D, in line with previous data (Sai, 
Walters, Fang, & Gallagher, 2011). The placebo group showed elevated iPTH concentration 
whereas the opposite was observed for VITD, which may be explained by the understanding 
that 1,25-dihydroxyvitamin D represses the transcription of the PTH gene and also indirectly 
regulates PTH secretion by regulating the expression of calcium sensing receptors (Kumar & 
Thompson, 2011). Thus, in addition to providing evidence that there is no negative effect of 
high serum 25[OH]D concentrations (> 100 nmol.L-1) on skeletal muscle function, it is 
demonstrated that the supplementation protocol chosen offers a positive effect on the 
maintenance of iPTH concentrations. Some authors suggest that high serum 25[OH]D 
concentrations (> 100 nmol.L-1) may indeed be necessary for prevention of diseases such as 
tuberculosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases, 
hypertension, and specific types of cancer (Heaney, 2011; Vieth, 2011), thus the current data 
would imply that such concentrations needed to optimise other biological functions are 
unlikely to be detrimental to the normal function of skeletal muscle. 
It is important to also consider the available evidence that suggests Vitamin D 
supplementation has a beneficial impact on muscle function. Case studies describe a 
proximal muscle weakness associated with nutritional osteomalacia that is responsive to 
supplementation with Vitamin D implying that improving Vitamin D status can improve 
musculoskeletal function (Al-Said et al., 2009; Irani, 1976; Smith & Stern, 1967; Ziambaras 
& Dagogo-Jack, 1997). Additionally, in a recent report and in contrast to the current findings, 
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an improvement in 10-m sprint times and vertical jump height following supplementation in 
a group of Vitamin D deficient young athletes has been observed (Close et al., 2013b). In a 
sample of severely deficient individuals (< 15 nmol.L-1), supplementation with 20,000 IU of 
Vitamin D3 on alternate days for 10-12 weeks significantly elevated serum 25[OH]D (> 100 
nmol.L-1) and resulted in significant improvements in phosphocreatine recovery half-time 
(τ½ PCr) of the soleus muscle, indicative of improved mitochondrial oxidative function as 
measured by 31P-magnetic resonance spectroscopy (Sinha et al., 2013). The disparity 
between findings may be explained by a recent systematic review and meta analysis 
(Stockton, Mengersen, Paratz, Kandiah, & Bennell, 2011). It was found that although 
participants with baseline total serum 25[OH]D >25 nmol.L-1 show no change in muscle 
strength with Vitamin D supplementation, a limited number of  trials demonstrate an 
increase in proximal muscle strength in adults with Vitamin D deficiency (<25 nmol.L-1). It 
is reasonable to postulate based on such findings, that skeletal muscle function only displays 
perceptible perturbations in function when Vitamin D status of the sample population 
reaches concentrations < 25 nmol.L-1 as suggested by Stockton et al. (2011). 
 
 
 
 
 
 
 
Figure 4.10. Schematic representation of a proposed theory that functional decrements occur in muscle when 
Vitamin D status is deficient. No additive improvements occur at concentrations > 25 nmol.L-1. (Reviewed 
citations taken from systematic review and meta analysis by Stockton et al., 2011). 
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Taking the available evidence into account, it can be proposed that a possible reason that an 
improvement in muscle function was not detected in the current study, is because muscle 
function was not impaired to begin with, as only a small number (n = 4) of participants had 
total serum 25[OH]D concentrations < 25 nmol.L-1 and no participants presented with severe 
Vitamin D deficiency. If one assumes a sigmoidal physiological response of skeletal muscle 
to Vitamin D, it may be difficult to detect a response when nutrient status is already on the 
ascending limb or plateau of the response curve (Lappe & Heaney, 2012). Thus skeletal 
muscle may only display sharp decrements in function at serum 25[OH]D concentrations < 
25 nmol.L-1 and thereafter show no perceptible added benefit of increasing concentrations. 
This could be due to a disturbance of systemic and intracellular calcium concentrations that 
occurs in severe deficiency, affecting both contractile activity and intracellular signalling, a 
notion previously put forward (Girgis, Clifton-Bligh, Hamrick, Holick, & Gunton, 2012). 
Although speculative, this would explain much of the human data available on Vitamin D 
status and muscle function. 
As described, in the current study only four participants from the supplemental Vitamin D 
group exhibited serum 25[OH]D <25 nmol.L-1 (range = 16 – 25 nmol.L-1). In keeping with 
the notion that such concentrations associate with perturbed muscle function, these data sets 
were extracted from the group and analysed as a sub group. However, despite all participants 
improving serum 25[OH]D from < 25 nmol.L-1 to > 75 nmol.L-1 no changes MVC torque at 
60 deg.sec-1 extension (pre test = 232 ± 11.2 vs 12 weeks = 241 ± 41 Nm), 60 deg.sec-1 
flexion (pre test = 132 ± 20 vs 12 weeks = 131 ± 22 Nm), 180 deg.sec-1 extension (pre test = 
177 ± 34 vs 12 weeks = 186 ± 19 Nm) and 180 deg.sec-1 flexion (pre test = 108.7 ± 19 vs 12 
weeks = 110.8 ± 19.9 Nm) were detected. Similarly, involuntary functional measures 
including time to peak tension (pre test = 0.114 ± 0.006 vs post test = 0.115 ± 0.007 sec) and 
half relaxation time (pre test = 0.069 ± 0.009 vs post test = 0.061 ± 0.004 sec) were also 
unchanged (P > 0.05). Data are presented in Figure 4.11 
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Figure 4.11. Sub group analysis of four individuals presenting with < 25 nmol.L-1 total serum 25[OH]D 
corrected to > 100 nmol.L-1 with twelve weeks supplementation of Vitamin D3 (10,000 IU.day-1). a) peak 
isokinetic torque of the knee extensors and flexors at 60 and 180 deg.sec-1. b) time to peak tension and c) half 
relaxation time of the knee extensors. 
 
In summary, the data presented from the first investigation of this determined that at the 
whole tissue level, supplemental Vitamin D to increase total serum 25[OH]D >100 nmol.L-1 
offered no benefit to skeletal muscle contractile properties. Retrospective analysis of the data 
and available literature would suggest that this is because serum concentrations of 25[OH]D 
in the range of deficiency (possibly <25 nmol.L-1) are necessary to hinder musculoskeletal 
performance. However, when a small sub group of individuals with serum 25[OH]D <25 
a 
b c 
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nmol.L-1 were analysed, still no changes in muscle function were observed. On the other 
hand, the investigative outcome measures may not have been sensitive enough to detect 
decrements in muscle function at the whole tissue level. 
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Vitamin D and Skeletal Muscle Contractile Properties Ex Vivo 
4.7 Aims and Hypotheses 
As a subsequent investigation to study 1, the present study aimed to examine skeletal muscle 
contractile properties at the single fibre level from individuals with serum 25[OH]D 
concentrations ≤25 nmol.L-1. The single fibre technique allows for a more sensitive measure 
of cross bridge kinetics to be studied in the absence of other contributors to muscle specific 
tension. It was hypothesized that supplementation to improve serum 25[OH]D >75 nmol.L-1 
from a level of deficiency will result in improvements in skeletal muscle contractile 
properties undetectable at the whole muscle level.   
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4.8 Method 
4.8.1 Participants  
Two young, healthy and physically active males met the inclusion criteria (Chapter 3, 
section 3.2) and were permitted in the trial (see Table 4.3). The participants were selected 
based on their basal 25[OH]D and willingness to provide a muscle biopsy for the isolation of 
single muscle fibres.  
4.8.2 Vitamin D Supplementation 
Participants were supplemented with 4,000 IU.day-1 Vitamin D3 for eight weeks during the 
months February through March. Although the dose of 10,000 IU.day-1 was chosen in study 
1, recent reports from the European Food Safety Authority (EFSA) suggest a 4,000 IU.day-1 
upper limit for Vitamin D3 intake (EFSA, 2012). Blood samples were drawn pre and post 
supplementation and analysed for total serum 25[OH]D as described in the General Methods 
chapter of this thesis. 
Table 4.3. Participant characteristics and baseline Vitamin D status. 
Participant Age (years) Height (cm) Weight (kg) Basal 25[OH]D 
(nmol.L-1) 
1 29 186 95 23 
2 22 183 82 25 
 
4.8.3 Muscle Biopsy 
Muscle biopsies were obtained as described in the General Methods section to this thesis. 
Biopsy passes were immediately transferred to ice cold relax solution containing (in mM) 
4.5 MgATP, 1 free Mg2+, 10 imidazole, 2 EGTA, and 100 KCL (pH 7.0 at 4oC) (Degens et 
al., 2010). In order to preserve the biopsy passes for later analysis, biopsy specimens were 
transferred to 0.5 mol.L-1 sucrose relax, 1 mol.L-1 sucrose relax, 1.5 mol.L-1 sucrose relax 
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and 2.0 mol.L-1 sucrose relax, each for 30 min. The fibre bundles were then snap frozen in 
liquid nitrogen and stored in pre-cooled centrifuge tubes at -80oC. For thawing, the opposite 
procedure was followed (Frontera & Larsson, 1997). 
4.8.4 Single Fibre Preparation 
Single muscle fibres were isolated from biopsy specimens and maintained in ice-cold relax 
solution. Fibres were treated with 50 µg.ml-1 saponin from Quillaja bark (Sigma Aldrich) in 
relax solution for 15 minutes on ice to permeabilize the fibre. Saponins selectively interact 
with cholesterol on the fibre sarcolemma and remove it to create pores. Fibres were then 
mounted onto an 802D permeabilized fibre apparatus (Aurora Scientific. Ontario, Canada) 
and were attached to insect pins affixed to a 403A (5mM) force transducer and 312C length 
controller, using ultra-fine nylon thread (see Figure 4.12 b). Fibres were maintained in relax 
solution throughout assembly. Sarcomere length (SL) was measured using 900B Video 
Sarcomere Length (VSL) software (Aurora Scientific. Ontario, Canada) and adjusted on 
each fibre to 2.4-2.6 µm. Fibre diameter was measured at four intervals along the fibre 
length, and a circular circumference assumed for the basis of cross sectional area (CSA) 
calculation. Fibres were maximally activated in Ca2+ activating solution (pCa 4.5), 
containing in addition to Ca2+, (in mM) 5.3 MgATP, 1 free Mg2+, 20 imidazole, 7 EGTA, 
19.6 PCr, and 64 KCl (pH 7.0 at 4°C). Peak force was recorded and normalised to fibre CSA 
(Degens et al., 2010). Four fibres per participant were measured pre and post 
supplementation. 
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4.9 Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. a) Response of total serum 25[OH]D (nmol.L-1) of the two participants that received 4,000 IU.day-1 
Vitamin D3 for eight weeks. * denotes significance for both individuals versus baseline; b) a single skeletal 
muscle fibre attached to insect pins with ultra fine nylon thread; Single Fibre Characteristics prior to- and 
following supplementation with 4,000 IU.day-1 Vitamin D3 for 8 weeks on c) average fibre CSA as calculated by 
averaging 3 fibre diameter measures and assuming a cylindrical fibre structure d) average fibre absolute force 
and e) average fibre specific force calculated from absolute force over fibre CSA multiplied by 1x106 (for force 
in kN.m2). 
 
 
*	  a 
c d e 
b 
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In a similar response to that observed in study 1, total serum 25[OH]D was elevated 
following daily supplemental Vitamin D3 (4,000 IU) in both participants. However, despite 
significant increases in serum 25[OH]D there were no changes in fibre CSA absolute force 
or specific force following supplementation (Figure 4.12).   
 
4.10 Discussion 
The additional single fibre experiments undertaken aimed to determine whether changes in 
skeletal muscle contractile properties occur in individuals with serum concentrations ≤25 
nmol.L-1. It was hypothesized that with this sensitive investigative technique, positive 
changes in skeletal muscle contractile properties would be detected when elevating total 
serum 25[OH]D from ~25 nmol.L-1 to >75 nmol.L-1.  
Findings from these preliminary data do not support the hypothesis put forward and do not 
infer a role for Vitamin D in skeletal muscle contractile properties of single skeletal muscle 
fibres. Measurements were also comparable to those cited in previous investigations (Trappe 
et al., 2003). At this level of investigation, other contributors to muscle specific force are 
removed to allow investigation of cross bridge kinetics and calcium handling. Based on the 
data obtained, no changes in any of the observed measures could support the notion that 
Vitamin D regulates these processes. 
It is acknowledged that these data can only be considered preliminary as only two 
participants were analysed. This investigation is significantly underpowered to be able to 
draw definitive conclusions, however the data provide the first insights at the single fibre 
level of the relationship between Vitamin D status and skeletal muscle function. Employing 
this technique across a large number of individuals and isolated fibres from those individuals 
in a state of Vitamin D deficiency and repletion will establish definitively whether in young 
otherwise healthy muscle, Vitamin D status is important for contractile function. 
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4.11 Chapter Synthesis  
The first chapter of this thesis aimed to determine whether a relationship between Vitamin D 
status and skeletal muscle function exists in young non-pathological muscle. Skeletal muscle 
function was examined in vivo using IKD and EMS and ex vivo using the single fibre 
technique. Taken together, the data from these trials do not lend support to previous 
suggestions that Vitamin D is a regulator of muscle function as no changes in any of the 
chosen outcome measures of muscle function in vivo or ex vivo were detected. 
A number of in vitro investigations report potential mechanisms by which exogenous 
Vitamin D can regulate Ca2+[i] in isolated primary myoblasts and immortalised cell lines 
(Vazquez et al., 1998). This has led to the notion that sub optimal circulating 25[OH]D 
concentrations may cause aberrant Ca2+ handling in skeletal muscle in vivo (Girgis et al., 
2012). Indeed, in elderly populations there is correlative evidence to suggest that Vitamin D 
may correlate with muscle function supporting in vitro data (Bischoff-Ferrari et al., 2004a). 
These findings may however be flawed in that Vitamin D deficiency is only one of many 
factors that influence muscle health in the elderly. Severe comorbidity may cause muscle 
weakness and functional impairment and an indoor lifestyle may be attributable for the low 
serum 25[OH]D. Nevertheless, case reports have suggested that supplemental Vitamin D can 
improve muscle strength in those with chronic severe Vitamin D deficiency (Irani, 1976; 
Ziambaras & Dagogo-Jack, 1997). In non-aged/pathological muscle, findings are equivocal. 
The current data support the proposition that serum 25[OH]D concentrations typically 
observed in young individuals across Europe are unlikely to affect muscle function even at 
concentrations previously suggested to associate with muscle function impairments i.e. < 25 
nmol.L-1 (Stockton et al., 2011). All available evidence implies that in high-risk groups of 
frail, institutionalized individuals there is potential for Vitamin D to influence muscle 
function however in young persons with non-pathological muscle there is unlikely to be 
observable deficits in muscle function with serum concentrations ≥25 nmol.L-1. However, it 
is still not understood whether serum 25[OH]D <12.5 nmol.L-1 associated with 
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hypercalcemia, influences muscle function through disturbances in Ca+2. Such 
concentrations are rare in adult normal populations and it will be a challenge to the 
researcher to obtain a sample large enough to study muscle function. As such, the direction 
of investigation will now be driven toward the potential role of Vitamin D in skeletal muscle 
regeneration as part of the second major aim of this thesis 
Comparably to the link between Vitamin D and muscle function, data on muscle 
regeneration in the context of Vitamin D are largely observational with some in vitro reports 
defining potential mechanisms by which Vitamin D may mediate the regeneration process. It 
is important that well controlled, translational investigations are conducted to elucidate how 
Vitamin D may be important for muscle regeneration and to understand how to optimize 
Vitamin D status to support this function if a link exists. 
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Chapter 5 
 
Vitamin D and Muscle Regeneration In Vivo 
  
This chapter assesses the second major aim of this thesis; to investigate muscle regeneration 
in the context of Vitamin D. An in vivo model of muscle damage was employed to assess 
functional recovery in participants with Vitamin D deficiency prior to and following 
supplementation with Vitamin D. Findings suggest that supplemental Vitamin D may 
potentiate the recovery of force from damaging eccentric exercise when baseline Vitamin D 
status is insufficient. 
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5.1 Abstract 
Purpose – Vitamin D concentration associates with the recovery of maximal force following 
eccentric exercise. Although potential mechanisms have been identified that may explain 
this, a definitive cause-effect relationship remains to be established by randomized 
controlled trials (RCTs). The main objective of the current study was to implement a 
randomized controlled trial to assess the relationship between Vitamin D concentration and 
maximal torque recovery following eccentric exercise.  
Methods - A randomised, placebo-controlled trial was performed in twenty males with low 
serum 25[OH]D (45 ± 25 nmol.L-1). Prior to and following 6-weeks of supplemental 
Vitamin D3 (4,000 IU.day-1) or placebo (50 mg cellulose), participants performed 20 × 10 
damaging eccentric contractions of the knee extensors with peak torque measured over the 
following 7 days of recovery. Serum 25[OH]D was measured pre and post supplementation 
via LC-MS/MS. 
Results - Supplemental Vitamin D3 increased serum 25[OH]D (pre = 45 ± 25 vs. post = 115 
± 31 nmol.L-1, P < 0.005) and improved recovery of peak torque (60 deg.sec-1) at 48 hours 
(14 %) and 7 days (13.7 %) post-exercise. No changes were observed in perceived muscle 
soreness in either of the experimental groups. 
Conclusion - These data are the first to characterise a role for Vitamin D in human skeletal 
muscle regeneration by implementing an appropriately controlled RCT and suggest that 
maintaining serum 25[OH]D may be beneficial for enhancing reparative/remodelling 
processes following eccentric exercise.  
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5.2 Introduction 
 
Eccentric contraction, contusions and toxic insults cause skeletal muscle damage that leads 
to decrements in functional capacity. Yet skeletal muscle is uniquely equipped to regenerate 
via the activation, proliferation, migration and differentiation of resident muscle stem cells, 
known as satellite cells (Relaix & Zammit, 2012); indeed muscle regeneration is 
significantly compromised when satellite cells are ablated (Relaix & Zammit, 2012). 
Effective repair usually leads to full functional recovery of the damaged tissue whilst 
ineffective repair leads to fibrosis and sub optimal rescue of function (Mann et al., 2011).  
 
Many intrinsic, local and systemic factors interact to orchestrate the repair process and thus 
identifying and targeting modifiable risk factors that compromise any step of this process 
can augment functional recovery. Recent insights from human trials have reported that 
Vitamin D3, a member of a group of pleiotropic pro-steroid hormones is implicated in 
numerous biological processes. However, worldwide, low circulating Vitamin D 
concentrations (measured as total serum 25[OH]D) prevail in humans and are associated 
with numerous preventable disease states. Vitamin D may be implicated in skeletal muscle 
regeneration and remodelling (reviewed in (Owens et al., 2014)) and indeed, sufficient 
25OHD positively correlates with muscle force recovery from damaging eccentric exercise 
(Barker et al., 2013a; Barker et al., 2013b). These studies, while promising, are 
compromised by the observational nature of their design and raise the question of the 
potential cause-effect mechanisms between Vitamin D and muscle repair and recovery.  
 
Fragments of evidence from animal and cellular models have provided supporting 
preliminary human data for the observational insights in humans. In-vivo crush injury rat 
models, Vitamin D sufficiency culminates in significant increases in BrdU positive 
proliferating myoblasts, decreased apoptosis via staining tissue for DNA damage and 
subsequent improvements in maximal force recovery in comparison to deficient rats (Stratos 
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et al., 2013). In addition, Vitamin D supplementation, following BaCl2 damage of murine 
tibilais anterior, culminates in improved regeneration and increased expression of the VDR 
(Haussler, Jurutka, Mizwicki, & Norman, 2011), highlighting the potential of the Vitamin D 
pathway in controlling aspects of the regeneration process (Srikuea et al., 2012). 
Complementing these in vivo rodent studies, in vitro studies using C2C12 murine myoblasts 
also indicate that myoblast proliferation, differentiation, myotube hypertrophy and survival 
are mechanisms facilitated by Vitamin D, however, similar human muscle cell studies 
remain to be performed (Garcia et al., 2013; Salles et al., 2013; Srikuea et al., 2012). This is 
particularly relevant, given that circulating 25[OH]D and 1α,25[OH]2D are undetectable in 
many rodent species. Taken together, a definitive cause-effect relationship between Vitamin 
D and skeletal muscle repair and remodelling is yet to be established in humans by well-
controlled, translational investigations.  
 
5.3 Aims and Hypotheses 
The main aim of the investigation was to identify whether there is a causal relationship 
between Vitamin D concentration and muscle force recovery, indicative of muscle 
regeneration, following eccentric exercise induced damage by employing a randomized 
placebo controlled trial. 
 
It was hypothesized that low serum 25[OH]D will associate with inferior recovery of peak 
torque over 7 days following eccentric contraction induced damage and that supplementation 
to correct elevate serum 25[OH]D to >75 nmol.L-1 will correct this impairment as evidenced 
by quicker recovery of MVC force and a dampened perception of muscle soreness. 
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5.4 General Methodology 
5.4.1 Participants 
Twenty-five healthy males	   volunteered to partake in the current trial of which twenty 
participants (21 ± 1 years, 179 ± 4 cm, 84 ± 13 kg) presented with serum 25[OH]D < 75 
nmol.L-1 and met the inclusion criteria described in the General Methods chapter of this 
thesis and completed all experimental protocol. Participants received detailed information 
regarding the study procedures and were required to complete a PAR-Q, a medical history 
questionnaire and provide written informed consent before inclusion in the trial.. Ethical 
approval was granted by the local ethics committee of Liverpool John Moores University 
and all data were collected in accordance with the Declaration of Helsinki. 
 
5.4.2 Pilot data & Eccentric Exercise Protocol 
In order to validly investigate the influence of Vitamin D on muscle force recovery from 
eccentric contraction induced damage, it was first necessary to validate our muscle damage 
protocol. The protocol developed aimed to induce damage significant enough to result in a 
significant loss of force by 24-48 hours post exercise. The protocol was based on previously 
published data that describe a significant loss of force immediately post exercise (47 ± 5%) 
that remained significantly lower than baseline at 23 hours post exercise (35 ± 6% force 
reduction) and significant elevation in muscle soreness at 47 hours post exercise (Paulsen et 
al., 2007). The exercise bout was performed on a Cybex isokinetic dynamometer and 
consisted of 200 unilateral eccentric contractions at 30o.sec-1 (0.52 rad.sec-1) executed as 20 
sets of 10 contractions interspersed by 30 second rest intervals. Exercise was performed 
through the participants’ full range of motion (ROM), thus was specific to each participant. 
To assess maximal voluntary contraction force (MVC), peak toque was generated by 4 
maximal voluntary contractions at two fixed movement velocities of 60 and 180o.sec-1 
(1.047 and 3.14 rad.sec-1, respectively).  
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Pilot data (N = 4) revealed that a significant interaction was present between peak torque and 
time at both 60 deg.sec-1 (P = 0.002) and 180 deg.sec-1 (P = 0.032). Post-hoc analysis of the 
data revealed significant losses in isokinetic torque at 60 deg.sec-1 immediately post damage 
(P = 0.015), which remained significantly lower than pre damage at 24 hours (P = 0.046). 
Torque remained low at 48 hours although statistically insignificant (P = 0.054) and 
recovered to 96% by day 7, post damage. Similarly, at 180 deg.sec-1 force was significantly 
impaired immediately post exercise (P = 0.05) and remained lower at 24 (45%) and 48 hours 
(28%) versus pre damage, although not statistically significant (Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Pilot data demonstrating force recovery from 20 sets of 10 eccentric contractions at 60 and 180 
deg.sec-1 immediately post damage (DMG), 24 hours, 48 hours and 7 days post damage. * denotes significance to 
pre DMG. 
  
*	  *	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5.4.3 Familiarization 
All participants were familiarized with the MVC protocol before undertaking any 
experimental procedures. Only when participants obtained a CV% <10 % were they 
permitted to undertake the experimental trials (Atkinson & Nevill, 1998). Mean CV% for 
peak torque (nm) at 60o.sec-1 was 4% (± 3 %) and at 180o.sec-1 was 4% (± 3 %). Mean torque 
values at both movement velocities can be found in Table 5.1. 
 
5.4.4 Statistical Methods 
Statistical analyses were performed as described in Chapter 3 with additional power 
calculations being performed in the same manner as described in Chapter 4 section 4.3.4. 
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5.5 Experimental Trial 
5.5.1 Methodology 
Once familiarized with the experimental procedures, participants were block randomized to 
either the Vitamin D treatment group (4,000 IU.day-1) or placebo control based on peak 
torque attained at 60 deg.sec-1 and on baseline total serum 25[OH]D. 
 
Table 5.1. Block randomization data including mean total serum 25[OH]D concentration presented as 
nmol.L-1 and mean peak isokinetic torque from a knee extension at 60 deg.sec-1. 
 
 PLB (n = 10) VITD (n = 10) 
Mean total 25[OH]D (nmol.L-1) 45 45 
±SD 15 25 
t-test t = 0.017; P = 0.987 
Mean Isokinetic Peak Torque (Nm) 211 232 
±SD 48 25 
t-test t = 1.113, P = 0.290 
 
Participants were instructed to abstain from alcohol, caffeine and other over the counter 
stimulants 48 hours prior to the experimental trials. On the day of the trial a measure of 
muscle soreness was taken via a pressure algometer at two points on the right quadriceps; 
5cm from the patella and at the midpoint of the quadriceps as measured with a tape measure 
from the inguinal crease to the top of the patella when the leg was flexed at 90o. The 
algometer was pressed with gradually increasing pressure at the two separate measurement 
points and removed when the participant indicated that pressure had become pain. The value 
given on the algometer in kg was recorded as a measure of muscle soreness. Participants 
were then seated in the isokinetic dynamometer as described in Chapter 4 IKD Methods 
(section 4.3.3) and allowed to perform four submaximal practice repetitions increasing in 
intensity at 60 o.sec-1 to activate the muscle to be tested.  
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Maximal voluntary torque was obtained by performing four isokinetic contractions at two 
fixed movement velocities of 60 and 180o.sec-1, separated by a five-minute rest period. 
Muscle soreness was also measured prior to the eccentric exercise bout. Participants were 
then given a five-minute rest period following the MVC measures at which point they were 
asked to perform 20 sets of 10 maximal eccentric contractions as described in the pilot data 
section above. Immediately following the damaging procedure a second MVC measure was 
taken and a second muscle soreness measurement was obtained following which participants 
were allowed to leave the laboratory. MVC and muscle soreness measures were then taken 
at 24 hours, 48 hours and then at 7 days post damage to monitor recovery from the damaging 
event. 
 
 
Figure 5.2. Schematic representation of experimental procedures. * denotes peak torque and muscle soreness 
measurement. Serum 25[OH]D measure before and after all experimental procedures. Blood was collected at 
baseline and then again following the six week supplementation period. 
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5.6 Results 
5.6.1 Total Serum 25[OH]D 
At baseline, no significant differences were detected between experimental group for total 
serum 25[OH]D (P < 0.005) with both groups presenting with mean serum concentrations of 
45 ± 15 and 45 ± 25 nmol.L-1 for PLB and VITD, respectively. Following 6 weeks of 
supplementation with 4,000 IU.day-1 Vitamin D3, a significant interaction effect was 
observed between treatment group and time (P < 0.005). Post-hoc analysis revealed that the 
VITD group showed a significant increase in total serum 25[OH]D at week 6 compared with 
baseline (pre = 45 ± 25 vs post = 115 ± 31 nmol.L-1,  P < 0.005) and a significant difference 
when compared with PLB (P < 0.005). Conversely, the PLB group demonstrated a 
significant decline in serum 25[OH]D at week 6 compared with baseline (pre = 45 ± 25 vs 
post = 33 ± 13 nmol.L-1, P = 0.013). 
 
 
 
 
 
 
 
 
 
Figure 5.3. Response of total serum 25[OH]D to either 4,000 IU.day-1 Vitamin D3 or placebo for 6 weeks from 
January to March. # denotes significance to baseline and * denotes significance to PLB. 
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5.6.2 Supplemental Vitamin D to Increase Serum 25[OH]D Improves Recovery 
From Eccentric Exercise Induced Muscle Damage 
A significant interaction effect was observed between recovery time point, test week (pre-
post supplementation) and treatment group at 60 deg.sec-1 (P = 0.049). Exploration of this 
interaction identified a significant improvement in force recovery in the supplemental VITD 
group following supplementation at 48 hours (10.7% improvement, P = 0.042) and 7 days 
post damage (12.4% improvement, P = 0.001) compared with pre supplementation (Figure 
5.4). Although a slight improvement was observed for VITD post supplementation at 180 
deg.sec-1 this result failed to meet statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Recovery profile of peak isometric torque at 60 and 180 deg.sec-1 following six weeks 
supplementation with a) 4,000 IU.day-1 Vitamin D3 or b) visually identical placebo. * denotes significance to 
post damage torque. 
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5.6.3 Supplemental Vitamin D Does Not Attenuate Muscle Soreness Following 
Eccentric Exercise Induced Damage 
Both VITD and PLB demonstrated a significant increase in muscle soreness at both 
measurement sites (P < 0.05 mid quad and 5cm patella), however this was unchanged 
following supplementation at both 5cm patella (P = 0.418) and mid quadriceps (P = 0.71). 
Thus supplemental Vitamin D did not attenuate muscle soreness following damaging 
eccentric exercise (Figure 5.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
Figure 5.5. Upper bar charts represent muscle soreness scores 5 cm from the patella pre and post eccentric 
exercise and then at 24, 48 hours and 7 days post damage a) in the VITD supplemental group pre and post 
supplementation and b) the PLB group pre and post supplementation. Lower bar charts represent muscle 
soreness scores from the same time points as upper charts from the mid-quadriceps c) in the VITD 
supplemental group pre and post supplementation and d) the PLB group pre and post supplementation. 
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5.7 Discussion 
The main aim of the investigation was to identify whether a causal relationship exists 
between Vitamin D concentration and muscle force recovery, indicative of muscle 
regeneration, following eccentric exercise induced damage. It was hypothesized that 
Vitamin D concentrations <75 nmol.L-1 would associate with inferior recovery of peak 
torque at two dynamic movement velocities over 7 days following eccentric contraction 
induced damage. Further it was proposed that supplementation with 4,000 IU.day-1 Vitamin 
D3 to elevate serum 25[OH]D concentrations >75 nmol.L-1 would correct this impairment. 
The main findings of the investigation partly support the proposed hypotheses. It was 
observed that supplementation with 4,000 IU.day-1 Vitamin D3 for 6 weeks significantly 
elevated total serum 25[OH]D concentration >75 nmol.L-1 whereas supplementation with 
PLB led to a decrease in total serum 25[OH]D. This finding is similar to that observed in 
Chapter 4 of this thesis and many other published investigations supporting the efficacy of 
supplemental Vitamin D. The observed increase in serum 25[OH]D may also explain the 
improvement in force recovery observed in the VITD group at 48 (14 % improvement) 
hours and 7 days (13.7 % improvement) at 60 deg.sec-1. Supporting this observation, the 
significant decrease in PLB total serum 25[OH]D corresponded to decreases in force 
recovery at 48 hours (-4 % decrement) and 7 days (-2.8 % decrement), although not 
statistically significant. Improving serum 25[OH]D did not however have any perceptible 
effect of muscle soreness as values were unchanged following the supplemental period in 
both VITD and PLB. 
The current findings are in line with previous data from correlative investigations. It has 
been reported that supplemental Vitamin D resulted in ~70% increase in serum 25[OH]D 
and improved force recovery from eccentric exercise by 8% at 24 hours post damage 
without affecting muscle soreness (Barker et al., 2013b). Similarly, serum 25[OH]D has 
been shown to predict the severity of force loss following eccentric seated leg press exercise 
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in a small cohort of recreationally active adults (Barker et al., 2013a). Supplemental Vitamin 
D has also been shown to enhance the recovery of force following cruciate knee ligament 
injury (Barker et al., 2015). 
There are a number of potential explanations for the current data and those observations 
made previously by others. The muscle regeneration process is a complex series of 
individual but overlapping and mechanistically linked events that involve intracellular, 
cellular and systemic processes to be successful. Theoretically, there are therefore a number 
of targets that Vitamin D may interact with to mediate the resolution of damaged muscle 
tissue. First, 1α,25[OH]2D3 may directly influence muscle progenitor cell (myoblast) 
behaviour. In order to regenerate skeletal muscle following different types of damaging 
exercise, the muscle SC is required (Hyldahl et al., 2014; Relaix & Zammit, 2012). The SC 
is first activated by one or a combination of many biochemical and biophysical cues and will 
undergo cellular division to become a daughter cell or a committed myoblast (Bentzinger, 
Wang, & Rudnicki, 2012). The myoblast must then undergo proliferative cycles to increase 
the population number, migrate to the site of damage and differentiate and fuse to that 
damaged site to regenerate the tissue. Data report that exogenous treatment of muscle 
progenitor cells with 1α,25[OH]2D3 modulates proliferation and differentiation as well as 
enhancing the expression of pro-myogenic growth factors (Buitrago et al., 2012; Garcia et 
al., 2011; Srikuea et al., 2012). Additionally, in vascular smooth muscle cells, Vitamin D 
treatment enhances migration capacity, although this has not been confirmed in skeletal 
myoblasts (Rebsamen, Sun, Norman, & Liao, 2002). Upon migrating and fusing to the 
damaged site, the newly added nuclei permit hypertrophy at the damaged site. Recent data 
also suggest that Vitamin D can regulate such growth pathways through MAPK/ERK 
(Buitrago et al., 2013; Ronda et al., 2007) and Akt/MTOR (Buitrago et al., 2012) whilst also 
enhancing the anabolic effect of insulin and leucine (Salles et al., 2013). The importance of 
these events in the short term recovery of skeletal muscle following eccentric exercise is 
evidenced by data that report increases in embryonic MHC at only 48 hours post eccentric 
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exercise in rodents, indicative of SC incorporation into the muscle (Peters et al., 2003). 
Notably, this increase in embryonic MHC was the only regenerative marker of those 
examined that was synchronous with recovery of force. 
Vitamin D may also function indirectly to re-establish an appropriate vascular network to the 
damaged muscle. Vitamin D has been shown to improve angiogenic properties of 
endothelial progenitors (Grundmann et al., 2012) and enhances the migration of vascular 
smooth muscle cell progenitors (Rebsamen et al., 2002). Furthermore, in muscle progenitor 
cultures, exogenous treatment with 1α,25[OH]2D3  increases VEGFa and FGF-1: two pro-
angiogenic growth factors that promote neo-vascularization and tissue regeneration, and 
decreases FGF-2 and TIMP-3: two myogenic and  angiogenic inhibitors (Garcia et al., 
2013). In a similar indirect manner, Vitamin D may improve recovery of muscle force 
through the optimised reinnervation of the damaged fibre. In a rat model of nerve 
regeneration it was observed that treatment with Vitamin D3 at a high dose (500 IU/kg/day) 
induces a significant locomotor and electrophysiological recovery. Further, increases in the 
number of preserved or newly formed axons in the proximal nerve end, the mean axon 
diameter in the distal end, and neurite myelination in both distal and proximal nerve ends 
was observed with D3 treatment (Chabas et al., 2013). In accordance, recent data provide 
evidence that Vitamin D enhances the expression of IGF-1, myelin basic protein, and VDR 
in rat primary Schwann cells following running exercise in rats. Signalling through the VDR 
was demonstrated to regulate neuromuscular maintenance and enhance locomotive ability 
following exercise (Sakai et al., 2015). Finally, it is possible that Vitamin D may also 
enhance reparative processes in skeletal muscle via the regulation of the immune response to 
muscle damage. Indeed, as discussed previously, the inflammatory response is necessary to 
regenerate muscle when fibre damage occurs (Arnold et al., 2007). Furthermore, in cell 
culture systems, inflammatory cells such as macrophages enhance the proliferation and 
differentiation of skeletal myoblasts (Saclier, Cuvellier, Magnan, Mounier, & Chazaud, 
2013a; Saclier et al., 2013b).Vitamin D is known potent regulator of innate and acquired 
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immunity and functions in both stimulating and repressing immune processes (Hewison, 
2010). Although direct evidence is not yet available, it is plausible that regulation of the 
inflammatory response by Vitamin D is a contributing factors to our observations. 
To summarize, the investigation presented is the first to employ an appropriately controlled 
RCT to study Vitamin D status and muscle regeneration. The data suggest that supplemental 
Vitamin D may enhance maximal force recovery following eccentric exercise induced 
damage when baseline Vitamin D status is <75 nmol.L-1 however it is unlikely that Vitamin 
D status has any influence on the perception of muscle soreness. Mounting evidence 
inclusive of the current data set strongly suggest that Vitamin D may function to facilitate 
aspects of the muscle regeneration process. However, limited insights are available that 
adequately describe cellular mechanisms by which this may occur. The muscle regeneration 
process requires a series of well-orchestrated cellular events that lead to the resolution of the 
damaged tissue. Efforts are now required to study these events in the presence or absence of 
exogenous Vitamin D to determine whether the sterols apparent role in tissue repair is direct 
on satellite cells and muscle progenitors or indirect through regulation of the inflammatory 
response, neuro-regeneration, angiogenesis or a combination of all of these processes 
required for tissue repair.  
The final investigation of this thesis will aim to elucidate cellular mechanisms by employing 
an in vitro model of muscle wound repair and myogenesis in primary human muscle derived 
cells. The major aim is to increase the translational application of findings in this field and 
provide adequate evidence to suggest Vitamin D status causally interacts with muscle 
regeneration. 
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Chapter 6 
Optimization of an In Vitro Model of Muscle 
Regeneration  
  
This chapter describes pilot experiments undertaken to optimize an in vitro model of muscle 
regeneration to investigate cellular aspects of the regeneration process in the context of 
Vitamin D. A summary of optimal assay conditions is provided at the end of the chapter. 
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6.1 Abstract 
Purpose – In order to identify potential cellular mechanisms that account for in vivo 
observations made in Chapter 5, an in vitro model of muscle repair was required. The main 
objective of the current chapter was to optimize the 2D scratch assay for the study of skeletal 
muscle regeneration in the presence and absence of Vitamin D. 
Methods – The C2C12 murine myoblast cell line and human derived muscle cells were used 
in a variety of experimental variations of the scratch assay. Pilot study 1 investigated the 
seeding density (4 x 104 vs 8 x 104 cells.ml-1) and serum conditions (2 %, 20 % or serum free 
differentiation media) most appropriate to induce migration following damage.  Pilot study 2 
aimed to identify whether a lateral or horizontal wound induced differential migration 
characteristics across the three serum conditions used in pilot study 1. Pilot study 3 
examined the influence of potentially interfering proliferative cycles on the migration 
process across 48 hours. Finally, pilot study 4 examined whether human muscle derived 
cells were capable of fusion following mechanical scrape wounding and treatment with an 
inhibitor of proliferation (mitomycin-C at 10 µg.ml-1). 
Results – The main outcomes from the studies indicated that a seeding density of 8 x 104 
cells.ml-1 in 2% serum were optimal culture conditions for the study of migration following 
wounding. There were no differences between wound directions. Finally, significant 
proliferation occurred following scrape damage and this was inhibited by mitomycin-C pre 
treatment, which displayed no effect on the ability of cells to fuse following wound closure.  
Conclusion – The 2D scratch assay first described by Dimchev et al. (2013), allows the 
study of myoblast migration on a protein substratum. Moreover, at 7 days post wound 
closure human derived myoblasts fuse normally to form mature myotubes. Using this system 
and implementing a cell seeding density of 8 x 104 and 2 % serum differentiation medium 
allows the study of cellular events specific to muscle following damage. 
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6.2 Introduction 
In order to investigate the cellular mechanisms that account for in vivo observations in 
Chapter 5, an in vitro model of muscle regeneration was developed. Since myoblast 
migration to the site of damage and fusion at the site of damage are integral cellular 
processes in muscle regeneration, these aspects were necessary to incorporate into the model. 
To assess directional migration, the in vitro wound healing scratch assay was implemented. 
Other assays to study cell migration have previously been adopted including the Boyden 
chamber assay, in which a microporous membrane separates two chambers. Chemotactic 
agents are then added to one chamber and cells that migrate through the membrane toward 
the chemotactic signal are counted. Another commonly implemented assay is the Oris or 
stopper assay. As the name suggests, the assay utilises a plate with a circular ‘stopper’ at its 
centre to prevent cell growth. Upon removal of the stopper, cells will migrate into the central 
circular area where they are not contact inhibited by other cells. Both of the described 
methods have pitfalls that limit their usefulness when studying the migration of myoblasts. 
The Boyden chamber, although ideal for studying non-adherent cell types, is limited for 
investigation adherent mesenchymal cells such as myoblasts that will migrate through the 
porous membrane and adhere to the underside of the membrane. The Oris method, although 
accounting for the lack of application for adherent cell types typically displays slow 
migration due to the size of the plate. The 2D wound healing assays overcomes the 
drawbacks of the previously described assays. As demonstrated in the pilot trials described, 
an area of a cell monolayer is scratched (typically laterally) forming a wound area. This 
stimulates chemotactic agents to be released from the ruptured cells and triggers intrinsic 
repair mechanisms, potentially simulating more closely the migration mechanisms that 
would be activated following an injury in vivo (Goetsch, Myburgh, & Niesler, 2013). 
Following migration to the wound site, it was important to also assess myoblast fusion at the 
wound. A classic method of serum withdrawal was opted for as this technique provides the 
optimal conditions to stimulate replication arrest and allow induction of the myogenic 
152 
	  
differentiation programme (Blau, Chiu, & Webster, 1983; Spizz, Roman, Strauss, & Olson, 
1986). 
For the pilot experiments described within this chapter the C2C12 murine myoblast cell line 
was used. C2C12 are derived from satellite cells, with behaviour corresponding to that of 
progenitor lineage. C2C12 myoblasts will spontaneously differentiate in culture after serum 
removal (Blau et al., 1983). Sarcomeric actin and myosin are present also in undifferentiated 
myoblasts, but progressively acquire a structured pattern up to the appearance of sarcomeres 
and myofibrils at about 5 days after differentiation induction (Burattini et al., 2004). 
Therefore the use of C2C12 myoblasts was an appropriate choice to use as a model for 
optimizing the model of regeneration to avoid depleting precious primary human muscle 
derived cells that were to be used for experimental procedures. 
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6.2 Pilot Study 1 - Determination of Optimal Seeding Density & 
Optimal Serum Concentration for Myoblast Migration 
6.2.1 Aim & Hypothesis 
Spatial proximity influences growth and differentiation of skeletal myoblasts in vitro. 
Furthermore, the presence or absence of growth factors in commercially available media and 
sera may have different effects on myoblast migration. Therefore pilot study 1 aims to 
determine the optimal seeding density and media composition to study myoblast migration 
in vitro. It is hypothesised based on published literature (Dimchev et al., 2013) that cells 
seeded at 8x104 cells.ml-1 will provide an optimal cell density following 24 hours of culture 
to study myoblast migration following mechanical scrape injury and that a low serum media 
(2%) will allow migration into the wound site more effectively than high serum (20%) or 
serum free media. 
6.2.2 Cell Culture and Treatments 
Low passage C2C12 myoblasts were seeded in pre-gelatinised six well plates at two densities 
of 8x104 and 4x104 cells.ml-1 in MGM. Following a 24 hour incubation, once ~80% cell 
confluence was reached, a lateral wound was inflicted using a sterilised pipette tip (~800-
1000 µm diameter). MGM was then removed and cell monolayers washed twice with PBS. 
One of three media types was then added to the 6-well plates; MGM (20% serum), MDM 
(2%) or serum-free DMEM. Wound images were captured at 0, 24 and 48 hours following 
damage to assess wound closure and split into wound segments as described in Chapter 3, 
section 3.14. Experiments were conducted on three separate C2C12 cell populations with 
technical duplicates performed for each condition. No significant differences were detected 
in wound size immediately following damage (DM = 931 ± 109 vs GM = 945 ± 121 vs SF = 
933 ± 118 µm (P = 0.762)). See Figure 6.1 for schematic representation. 
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Figure 6.1. Experimental design employed to investigate the optimal conditions to study myoblast migration 
following a mechanical damaging scrape in vitro.  
8	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6.2.3 Results 
A significant interaction between seeding density and serum concentration was detected (P < 
0.0005) with both MGM and MDM being preferable when compared with SF (P < 0.0005) 
however no difference was detected between MGM and MDM (P = 0.215). Furthermore, a 
seeding density of 8x104 cells.ml-1 resulted in significantly more migrating cells than 4x104 
cells.ml-1 (P < 0.0005). Although migration of cells into the inner wound space occurred 
with MGM/20% serum, qualitative morphological analysis suggested this to be as a result of 
excessive proliferative cycles ‘pushing’ cells into the wound rather than migrating i.e. more 
cells appeared to be undergoing mitosis/cellular division and not locomotion. This was 
substantiated by observing a lack of migration/movement towards the inner space after an 
initial round of mitosis.  In conclusion, a cell seeding density of 8x104 cells.ml-1 in MGM 
and dropped to 2% serum media following mechanical wounding is the most appropriate 
condition of those tested for 48 hour live cell imaging as wound closure as a result of 
predominantly migrating cells achieved within this time frame (Figure 6.2).  
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Figure 6.2 a) representative phase contrast images of C2C12 myoblasts at 48 hours following mechanical 
scrape damage at 4x104 or 8x104 cells.ml-1 in MGM, MDM or SF media. Magnification is 15x, scale bar is 
100µm. b) Graphical representation of average cell number in the wound site at 48 hours. * denotes 
significance within media condition. 
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6.3 Pilot Study 2 - Determination of Appropriate Wound Direction 
6.3.1 Aims & Hypothesis 
Pilot study 1 established that a seeding density of 8x104 cells.ml-1 in 2% serum media 
(MDM) were the most effective conditions tested to study myoblast migration in in vitro. 
However, the direction of the wound is also a consideration to be investigated to optimize 
experimental conditions as it is unknown whether direction of the wound differentially 
effects cell-cell contact signalling. Therefore, the main aim of pilot study 2 was to establish 
whether a lateral or horizontal wound is most appropriate for studying muscle cell migration 
following mechanical scrap injury in vitro. It is hypothesised that C2C12 myoblast cells 
damaged by a lateral or horizontal wound inflicted by a 1ml pipette tip and dropped to a low 
serum (2% MDM) media will migrate in a similar manner to the site of damage by 48 hours. 
 
6.3.2 Cell Culture and Treatments 
Low passage C2C12 myoblasts were seeded in pre-gelatinised six well plates at 8x104 
cells.ml-1 in MGM as described in pilot trial 1. Following a 24 hour incubation, once cell 
confluence was reached, a wound was inflicted in one of two ways; vertical or horizontal 
scrape with a sterilised 1ml pipette tip (800-1000 µm). MGM was then removed, cell 
monolayers were washed twice with PBS and one of three media types (MGM, MDM or 
serum-free) was added to the 6-well plates as described in pilot trial 1. Wound images were 
then captured at 0, 24 and 48 hours post damage to analyse wound closure (Figure 6.3). No 
significant difference in wound size immediately post damage was detected between 
conditions (lateral = 989 ± 180 vs horizontal = 966 ± 125 µm (P = 0.512)). 
 
 
 
158 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
x3	  –	  MDM,	  MGM,	  SF	  
Figure 6.3. a) Schematic representation of the experimental set up of culture plates for the current pilot 
investigation b) Representative phase contrast images of C2C12 myoblasts following mechanical scrape 
damage and seeded at 8x104 cells.ml-1 in MGM, MDM or SF media and damaged with a lateral or horizontal 
wound. Magnification is 15x, scale bar is 100µm. 
Wound	  closure	  imaged	  at	  0,	  24	  and	  48	  hours	  following	  scrape	  damage	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6.3.3 Results 
A mixed design ANOVA was used to address difference in wound type (i.e. vertical versus 
horizontal) with serum type as three separate levels of analysis (MDM, MGM, SF).  A 
significant main effect for serum type was detected (P < 0.005) as MGM resulted in 
significantly more cells in the wound space at 48 hours in comparison to both MDM and SF 
(Figure 6.4). MDM also resulted in significantly more cells in the wound space when 
compared with SF. However, there was no difference between wound types in any serum 
condition (P = 0.943) indicating that both wound types result in similar migration patterns. 
Qualitative analysis of images suggested that the MGM condition resulted in more cells 
entering the wound space via mitosis rather than migration as described earlier, whilst MDM 
appeared to stimulated migration of cells rather than mitosis, likely due to a lack of growth 
factors as serum content was lower than the MGM condition. Since there was no effect of 
lateral of horizontal wound, the lateral wound with a 2% media was used for subsequent 
trials as has been reported previously (Dimchev et al., 2013). 
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Figure 6.4. a) Representative phase contrast images of C2C12 myoblasts at 48 hours following mechanical scrape 
damage and seeded at 8x104 cells.ml-1 in MGM, MDM or SF media and damaged with a lateral or horizontal 
wound. Magnification is 15x, scale bar is 100µm. b) graphical representation of average cell number in the wound 
site at 48 hours. ** denotes significance to MDM and SF, * denotes significant to SF. 
161 
	  
6.4 Pilot Study 3 - Influence of Interfering Proliferation on Human 
Muscle Derived Cell Migration  
6.4.1 Aims & Hypothesis 
Mixed population human derived muscle cells (MDCs) (typically predominantly myogenic 
cells with a smaller proportion of non-myogenic cells such as fibroblasts) will be used for all 
experimental trials. To further optimise the experimental model, it is therefore important to 
investigate 1) whether proliferation during wound healing impacts upon migration of human 
MDCs and 2) whether relative myogenic cell proportion (myogenic:non-myogenic) 
influences MDC migration of one cell type. 
It is hypothesised that inhibiting cell proliferation will result in fewer cells in the wound 
space at 48 hours post wounding by reducing the number of cells that enter the wound space 
through proliferative expansion and this will not incur any detrimental effects to the 
migration MDC populations. It is further hypothesized that the relative proportion of 
myogenic to non-myogenic cells will not favour the migration of one cell type over the other. 
6.4.2 Cell Culture and Treatments 
Human MDC populations retrieved from muscle biopsy specimens obtained as described in 
section 3.9.1 of the General Methods chapter of this thesis were resuscitated from liquid 
nitrogen, seeded at a density of 8x105 cells.ml-1 and allowed to proliferate for ~48 hours to 
reach confluence. Although ~24 hours was needed for C2C12 cultures to reach confluence, 
human MDCs grew at a slower rate vs. e.g. murine C2C12 cells and therefore a longer 
incubation time in GM was required. Two populations were initially studied representing the 
extremes of both low and high myogenic (desmin positive - immunohistological analysis 
described in Chapter 3 section 3.9.3) populations (23% and 60% respectively). Once cell 
confluence was reached, GM was removed and cells were washed twice with PBS before 
being incubated for 20 hours in quiescent media (QM) in an attempt to allow cells that had 
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already began a proliferative cycle to complete and exit the cycle. Following 20 hours QM 
incubation, QM was removed and two wells were incubated for a further 3 hours in QM 
whilst two were incubated in QM in the presence of mitomycin-C (10 µg.ml-1 in QM). 
Mitomycin C is a potent DNA cross-linker thus acts to cause replication arrest. After 
incubation with QM or QM+mitomycin, cells were damaged with a vertical linear scrape 
inflicted by a 1ml pippette tip. Media was then aspirated, monolayers were washed three 
times with 1ml PBS per well to ensure removal of all pre-treatment media and DM was then 
added. Monolayers were then imaged and fixed periodically as described in the General 
Methods chapter of this thesis at 0, 6, 17, 26, 40 and 48 hours post wounding for subsequent 
morphological and immunocytochemical analysis. No significant difference was detected in 
wound size immediately post damage between treatments (Mitomycin-C = 949 ± 146 vs 
untreated control = 927 ± 103 µm). 
6.4.3 Immunocytochemistry 
Following fixation at each time point, monolayers were blocked and permeabilized 
following which they were probed for desmin (myoblast marker), TE7 (fibroblast marker) 
and counterstained with DAPI nuclear stain as described in the Chapter 3 of this thesis 
(section 3.9.3). 
 
 
 
 
 
 
Figure 6.5. Migration time course pilot experiment schematic. Cells monolayers were grown for 48 hours in GM 
followed by a) 20 hours in QM or b) 17 hours in QM and 3 hours QM + mitomycin-C at 10 µg.ml-1. 
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6.4.4 Results 
A two way ANOVA was used to compare the effect of mitomycin-C treated versus 
untreated cells in segment 1 and 2 of the wound space as two separate levels. Comparison of 
mitomycin-C treated and untreated cells in segment 1 and 2 revealed a significant interaction 
between treatment group and segment (P = 0.030). Post hoc analysis identified a significant 
‘treatment group’ main effect was present (P = 0.028) with on average, more untreated 
control cells migrating into the wound site when compared to mitomycin-C treated cells 
(Figure 6.6). Observation of images implied that the greater number of cells in segments 1 
and 2 of the untreated group may be as a consequence of proliferative cycles following 
infliction of the wound. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Effect of 3 hours mitomycin-C (10µg.ml-1) pre-treatment on MDC migration across 48 hours 
following a damaging insult with a sterilised 1ml pipette tip. Segment 1 represents the areas adjacent to the 
wound edge whilst segment 2 represents the central wound area. * denotes significant difference between groups 
at time point for segment 1 and 2. 
 
*	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Figure 6.7. Representative images visualising the wound healing process over 48 hours in a high Desmin+ 
population of MDCs following 23 hours pre-incubation in QM. Myoblasts are stained for Desmin 
(Red/TRITC) and fibroblasts are stained for TE7 (Green/AlexaFluor488). Nuclei are blue (DAPI). Images 
were captured at 0, 6, 17, 26, 40 & 48 hrs post insult. 
0 hrs 6 hrs 
17 hrs 26 hrs 
40 hrs 48 hrs 
Condition 1: High Desmin+ without Mitomycin-C pre-treatment. 
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Figure 6.8. Representative images visualising the wound healing process over 48 hours in a high Desmin+ 
population of MDCs following 20 hours pre-incubation in QM and 3 hours of pre-treatment with mitomycin- 
C. Myoblasts are stained for Desmin (Red/TRITC) and fibroblasts are stained for TE7 (Green/AlexaFluor488). 
Nuclei are blue (DAPI). Images were taken at 0, 6, 17, 26, 40 & 48 hours post insult. 
0 hrs 6 hrs 
17 hrs 26 hrs 
40 hrs 48 hrs 
Condition 2: High Desmin+ with Mitomycin-C pre-treatment. 
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Condition 3: Low Desmin+ without Mitomycin-C pre-treatment. 
0 hrs 6 hrs 
17 hrs 26 hrs 
40 hrs 48 hrs 
Figure 6.9. Representative images visualising the wound healing process over 48 hours in a low Desmin+ 
population of MDCs following 23 hours pre-incubation in QM. Myoblasts are stained for Desmin 
(Red/TRITC) and fibroblasts are stained for TE7 (Green/AlexaFluor488). Nuclei are blue (DAPI). Images 
were captured at 0, 6, 17, 26, 40 & 48 hours post insult. 
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Condition 4: Low Desmin+ with Mitomycin-C pre-treatment. 
0 hrs 6 hrs 
17 hrs 26 hrs 
40 hrs 48 hrs 
Figure 6.10. Representative images visualising the wound healing process over 48 hrs in a low Desmin+ 
population of MDCs following 20 hours pre-incubation in QM and 3 hrs of pre-treatment with mitomycin- 
C. Myoblasts are stained for Desmin (Red/TRITC) and fibroblasts are stained for TE7 
(Green/AlexaFluor488). Nuclei are blue (DAPI). Images were captured at 0, 6, 17, 26, 40 & 48 hrs post 
insult. Scale bar is 100 µm. 
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A mixed design ANOVA was also implemented to identify whether the proportion of 
myogenic cells (i.e. High versus Lo desmin+) affected the migration of one cell type or the 
other. Data analysis revealed that high Desmin positivity resulted in fewer cells of both cell 
types migrating into segments 1 and 2 at 48 hours following damage when compared with 
low Desmin positivity. However, no significant differences were observed in the relative 
proportion of Des+ or TE7+ migrating cells over 48 hours (Figure 6.11). This may suggest 
that it is unlikely that Desmin positivity was the factor that led to lower numbers of 
migrating cells in high versus low populations, rather the observed difference was due to 
individuals differences in the intrinsic capacity for migration of the MDCs obtained from 
two different participants. 
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b 
Figure 6.11. The effect of high (hi) and low (lo) myogenic  cell populations on migration of a) myoblasts 
(Des+) and b) fibroblasts (TE7+) following mechanical scrape damage inflicted at 23 hours incubation in QM 
without Mitomycin-C. 
a 
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Figure 6.12. The effect of high (hi) and low (lo) myogenic cell populations on migration of myoblasts 
(Des+) and fibroblasts (TE7+) following mechanical scrape damage inflicted at 20 hours incubation in QM 
and 3 hours Mitomycin-C treatment (10 µg.ml-1). 
a 
b 
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6.5 Pilot Trial 4 – Capability of Human MDCs to Form Mature 
Myotubes Following Mitomycin-C Pre-Treatment and Mechanical 
Scrape Damage 
6.5.1 Aims and Hypothesis 
Pilot studies 1-3 determined appropriate conditions for studying muscle derived cell 
migration in an in vitro wound-healing model. Although these data allow analysis of 
migration dynamics, it is also important to assess myoblast fusion at the wound space in 
order to create an appropriate model of muscle regeneration. This final pilot experiment 
therefore aims to simply establish whether MDCs are capable of fusing in the wound space 
following mitomycin-C pre-treatment and mechanical scrape damage. Furthermore, if fusion 
occurs in this model, the time course over which this occurs will be identified. It is 
hypothesized that human MDCs will be capable of fusion at the inner wound space but this 
will take longer than observed in typical models of myogenesis in which fusion occurs 
within 72 hours of serum depletion. 
6.5.2 Cell Culture and Treatments 
Two human MDC populations (n = 2) retrieved from muscle biopsy specimens were seeded 
at a density of 8x105 cells.ml-1 and allowed to proliferate for ~48 hours to reach confluence. 
Once cell confluence was reached, GM was removed and cells were washed twice with PBS 
before being incubated for 20 hours in quiescent media (QM) in an attempt to allow cells 
that had already began a proliferative cycle to complete and exit the cycle. Following 20 
hours QM incubation, QM was removed and two wells were incubated for a further 3 hours 
in QM whilst two were incubated in QM in the presence of mitomycin-C (10 µg.ml-1 in QM). 
After incubation with QM or QM+mitomycin cells were damaged with a vertical linear 
scrape inflicted by a 1ml pippette tip. Media was then aspirated, monolayers were washed 
twice with 1ml PBS per well and DM was added. Monolayers were then imaged and fixed 
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periodically as described in the General Methods chapter of this thesis at 0, 48, 7 and 10 
days following wounding. 
6.5.3 Immunocytochemistry 
Following fixation at each time point, monolayers were blocked and permeabilized 
following which they were probed for desmin and counterstained with DAPI nuclear stain as 
described in the General Methods chapter of this thesis (section 3.9.3). 
6.5.4 Myotube Morphology 
Three images per well were captured at each time point from which total myotube number 
per field of view, nuclei per myotube, myotube are and myotube diameter were analysed via 
ImageJ. Myotubes were defined as having 2 or more nuclei and only myotubes for which the 
whole area of the cell was visible were considered in counting. 
6.5.5 Results 
Image analysis demonstrated that no myotube formation had occurred at 48 or 72 hours 
following wounding and therefore no statistical analysis was performed for these time points. 
A two-way ANOVA was used to analyse myotube number and morphology at 7 and 10 days 
following damage. There was a significant main effect of time for myotubes formed per field 
(P < 0.005) with 2 fold changes being observed in both groups between 7 and 10 days, 
however no treatment group differences were observed (P > 0.05). Myotube area (7 days; 
mitomycin C = 3438 ± 1318 vs untreated = 3582 ± 1261 µm2 and 10 days; mitomycin C 
4413 ± 1971 vs untreated = 3890 ± 1758 µm2) and diameter (7 days; mitomycin C = 11.3 ± 
3.3 vs 11 ± 2.9 µm and 10 days; mitomycin C = 12.7 ± 3.5 vs untreated = 11.9 ± 4.1 µm) 
increased similarly in both treatment groups but failed to meet statistical significance 
between 7 and 10 days. Myonuclear accretion did however show a significant main effect of 
time (P = 0.001) with more nuclei per myotube observed at 10 days versus 7 but no 
difference between treatment group (7 days; mitomycin C = 3 ± 1.7 vs untreated = 3 ± 0.7 
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nuclei per myotube and 10 days; mitomycin C = 3.8 ± 1.6 vs untreated = 3.6 ± 1.2 nuclei per 
myotube, P > 0.05). As no myotube parameters assessed showed statistical differences 
between groups this provides support that human MDCs are capable of fusion upon serum 
withdrawal following a mechanical scrape insult in co-culture with non-myogenic cells such 
as fibroblasts and furthermore that mitomycin-C pre-treatment at a concentration of 
10µg.ml-1 in QM does not affect the ability of myoblasts to fuse (Figure 6.13).   
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Mitomycin-­‐C	  treated	   Untreated	  control	  
Figure 6.13. Fusion capability parameters of 
human muscle derived cells upon serum withdrawal 
at 7 and 10 days post mechanical scrape damage 
following a 3 hour incubation in QM with or 
without 10µg.ml-1 mitomycin C. a) representative 
fluorescent images captured at 10 days post 
wounding. Myotubes are staned for Desmin 
(Red/TRITC) and nuclei are stained with DAPI 
(blue). Scale bar is 100 µm; b) average myotubes 
per field of view; c) average myotube area (µm2); 
d) average myotube diameter (µm); e) average 
nuclei per myotube per field and f) average 
myonuclear domain size (µm2).  
a 
b c 
e d 
f 
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6.6 Discussion 
The purpose of performing the described pilot experiments was to optimize the experimental 
conditions for studying the migration and fusion of human MDCs in vitro as a model of 
muscle damage and regeneration. Important considerations explored were seeding density, 
wound size, serum concentration of media, interfering proliferation, myogenic proportion of 
the cell population and fusion capability. The results gathered show that the optimal 
conditions for studying cell migration following a mechanical scrape insult is as follows: 
Table 6.1. Optimal culture conditions for studying wound healing in an in vitro mechanical scrape model of 
muscle wound repair. 
Variable Optimum 
Seeding density 8x104 cells.ml-1 
Wound direction Vertical or horizontal linear 
Wound size 1ml pipette tip (~800-1000µm) 
Media 2% serum differentiation medium 
Myotube formation in wound space Min. 7 days 
 
In addition to the experiments undertaken on C2C12 myoblasts, the data obtained from the 
final pilot trial show that primary human MDCs derived from human biopsies in an unsorted 
population of varying myogenicity migrate similarly between samples (within the range 
obtained in this study), regardless of myogenic cell proportion. Moreover, additional 
proliferative cycles are likely to give a false indication of migration capacity as treatment of 
cells with a inhibitor of cell proliferation (mitomycin-C; 10 µg.ml-1) prior to wounding 
resulted in significantly fewer cells in the wound site at 48 hours post insult likely as a result 
of mitotic inhibition. Taken together, the conditions described in Table 6.1 are appropriate to 
study the migration and fusion of human MDCs in an in vitro model of muscle damage and 
repair.   
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Chapter 7 
Vitamin D and Muscle Regeneration In Vitro 
  
This chapter utilised the in vitro model that was optimised in chapter 6 to explore the role of 
Vitamin D in cellular aspects of muscle regeneration with the main aim of providing a 
mechanistic underpinning for the in vivo findings of chapter 5. The main outcomes suggest that 
treatment of human derived cells with 10 nmol 1α,25[OH]2D3  improves muscle derived cell 
migration over 48 hours and myoblast fusion at 7 and 10 days following a damaging 
mechanical scrape.  
Publications resulted from this chapter: Owens D.J., Sharples, A.P., Polydorou, I., Alwan, N., 
Tang, J.C.Y., Donovan, T., Fraser, W.D., Morton, J.P., Stewart, C & Close, G.L. (2015). A 
Systems Based Investigation into Vitamin D and Skeletal Muscle Repair, Regeneration and 
Hypertrophy. Am J Physiol Endocrinol Metab. Doi: 10.11.1152/ajpendo.00375.2015. 
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7.1 Abstract 
Purpose – Skeletal muscle is a direct target for Vitamin D. In Chapter 5 of this thesis it was 
demonstrated that raising serum 25[OH]D improved maximal torque recovery following 
eccentric exercise. However, mechanisms underlying this observation have not been 
established. In order to address this gap in knowledge in relation to damage repair, the main 
objective of the current study was to identify whether aspects of muscle regeneration are 
responsive to Vitamin D in vitro, utilising the model developed in Chapter 6. 
Methods – Human skeletal muscle derived myoblast cells from biopsies of 14 males with 
low serum 25[OH]D (37 ± 11 nmol.L-1) were subjected to mechanical wound injury, which 
enabled in vitro studies of muscle repair (migration, filmed over 48 hours), regeneration and 
hypertrophy (myotube morphology, biochemical and gene markers at 7 and 10 days post 
wound) in the presence and absence of 10 nmol or 100 nmol 1α,25[OH]2D3. 
Results – Ten nmol 1α,25[OH]2D3 improved muscle cell migration dynamics (migration 
velocity and distance) and resulted in improved myotube fusion/differentiation at the 
biochemical (creatine kinase activity), morphological and molecular level together with 
increased myotube hypertrophy at 7 and 10 days post-damage. 
Conclusion - Together with data from the study described in Chapter 5, these data provide a 
strong basis of support for the notion that Vitamin D interacts with skeletal muscle to 
mediate aspects of muscle regeneration and remodelling. Additionally, given the improved 
capability to recruit nuclei to each myotube, Vitamin D may also enhance post eccentric 
exercise remodelling and prime muscle for further bouts of mechanical stress.  
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7.2 Introduction 
In Chapter 5 of this thesis, supplemental Vitamin D (4,000 IU.day-1 for 6 weeks) to increase 
serum 25[OH]D led to an improvement in the recovery of maximal isokinetic torque at 48 
hours and 7 days post eccentric exercise. These data and available insights from other 
investigations may imply a role for Vitamin D in the regeneration of skeletal muscle in vivo. 
However, limited information is available to explain the mechanisms that underpin these 
observations at the cellular and molecular scale. As described in the Literature Review of 
this thesis, the cellular events of skeletal muscle cells that lead to muscle regeneration 
include activation of the resident muscle stem cell, expansion of the committed myoblast 
population, migration to the site of damage and fusion with damaged myofibres to repair the 
injury. Targeted ablation of the skeletal muscle stem cell results in an inability to regenerate 
the tissue (Relaix & Zammit, 2012), highlighting the importance of these cells in skeletal 
muscle homeostasis. 
Available evidence suggests that 1α,25[OH]2D3 rapidly activates signalling networks that are 
linked to the control of cytoskeletal reorganization and cell migration, although a direct link 
between these signalling cascades and skeletal muscle cell migration is yet to be established. 
Such pathways activated in myoblasts in the presence of Vitamin D include Src/PI3K/Akt 
and MAPK/ERK (Buitrago et al., 2013). In other cell types such as vascular smooth muscle 
cells, 1α,25[OH]2D3 promotes migration through PI3K (Rebsamen et al., 2002) and indeed 
the requirement for PI3K in myoblast migration has previously been demonstrated (Dimchev 
et al., 2013).  Moreover, Vitamin D has also been demonstrated to enhance other aspects of 
the repair process in immortalized cell models such as the C2C12 murine myoblast cell line 
(Srikuea et al., 2012). Interestingly, these pro myogenic effect observed in C2C12 cells is 
similar to that of other steroids such as testosterone that improve fusion capability and 
induce hypertrophy (Deane et al., 2013; Sinha-Hikim et al., 2002). Collectively, these data 
may imply that Vitamin D interacts with skeletal muscle to enhance muscle repair, however 
these data are yet to be produced. 
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Given that myoblast migration, fusion and hypertrophy are key processes in muscle 
regeneration and remodelling, the main objective of this study were to identify whether 
treatment of primary human MDCs isolated from biopsy specimens, with 1α,25[OH]2D3 
following a mechanical scrape wound influences migration dynamics, including: migration 
velocity, distance and directionality. Furthermore, improved migration to the wound site is 
only impactful if the myoblasts subsequently fuse efficiently to effectively repair the site of 
damage. Thus, a further objective  was to examine the cellular events post wound closure in 
the presence or absence of 1α,25[OH]2D3 to establish whether there is indeed a positive role 
in muscle regeneration. 
7.1.1 Aims and Hypotheses 
The main aims of this investigation were twofold; to identify whether exogenous treatment 
of MDCs following a mechanical injury would improve 1) the migration characteristics and 
2) fusion capability of human MDCs. It was hypothesised that exogenous treatment with 
1α,25[OH]2D3 (10 nmol (Lo) or 100 nmol (Hi)) following damage would improve the 
described aspects of cell migration and fusion in a dose dependent manner i.e. 100 nmol 
superior to 10 nmol and both treatment superior to a vehicle control. 
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7.2 General Methods 
7.2.1 Participants 
Following ethical approval and informed consent, fourteen male participants (age = 25 ± 
3yrs; height = 181 ± 5cm; weight = 81 ± 10kg) volunteered to partake in the trial. After 
meeting the initial inclusion criteria (Chapter 3, section 
3.2), participants provided a venous blood sample that 
was analysed for total serum 25[OH]D concentration by 
LC-MS/MS (Chapter 3, section 3.4). The average total 
serum 25[OH]D concentration for the group was 37±11 
nmol.L-1 with the range represented in Fig 7.1. A biopsy 
specimen was also then harvested from the Vastus 
Lateralis from all participants (Chapter 3, section 3.5).  
 
  
 
7.2.2 Cell Culture 
Cell populations derived from individual biopsy samples were resuscitated from liquid 
nitrogen and seeded on pre gelatinised T25 cm2 cell culture flasks for expansion. The 
seeding density was dependent on the cell number retrieved at passage 1 and ranged from 
3x105 cells.ml-1 to 1 x 106 cells.ml-1. Cells were grown in Hams F-10 GM and upon ~80% 
confluence were trypsinized, counted in the presence of Trypan blue and seeded at 8x104 
cells.ml-1 on pre gelatinised 6 well culture plates for subsequent experimental treatments. All 
cell cultures were maintained in a controlled humidified environment of 37oC, 5% CO2. The 
composition and preparation of growth media is detailed in section Chapter 3, section 3.11. 
 
Figure 7.1. Box plot representing basal Vitamin D status of all participants from whom a biopsy was obtained. 
Data are presented as upper and lower quartiles, median and maximum/minimum values. 
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7.2.3 Cell Treatments 
Once cell monolayers reached a confluent state, GM was removed, monolayers were washed 
twice with PBS and GM was replaced with QM for 20 hours, following which QM was 
exchanged for QM + mitomycin-C (10 µg.ml-1) for 3 hours to allow replication arrest as 
determined by the pilot experimentation described earlier and by previous work (Dimchev et 
al., 2013). Subsequent to 3 hours treatment with QM + mitomycin-C, cells were damaged by 
a vertical scrape with a 1 ml pipette tip. The mitomycin-C pre-treatment media was aspirated 
and damaged cell monolayers were washed three times with 1x PBS to remove cell debris 
and residual pre-treatment media. Each six well culture plate was subjected to a low dose of 
exogenous 1α,25[OH]2D3 (10 nmol total in 2ml DM, Lo), a high dose (100 nmol total in 2ml 
DM, Hi) or control vehicle (20 µl.ml-1 of 100% EtOH, Veh) in DM; n=2 wells per 
dose/experiment. The doses of Vitamin D chosen were based on previously published 
research evidence. Garcia et al. (2011) reported a dose response study performed in the 
C2C12 cell line, reporting 100 nmol as the optimal dose to elicit a cellular responses in their 
chosen model. This dose has been widely used in a number of other investigations to elicit 
cellular responses (see Table 7.1), therefore both 10 and 100 nmol doses were selected to 
determine whether potential responses in cell migration and fusion were dose dependent. It 
should be noted however that these widely used doses are supra-physiological as 
1α,25[OH]2D3 circulates in pmol concentrations. Immediately following the addition of 
treatments, monolayers were placed in a controlled live imaging microscopy environment of 
37oC, 5% CO2 (Chapter 3, section 3.13) and images were captured every 30 minutes for 48 
hours. All media composition is detailed in Chapter 3, section 3.11. 
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Table 7.1. Summary of investigations implementing exogenous Vitamin D on skeletal muscle cells. 
Authors Model Treatment 
concentration 
Outcome variable 
Girgis et al. (2014a) C2C12 myoblasts 1-100 nmol Myoblast proliferation, 
differentiation and myotube 
formation. 
Srikuea et al. (2012) C2C12 myoblasts 20 nmol Myoblast proliferation. 
Garcia et al. (2011). C2C12 myoblasts 100 nmol myoblast cell proliferation, 
progression, and differentiation 
into myotubes. 
Artaza, Sirad, Ferrini, 
and Norris (2010). 
Mesenchymal multipotent 
cells 
100 nmol cell morphology, cell 
proliferation, cell cycle 
progression and apoptosis. 
Cardus et al. (2006) Vascular smooth muscle cells 5-100 nmol VSMC proliferation. 
 
7.2.4 Cell Migration Analysis 
TIF files captured over the 48-hour filming period were exported from Leica Application 
Suite and loaded as TIF image stacks in ImageJ with a Cell Counter plug in. Cells in the 
outer (segment 1) and inner (segment 2) wound spaces were counted (refer to General 
Methods section 3.14). TIF files were also exported as TIF image stacks into ImageJ with a 
Manual Tracking Tool plug-in (ibidi GmbH: München, Germany). The individual trajectory 
of each cell was tracked in the xy axis and derived raw co-ordinate data exported in an 
ImageJ Chemotaxis and Migration Tool plug-in (ibidi GmbH: München, Germany) for 
analysis. The chemotaxis tool analyses raw data from the manual tracking tool and provides 
quantitative data on the migration of individual and grouped cell trajectories including; 
migration velocity, accumulated migration distance, Euclidean migration distance and 
directionality. These terms are defined below: 
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• Migration Velocity (V) is calculated by the rate of change in position of a cell per unit 
of time. In this case a change in the xy position in µm.sec-1. 
• Accumulated Migration Distance (DAcc) is the total distance covered of a cell 
trajectory (Figure 6.18). Individual and mean cell trajectory values are generated in µm. 
• Euclidean Distance (DEuc) is the length of the line segment connecting the start and end 
point of a cell trajectory (Figure 6.18). 
• Directionality (Di) is determined by comparing the Euclidean distance to the 
accumulated distance. It gives a measure of the directness of cell migration and is 
calculated by the following equation: 
	  
	  
	  
 
 
 
 
 
 
 
 
 
Figure 7.2. A) Example of a single cell trajectory as mapped by ImageJ. B-E) Examples of cell trajectories for a 
number of tracks with a range of directionality scores from 0 (B, far left) to 1 (E, far right). 
 
b c d e 
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Experiments were performed on six well plates of cell monolayers derived from 14 
populations isolated from 14 individuals (n = 14). All experimental treatments were 
performed in duplicate. Two live imaging movies were captured per treatment well giving a 
total of four movies per treatment per sample (56 movies per treatment in total). From these 
movies, an average of 20 individual cell trajectories was tracked per movie. Cells were 
tracked from the leading wound edge only and tracking was terminated if a trajectory left the 
filmed space at any time. 
7.2.5 Gene Expression 
Upon cessation of filming, media was aspirated and monolayers washed three times with 
PBS following which total RNA was isolated and quantified as described in section 3.6 of 
the General Methods chapter of this thesis. Following RNA quality and quantity 
measurement, the expression of the VDR was assessed by RT-qPCR also described in 
section 3.6. Three reference genes were initially assessed for their stability and ribosomal 
protein L13a (RPL13a) was selected as a stable reference gene as the co-efficient of 
variation between PCR samples was 1.86%.  
For the cell monolayers used for the analysis of myoblast fusion, total RNA was isolated and 
quantified as described above at 7 and 10 days. In addition to the VDR gene the late 
differentiation genes myogenic regulatory factor 4 (MRF4) and myogenin (MYOG) were 
also analysed at the 7 and 10 day time points. Ribosomal protein L13a (RPL13a) was again 
selected as a stable reference gene as the co-efficient of variation between PCR samples was 
2%. Primer information and can be found in Table 3.2 (Chapter 3). Statistical analyses were 
performed as described in Chapter 3, section 3.15. 
7.5.6 Creatine Kinase Activity  
Immediately following injury (0 hours), 48 hours, 7 and 10 days following injury 1 well per 
treatment per sample was lysed in tris-mes-triton buffer (50 mM tris-mes, 1% Triton X100) 
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for determination of CK activity as a marker of differentiation. The bichinconinc acid (for 
protein content) and CK assays were performed as described in Chapter 3, section 3.8.  
 
7.5.7 Morphology and Immunocytochemistry 
In order to determine myotube formation at 7 and 10 days, damaged monolayers were 
imaged at 4 sites per well in the wound site immediately post damage (0 hours). These 
image co-ordinates were then saved to allow monitoring of a consistent wound site to avoid 
experimental bias. Images were obtained at 7 and 10 days, exported as TIFF image files and 
analysed in ImageJ. Morphology was assessed by myotubes per field of view, myotube 
diameter and myotube area. Myotubes were counted via ImageJ cell counter plug-in and 
only myotubes for which the entire length of the tube was visible in the field of view were 
considered. Myotubes were determined as cells containing 2 or more nuclei. Myotube area 
was determined by manually drawing a line around the sarcolemma of each myotube.  By 
normalizing the pixel scale to the micron scale of each image a value expressed as µm2 is 
obtained. To calculate myotube diameter, three equidistant diameters along the length of the 
myotube (left centre, centre and right centre) were measured and averaged. A total of 3 
image per well were analysed per treatment, treatments were performed in duplicate and 
experiments performed on 14 cell populations from 14 different individuals. Therefore, 84 
images per condition were assessed. 
As intact monolayers were required determination of CK and extraction of RNA, 
experiments were repeated for immunocytochemical staining in order to visualise nuclei for 
the accurate determination of myonuclear fusion index myonuclear domain size. Monolayers 
were fixed and stained as described Chapter 3, section 3.9.3. Monolayers were stained for 
Desmin and DAPI nuclear stain. Fluorescent images were then captured at 10 days post 
damage and nuclei counted via ImageJ cell counter plug-in. A total of 3 image per well were 
analysed per treatment, treatments were performed in duplicate and experiments performed 
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on 7 cell populations from 7 different individuals. Although populations from 14 individuals 
were obtained, cell stocks were depleted from early passages from prior experiments leaving 
only 7 populations between passage 1-5 that could be used for the current experiments. 
 
7.6 Results 
Treatment of Muscle Derived Cells with 10 or 100 nmol 1α,25-dihydroxyvitamin2D3 
Improves Migration Dynamics In Vitro 
7.6.1. Live Cell Imaging Analysis  
To establish the influence of Vitamin D on muscle derived cell migration, cell monolayers 
were treated with 10 and 100 nmol 1α,25[OH]2D3 or vehicle (EtOH) following a mechanical 
scrape insult. A one way ANOVA was implemented to compare means of the three 
conditions for the migration parameters V, Dacc , DEuc and Di. A significant treatment group 
effect was detected for V, Dacc , DEuc and Di (P < 0.005). Both Hi and Lo dose 1α,25[OH]2D3 
significantly enhanced migration V compared to vehicle with 1.37 and 1.43 fold increases 
observed, respectively (P < 0.0005), versus control. Hi dose was also superior to Lo dose 
(0.331 ± 0.11 vs 0.318 ± 0.1 µm.min-1 respectively, P = 0.033). A similar observation was 
made in DAcc as Hi treatment promoted greater migration (953 ± 305 µm) distances than Lo 
((909 ± 281 µm) P = 0.009) whilst both Hi and Lo were superior to Veh ((666 ± 288 µm) P 
< 0.0005). However, although both Lo and Hi treatment improved DEuc when compared with 
Veh, there were no differences between the two doses (P = 0.193), which would imply a loss 
of directionality in the Hi dose treatment. Indeed, analysis revealed that Hi dose treated 
MDCs demonstrated a loss of directionality (0.498 ± 0.21 AU) compared to Lo (0.546 ± 0.2 
AU) and Veh (0.547 ± 0.23 AU) treated cells (P < 0.005) whereas Lo and Veh showed no 
differences. Data are presented graphically in Figure 7.3. No significant differences were 
evident in wound size between conditions (Lo = 949 ± 146 vs Hi = 927 ± 103 vs Veh = 925 
± 108 µm (P = 0.810)).  
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Figure 7.3. MDC migration dynamics following a mechanical scrape injury in the presence of Lo (10 nmol) or 
Hi (100 nmol) 1α,25[OH]2D3 or vehicle solution (100% EtOH); a) representative phase contrast microscope 
images captured at 48 hours post wounding. Scale bar is 100 µm. n = 14; b) representative migration plots 
produced via ImageJ chemotaxis tool; c) average number of cells migrated into segment 1 and 3 at 48 hours post 
damage; d) migration Di (0-1); e) migration V (µm.min-1);  f) migration DEuc and g) migration DAcc (µm); * 
denotes significance to Veh and ** denotes significance to all other treatments. 
c d 
b 
188 
	  
Treatment of Muscle Derived Cells with 10 nmol 1α,25-dihydroxyvitamin2D3 Enhances 
Myoblast Fusion Following Mechanical Scrape Injury In Vitro 
7.6.2. Morphological Analysis 
Treatment of MDC cultures with 10 or 100 nmol 1α,25[OH]2D3 resulted in greater migration 
dynamics,  however the same dosing strategy led to differential effects on myoblast fusion at 
7 and 10 days following the damaging event. Morphological data were analysed via a mixed 
design ANOVA and revealed that myoblast fusion was significantly inhibited as fewer 
myotubes were observed per field with 100 nmol 1α,25[OH]2D3 versus 10 nmol and vehicle 
at 7 days post damage (Hi = 2 ± 2 vs Lo = 6 ± 4 vs Veh = 3 ± 1 myotubes per field (P < 
0.0005)). In contrast, Lo treatment led to significant improvements in myotube number 
compared with 100 nmol and Veh at both 7 (as above) and 10 days (Lo =10 ± 3 vs Hi = 6 ± 
2 vs Veh = 6 ± 2 myotubes per field (P < 0.005)). This observation was also similar for 
myotube area with Lo treatment resulting in significantly greater myotube area versus Hi 
and Veh at 7 (Lo = 4984 ± 2776 vs Hi = 4603 ± 1697 vs 4227 ± 1768 µm2 (P = 0.003)) and 
10 days (Lo = 5488 ± 2853 vs Hi = 4671 ± 2932 vs Veh = 4388 ± 2312 µm2 (P < 0.0005)). 
Myotube diameter was significantly greater at 7 days in both Lo and Hi dose treatments 
versus Veh (Lo = 14.13 ± 4 vs Hi = 13.7 ± 4.5 vs Veh = 12.12 ± 3.8 µm (P = 0.005)), 
however this effect was lost at 10 days (Lo = 13.6 ± 4 vs Hi = 12.6 ± 4.1 vs Veh = 12.1 ± 3.7 
µm (P = 0.256)). All morphological data are presented graphically in Figure 7.4.  
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Figure 7.4. Effect of Lo or Hi dose 1α,25[OH]2D3 versus Veh on myotube morphology following 7 and 10 days 
in DM following mechanical scrape wounding; a) Average myotubes per field of view; b) average myotube 
area (µm2); c) average myotube diameter (µm) and d) representative phase contrast microscope images captured 
at 10 days in the wound space of each condition. Scale bar is 100µm. 
a 
b 
c 
d 
Lo	  (10	  nmol)	  
Hi	  (100	  nmol)	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  EtOH)	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7.6.3. Biochemistry and immunocytochemistry 
Findings from biochemical and fluorescent imaging were in agreement with morphological 
findings. Creatine kinase activity data were analysed via a mixed design ANOVA. Results 
show CK activity was elevated above Veh with Lo treatment and repressed with Hi 
compared with both Lo and Veh at 7 days (Lo = 302.5 ± 173 vs Hi = 186.7 ± 132 vs Veh = 
290 ± 160.5 mU.mg.ml-1), although this effect did not reach statistical significance. At 10 
days, Lo treatment cells demonstrated significantly higher CK activity compared with both 
Hi and Veh (Lo = 340.4 ± 183 vs Hi = 258.4 ± 188 vs Veh = 229.4 ± 139.5 mU.mg.ml-1 (P = 
0.017)). Myonuclei and myonuclear domain size were analysed by one-way ANOVA. The 
CK observations correlated with a significantly greater accretion of myonuclei in Lo treated 
cells versus Hi and Veh at 10 days post damage (Lo = 5.9 ± 2.3 vs Hi = 3.5 ± 1.4 vs Veh = 
3.4 ± 1.2 nuclei per myotube per field (P < 0.0005), however myonuclear domain size was 
smaller at 10 days with Lo treatment (Lo = 986.5 ± 439.4 vs Hi = 1460 ± 726.3 vs Veh 
1257.3 ± 584 µm2 (P < 0.0005)). 
 
  
Figure 7.5. Effect of Lo or Hi dose 1α,25[OH]2D3 versus Veh on biochemical aspects of myotube formation 
and immuncytochemical analysis of nuclear accretion; a) Representative fluorescent microscopy images taken 
at 10 days following damage. Scale bar is 100µm; b) Average CK activity (mU.mg.ml-1) at 48 hours, 7 and 10 
days following damage. * denotes significance to other conditions at a time point; c) average nuclei per 
myotube per field of view at 10 days following damage.   
 
b 
*	  
Lo	  (10	  nmol)	   Hi	  (100	  nmol)	   Veh	  (100%	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7.6.4. Gene expression 
To determine the impact of treatment on gene expression,	  ΔΔCt analysis was performed by 
comparing the fold change in target gene expression against both a non-treated 0 hours 
control and a stable reference gene (RPL13a). Data were then analysed by a mixed design 
ANOVA.  Results demonstrated that on average Lo treated cells up regulated MRF4 
expression to a higher extent at both 7 and 10 days (3.2 and 3.7 fold) than Hi (-0.5 fold and 
no change) and Veh treated cells (2.9 and 2.9 fold). Similarly, Lo treated cells showed an 
increased myogenin expression at 10 days (84 fold) compared with Hi (64 fold) and Veh (62 
fold), however these data failed to meet statistical significance, likely due to the large 
variation in basal expression of the MRFs (Figure 7.6). VDR expression showed no 
discernible difference between groups at any time point, however all significantly increased 
expression in a similar trend with myogenin between 48 hours and seven days (P = 0.022) 
suggestive of a role for VDR in myoblast fusion. Interestingly, Hi treated cells also showed 
an impairment (although no statistically significant) in the ability induce both MRFs at 7 
days post insult versus control and Lo treated cells which correlates with biochemical 
observations demonstrating lower CK activity in Hi treated cells at 7 days. 
Having obtained large variation in basal expression, raw cycle threshold (Ct) values were 
also analysed and are also presented with ΔΔCt in Figure 7.6. Analysis of raw Ct values 
showed similar results, with all treatment groups demonstrating a main effect for time in 
myogenin and VDR expression, with significantly increased expression from 48 hours to 7 
days. A main effect of time was not detected for MRF4, however observation of Ct values 
(Figure 7.6) suggests a trend of increasing expression with time in keeping with ΔΔCt scores.  
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a 
b 
c 
Figure 7.6. Time course effects of 1α,25[OH]2D3 on mRNA expression of a) Vitamin D Receptor; b) Myogenic regulatory 
factor 4 and c) myogenin. From left panels, figures represent basal variation of genes presented as fold changes versus lowest 
expressing sample, raw Ct values of individual samples and ΔΔCt fold changes against a stable reference gene (RPL13a) and an 
internal calibrator (0 hours sample). 
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7.7 Discussion 
The investigations in this chapter aimed to establish whether in vivo findings of Chapter 5 
could be explained by improved migration and fusion aspects of the regeneration process in 
the presence of Vitamin D. It was hypothesized that exogenous 1α,25[OH]2D3 would 
improve aspects of migration and fusion, regardless of whether the dose was 10 or 100 nmol, 
providing potential cellular mechanisms by which Vitamin D appears to mediate muscle 
regeneration in vivo. 
The main findings from the investigations suggest that 1α,25[OH]2D3 has the capacity to 
improve MDC migration dynamics including speed, accumulated and Euclidean distance 
when administered at both low (10 nmol) and high (100 nmol) doses. The Lo dose promoted 
faster migration with sustained directionality whilst the Hi dose further improved migration 
speed but at the expense of directionality. As both treatments resulted in significantly more 
cells in the wound space at 48 hours versus vehicle treatment, both treatments were equally 
beneficial in closing the wound space over 48 hours. A superior effect of the lower 10 nmol 
dose was revealed by morphological analysis of myoblast fusion in the wound site at 7 and 
10 days following the scrape wounding. Ten nmol 1α,25[OH]2D3 promoted both 
hypertrophy and hyperplasia above that of Hi treatment and vehicle control in the wound site 
at 7 and 10 days post damage. This finding was reinforced by biochemical analysis of CK 
activity, which showed small increases above Hi and Veh at 7 days and significant increases 
at 10 days following injury. Myonuclear domain size was however significantly smaller with 
Lo treatment at 10 days, indicating an improved ability to recruit myoblasts to a single 
myotube (myonuclear accretion) and perhaps a hypertrophic response that had not peaked by 
the final sampling stage at 10 days. Analysis of the late differentiation myogenic regulatory 
factors, MRF4 and myogenin showed large variability between samples and although no 
significant treatment group effects were detected, 1α,25[OH]2D3 administered at 10 nmol 
up-regulated both MRF4 and myogenin to a greater extent than 100 nmol 1α,25[OH]2D3 and 
slightly greater than vehicle solution, peaking with marked increases at 7 days and a 
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continued trend of increasing expression at 10 days. Interestingly, peak expression of VDR 
coincided with the induction of myogenin at 7 days post damage, suggestive of a role for 
VDR myoblast fusion and consistent with reports of increased VDR expression in 
C2C12myoblasts at 7 days following BaCl2 treatment (Srikuea et al., 2012). However, this 
was consistent between conditions raising new questions as to what the role of the VDR is in 
myogenisis. 
A second important finding of the current work was that Hi dose 1α,25[OH]2D3 treatment of 
MDC monolayers resulted in delayed fusion of myoblasts at the wound site when compared 
with Lo treatment. Hi treated monolayers formed fewer myotubes at 7 days post damage, 
only reaching control (Veh) levels by day 10 which was supported by significantly lower 
CK activity and lower expression of the MRFs compared with Lo treatment. An interesting 
observation on this point was that regardless of basal MRF expression, there appeared to be 
a critical ‘threshold’, particularly for myogenin, that must be reached to allow fusion of 
myoblasts (approximately PCR cycle 18 in the current study, Figure 7.6). Lo treated cells 
appeared to reach this threshold more effectively across all samples, whilst Hi treated did not 
meet this threshold until 10 days with some samples not reaching the threshold at all. These 
interesting changes in gene expression may account for the morphological observations 
made. 
The positive influence of Lo 1α,25[OH]2D3 administration on cell migration is analogous to 
effects observed in other cell types. For example, exogenous treatment of vascular smooth 
muscle cells with 1α,25[OH]2D3 induced migration following activation of PI3 kinase, with 
observed effects being abolished by the addition of the PI3 kinase inhibitor, LY294002 
(Rebsamen et al., 2002). Indeed the importance of PI3K in myoblast migration has 
previously been characterized (Dimchev et al., 2013), pointing towards stimulation of PI3K 
activity as a main mediator of improved MDC migration dynamics in the current trial. It is 
likely that this response occurs through direct interaction of ligand bound VDR with Src 
kinase (Buitrago et al., 2000) and does not require transcriptional activity, as addition of 
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RNA polymerase inhibitor, 5,6-dichlorobenzimidazole riboside is reported to have no effect 
on 1α,25[OH]2D3 mediated PI3K activation (Rebsamen et al., 2002). Activation of PI3-
kinases and their lipid product PI(3,4,5)P3 leads to increases in GTP bound Rac, which is an 
important small GTPase along with Rho in the control of downstream signalling that 
generates filamentous actin branching and lamellipodia formation (Raftopoulou & Hall, 
2004). Lamellipodia are transient membrane protrusions that along with effective rear edge 
detachment allow migration of many cell types including myoblasts and fibroblasts. Tight 
regulation of the networks that lead to lamellipodia formation by positive and negative 
feedback loops are responsible for directional persistence and migration speed and ‘steering’ 
of the cell toward specific stimuli (Krause & Gautreau, 2014). It could therefore be 
postulated based on available evidence that Vitamin D may function to stimulate myoblast 
migration through the activation of PI3 kinases and increased downstream activity of small 
Rho GTPases resultantly altering actin cytoskeletal dynamics. Future research should aim to 
investigate this pathway in the context of Vitamin D and examine lamellipdodia formation 
with high-resolution microscopy techniques implementing kymography and fluorescent 
probes.  
The finding that 1α,25[OH]2D3 improved myoblast fusion is perhaps not surprising as 
Vitamin D metabolites are a closely related hormone system with homologous receptors, 
with some of the characteristics of true steroids as receptor ligands, such as testosterone. 
Indeed testosterone has repeatedly been demonstrated to enhance myoblast differentiation in 
vitro (Deane et al., 2013; Sculthorpe et al., 2012). In a similar observation to the current 
study, these investigations also observed significant increases in hyperplasia and 
hypertrophy. However, hypertrophy in these reported trials was evidenced by increased 
myotube diameter, whereas the current study reported increases in myotube area but not 
diameter. Furthermore, the current trial saw decreases in myonuclear domain size as a 
consequence of both nuclear accretion and myotube area but no increases in diameter. This 
may be due to the different models employed as the current trial implemented human 
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derived myoblasts in co-culture with fibroblasts. Therefore, the immediate environment and 
extracellular regulatory signals are incomparable between models and may account for these 
differences. Alternatively, the observation may be as a consequence of a hypertrophic 
response that had not reached its peak in the Lo treated population as a result of a more 
sustained phase of nuclear accretion delaying subsequent hypertrophy. Nevertheless, 
exogenous treatment of MDCs with 10nmol 1α,25[OH]2D3 showed comparable effects on 
myogenesis with that of other true steroid hormones in vitro. These findings show 
similarities and contrasts with other models of myogenesis in the context of Vitamin D. As a 
contrasting example, increases in myotube diameter and MHC type II were detected 
following 100 nmol treatment of C2C12 myoblasts versus vehicle, indicative of a positive 
myogenic effect (Garcia et al., 2011). In another trial, following serum depletion 100 nmol 
1α,25[OH]2D3 was shown to suppress myotube formation in a similar manner to the current 
study with decreased mRNA expression for myogenin and myf5. However, the treatment led 
to a 1.8-fold increase in cross-sectional size of individual myotubes associated with slightly 
decreased myostatin expression (Girgis et al., 2014a). The disparity between the current 
work and previous findings may lie in fundamental differences in the metabolism of Vitamin 
D in humans and rodents. Although both species express the same components of the 
Vitamin D endocrine system, how they respond to various doses is unknown. Furthermore, 
modelling Vitamin D deficiency in rodents is a fundamentally dietary challenge whereas in 
humans it is environmental. Differences between species in the capacity to metabolism 
Vitamin D should be considered further in future work modelling Vitamin D deficiency in 
vivo and in vitro. 
A surprising finding from the current study was the variable response observed in MDC 
migration and fusion in response to 100nmol 1α,25[OH]2D3. These observations could be 
explained by negative regulation of the Vitamin D metabolic pathway. Large quantities of 
1α,25[OH]2D3 have been demonstrated to cause a dose dependent induction of the 
CYP24A1 gene encoding for the enzyme 24-hydroxylase (Girgis et al., 2014b). This enzyme 
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is responsible for 24-hydroxylation and subsequent inactivation of 1α,25[OH]2D3 (to 
24,25[OH]D), thus acts to ‘block’ 1α,25[OH]2D3 mediated VDR signalling activity. 
Moreover, unpublished observations from our laboratory have demonstrated that high dose 
Vitamin D3 supplementation in vivo causes rapid increases in total serum 25[OH]D and 
subsequently 1,25[OH]2D3 that cause a concomitant rise in 24,25[OH]D concentration, 
supporting these in vitro data and the current hypothesis. 
Taken together, these data provide novel evidence for a functional role of Vitamin D in 
skeletal muscle regeneration when administered at 10 nmol in vitro. Coupled with in vivo 
evidence there is now stronger data to further investigate the link between Vitamin D 
metabolites and the regeneration processes in a variety of populations. 
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Chapter 8 
 
Thesis Synthesis 
  
This chapter provides a synthesis of the main aims and outcomes of the 
investigations described in this thesis. Limitations and future direction of research 
are also discussed. 
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8.1 Realisation of Aims 
8.1.1. Aim 1 – To investigate the role of Vitamin D concentration in human skeletal 
muscle function in vivo. 
This aim was addressed in Chapter 4. Skeletal muscle function was assessed using an RCT 
in which individuals with total serum 25[OH]D <100 nmol.L-1 (41 ± 18.2 nmol.L-1) were 
supplemented with 10,000 IU.day-1 Vitamin D3 for 12 weeks. Voluntary and involuntary 
skeletal muscle function measures determined that despite increasing serum 
concentrations >100 nmol.L-1 this had no effect on skeletal muscle contractile properties. 
Furthermore, in a small sub group of individuals with more pronounced Vitamin D 
deficiency at baseline (<25 nmol.L-1), supplementation was also ineffective. Therefore, the 
hypothesis that improving serum 25[OH[D >100 nmol.L-1 would improve contractile 
properties could not be accepted.  
8.1.2. Aim 2 – To investigate the role of Vitamin D concentration in human skeletal 
muscle function ex vivo.   
Aim 2 was also addressed in Chapter 4. It was decided upon to isolate single skeletal muscle 
fibres from biopsy specimens obtained from individuals with Vitamin D concentrations < 25 
nmol.L-1 and analyse contractile properties ex vivo. Although a small n = 2 was analysed, no 
detectable differences in contractile properties were detected following a supplementation 
period of 8 weeks with 4,000 IU.day-1 Vitamin D3 despite significant increases in serum 
25[OH]D from <25 nmol.L-1 to >75 nmol.L-1. Thus the hypothesis that improving serum 
25[OH]D from a concentration of <25 nmol.L-1 to >75 nmol.L-1 would improve single fibre 
contractile properties was rejected. Taken together with findings from study 1, there is 
strong evidence to support the notion that skeletal muscle contractile properties of young 
otherwise healthy males is not affected by serum 25[OH]D ranging from  18 – 75 nmol.L-1. 
However, it remains to be established whether serum concentrations associated with 
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hypercalcemia (<12.5 nmol.L-1, severely deficient) also show no association with skeletal 
muscle contractile properties. 
8.1.3. Aim 3 – To investigate the role of Vitamin D concentration in human skeletal 
muscle regeneration in vivo. 
This aim was addressed in Chapter 5. Twenty males with serum 25[OH]D <75 nmol.L-1 (45 
± 20 nmol.L-1) underwent a bout of eccentric exercise (20 x 10 eccentric contractions) prior 
to and following supplementation with either 4,000 IU.day-1 Vitamin D3 or placebo. 
Maximal voluntary contraction force was assessed by isokinetic dynamometry at both 60 
and 180 deg.sec-1 immediately prior to-, following and at 24, 48 hours and then at 7 days 
following the exercise bout. Supplemental Vitamin D3 significantly elevated serum 
25[OH]D and resulted in a 10.7% and 12.4% improvement in MVC force at 60 deg.sec-1 at 
48 hours and 7 days following eccentric exercise, respectively. The placebo group showed 
no change prior to or following supplementation despite a significant reduction in serum 
25[OH]D during the 6 weeks supplementation period. These findings allow acceptance of 
the hypothesis that increasing total serum 25[OH]D >75nmol.L-1 would lead to an improved 
recovery of MVC force following eccentric exercise. Therefore, it was necessary to explore 
potential cellular mechanisms that may account for these observations. 
8.1.4. Aim 4 – To investigate the role of exogenous Vitamin D on the regeneration of 
human derived muscle cells in vitro. 
Aim 4 was addressed in Chapters 6 & 7. Chapter 6 optimised the methodological aspects of 
an in vitro model of muscle regeneration. Muscle regeneration was then investigated in the 
context of Vitamin D in Chapter 7. As the muscle regeneration process involves numerous 
complex and overlapping steps, it was important to isolate aspects that could be replicated 
appropriately in vitro. Therefore, muscle derived cell migration to the site of damage and 
myoblast fusion were investigated in the presence or absence of 10 and 100 nmol 
1α,25[OH]2D3. Findings from these investigations allowed partial acceptance of the 
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hypothesis that both 10 and 100 nmol doses would improve migration characteristics and 
fusion in a dose dependent manner. Both 10 and 100 nmol stimulated faster MDC migration 
speeds and distances, however only the 10 nmol dose led to improved biochemical and 
morphological aspects of myoblast fusion at 7 and 10 days post damage, whereas 100 nmol 
was detrimental to this process. These findings imply that Vitamin D3 is involved in the 
processes that mediate cellular responses to muscle damage providing novel cellular aspects 
by which Vitamin D concentration associates with muscle regeneration in vivo.  
 
8.2 Thesis Limitations 
8.2.1. Chapter 4 – There were a number of limitations in Chapter 4. Markers of Vitamin D 
toxicity were not analysed thus compromising the efficacy of the supplementation protocol. 
An early indication of adverse effects to Vitamin D supplementation is hypercalciuria (Vieth, 
2007); however this was not monitored in the current study. Symptoms of Vitamin D 
toxicity are wholly attributable to hypercalcemia/hypercalciuria, including nausea, 
dehydration and lethargy. No participants reported any of the associated symptoms. The 
dose of 10,000 IU.day-1 was selected as previous trials including our own (Close et al., 
2013a) have failed to achieve the desired serum 25[OH]D concentrations >100 nmol.L-1 
with lower doses. Additionally, data have demonstrated that oral Vitamin D intakes of 9,600 
IU·day-1 are needed to obtain serum 25[OH]D concentrations above 100 nmo.L-1 in 97% of a 
large cohort of 3667 participants (Garland, French, Baggerly, & Heaney, 2011). Clinical trial 
evidence and dermal photosynthesis of Vitamin D following UVB exposure supports our 
assumption that a prolonged daily dose of 10,000 IU.day-1 is unlikely to cause adverse 
effects in otherwise healthy persons (Vieth, 2007). Toxicity monitoring and analysis of 
24,25[OH]D (the product of Vitamin D catabolism) in future trials that employ high daily 
doses of Vitamin D will aid in establishing a safe upper limit for Vitamin D3. A further 
limitation was that the sample size calculation for the current study determined that to enable 
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a 10% (21 Nm) increase in peak torque between pre-supplementation and post-
supplementation with 80% power, n = 24 was required. Although 29 participants completed 
supplementation and blood sampling, only 22 completed all muscle function trials. This is a 
potential confounding factor, however it may be argued given that no trends were detected 
and observed P-values were strongly non-significant that it is unlikely a 2 participant deficit 
significantly affected these findings. 
Single skeletal muscle fibres were isolated in order to study the effect of increasing serum 
25[OH]D on single fibre contractile properties. Although a number of biopsies were 
obtained, only n = 2 were analyzed pre and post supplementation. This was due to 
constraints on the accessibility of the equipment needed to perform the analyses. Such a 
small sample does not allow definitive conclusions to be made and therefore larger samples 
should be analyzed to confirm the findings of section 4.8. Furthermore, the fibres analysed 
were not ‘fibre-typed’. As described in the literature review of this thesis (2.1.2), skeletal 
muscle fibres expressing different myosin heavy chain isoforms exhibit different contractile 
properties. In order to make definitive conclusions about the fibres analyzed pre and post 
supplementation, future work should aim to increase the sample size analyzed and determine 
myosin heavy chain isoform expression via electrophoretic separation of isolated protein 
from the fibres and characterization by silver staining or immunoblotting.   
8.2.2. Chapter 5 – The experimental design and interpretation of data in Chapter 5 are 
limited in that muscle damage was assumed to have occurred by measures of impaired 
voluntary contractile function without any histological or biochemical evidence. Therefore, 
it may be argued as to whether damage was indeed present since there are no direct markers 
provided. However, in argument against this notion, histological damage and uptake of 
extracellular dyes has been evidenced in animals and humans following eccentric exercise 
(Friden, Sjostrom, & Ekblom, 1981; Hamer, McGeachie, Davies, & Grounds, 2002; McNeil 
& Khakee, 1992; Newham et al., 1983). Furthermore, activation of satellite cells has been 
observed after a single bout of eccentric exercise (Hyldahl et al., 2014) suggesting the need 
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for adaptive remodeling in response to the damaging event. Future studies could expand on 
the work described in Chapter 5 by retrieving multiple biopsy specimens during the recovery 
from the exercise bout to assess the in vivo cellular response to eccentric exercise in Vitamin 
D deficient and sufficient individuals. 
The sample population recruited in the current study were healthy, physically active males 
engaging in regular exercise training outside of day-to-day activity. However, comparatively 
to that of the elite performer, the current cohort is still considered novice. Untrained muscle 
is known to be more susceptible to exercise induced damage than that of trained individuals 
(Newton, Morgan, Sacco, Chapman, & Nosaka, 2008) and therefore the likelihood of seeing 
an augmented response to a nutritional aid or therapy is increased in an untrained population. 
Nevertheless, trained muscle still experiences muscle damage and therefore low Vitamin D 
concentration may indeed hamper the regenerative process. In keeping with discussion of 
damage susceptibility, the ‘repeated bout effect’ is the phenomenon that describes the 
reduced susceptibility of muscle to damage from eccentric exercise with repeated bouts. It 
may be argued that the individuals in the VITD treatment group were less trained than those 
of the PLB group hence the potentiated recovery following supplementation. Although 
efforts were made to control for this by block randomizing participants based on MVC 
torque and employing a strict inclusion criteria, it is unknown whether the individuals of the 
PLB group regularly participated in exercise programmes that incorporate eccentric loading. 
Neural mechanisms proposed for this effect are an increased recruitment of type I motor 
units thus spreading the workload of high fibre stress and/or recruitment of a larger motor 
unit pool. Mechanical mechanisms may be increased dynamic muscle stiffness and increased 
passive stiffness and cellular adaptations may be the longitudinal addition of sacromeres 
following eccentric exercise, adaptations in the inflammatory response and adaptations to 
maintain excitation contraction coupling (McHugh, 2003) Whether 6 weeks is sufficient to 
lose any of these proposed adaptations gained from a single bout of eccentric exercise is 
debatable (Nosaka, Clarkson, McGuiggin, & Byrne, 1991; Paddon-Jones, Muthalib, & 
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Jenkins, 2000; Smith et al., 1994). Finally, it is reasonable to question why an improvement 
in peak torque recovery was only observed at 60 deg.sec-1 and not at 180 deg.sec-1. 
Observation of the data presented in Figure 5.3a shows that indeed an improvement did also 
occur in torque recovery of at 180 deg.sec-1 in the VITD group (3.6% improvement at 48 
hours and 8.4% improvement at 7 days). Although this does not reach statistical significance 
there is still an observed physiological benefit. It is likely that a significant change was 
undetected as maximal force production is known to be elicited at slower dynamic 
movement velocities (Baltzopoulos & Brodie, 1989) and therefore the ability to detect subtle 
changes in peak torque may be lost at faster velocities. 
8.2.3. Chapter 6 - For the optimisation of the in vitro model of muscle regeneration, the 
C2C12 was used. These cells line are derived from murine satellite cells and are a purely 
myogenic cell line. Therefore, their capacity for myogenisis is arguably greater than the 
mixed populations of human derived cells used in the experimental trials. However, the 
C2C12 cell line represents the best model to study myogenisis aside of primary cell lines 
isolated from whole tissue. Given that primary cells reach replicative senescence unlike 
immortalised cell lines, it was opted for to not deplete primary cell populations and utilise 
these stocks for experimental trials. 
8.2.4. Chapter 7 - For the experimental trials described in Chapter 7, human MDCs were 
used. It was decided that cells retrieved from biopsy specimens would not be sorted (for 
example by magnetic activated cell sorting or MACS) to isolate a purely myogenic cell 
population. This approach was adopted due to the importance of non-myogenic cell types, 
such as fibroblasts in the wound healing process. Indeed, the migration and proliferation of 
fibroblasts is an important step preceding secretion of temporary ECM components and is 
fundamental to allow efficient migration and alignment of myoblasts and also serves to 
stabilize the tissue for the formation of new myofibres in vivo (Goetsch, Hawke, Gallardo, 
Richardson, & Garry, 2003). Moreover, reciprocal interactions between fibroblasts and 
muscle progenitors have been found to contribute more effective muscle regeneration in 
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vitro (Murphy, Lawson, Mathew, Hutcheson, & Kardon, 2011) a finding that has been 
replicated in other organized co-culture trials (Rao et al., 2013). Thus although it may be 
argued that varied populations of skeletal myoblasts and fibroblasts were used, 
implementing a co-culture model permits better modelling of in vivo wound healing in an in 
vitro assay. 
A 2D model was utilised to study muscle regeneration in vitro. Although this method has 
strengths (see Chapter 6, section 6.1) and is appropriate for studying the migration of 
adherent cell types as well as the maturation of skeletal muscle myoblasts, there are aspects 
of the in vivo skeletal muscle niche that are not present in this model. Indeed mechanical 
stimuli, local and systemic factors implicated in cell behaviour during muscle regeneration 
are missing from 2D models of myogenesis. Bioengineering of 3D muscle constructs, a 
relatively new technique for the in vitro modelling of myogenisis partly overcomes the 
constraints of 2D systems by allowing better alignment and manipulation of mechanical 
stress (Sharples et al., 2012). Replication of the studies described in Chapter 7 of this thesis 
utilising a 3D cell culture system will provide more physiological insights as to how Vitamin 
D metabolites influence skeletal muscle regeneration. 
Additionally, 10 and 100 nmol doses of 1α,25[OH]2D3 were utilised for the experimental 
trials described in Chapter 7. As discussed in section 7.3.3. these doses have widely been 
used to study the role of Vitamin D in numerous cell types including skeletal muscle. 
However, given that 100 nmol resulted in a detrminetal outcome for myoblast directional 
migration and fusion, it remains to be established what the most apporiate dose of exogenous 
1α,25[OH]2D3 would be in a cell culture system to elicit beneficial responses. Although 10 
nmol improved both migration and fusion of human skeletal myoblasts, this dose may also 
be higher than the optimal concentration to maximise these processes. Thus if this work 
were to be repeated, a broad dose response study should be implemented. 
  
206 
	  
8.3 Future Directions 
Although Vitamin D has been strongly implicated in skeletal muscle function, the data 
generated from this thesis suggest that non-pathological muscle of Vitamin D insufficient 
males is unlikely to show perturbations in contractile properties. It may be speculated that 
although data point towards a role of Ca2+ regulation as the factor by which Vitamin D 
which in theory may regulate muscle function, this may not be the mechanism by which 
Vitamin D treatment has previously resulted in positive outcome trials. As discussed, 
positive outcome data are limited to elderly cohorts in whom a loss of muscle mass and 
function occurs with age regardless of Vitamin D status. It may be the case that Vitamin D 
contributes to the preservation of muscle mass with age thus preventing further functional 
deficits. In vitro, Vitamin D regulates pathways related to control of muscle mass such as 
Notch signalling (Domingues-Faria et al., 2014), PI3K/Akt/mTOR (Buitrago et al., 2013; 
Garcia et al., 2011; Salles et al., 2013) and the ubiquitin proteasome degradation pathway 
(Bhat et al., 2013). Further, Vitamin D can enhance the stimulatory effect of insulin and 
leucine on muscle growth in cultured myoblasts (Salles et al., 2013). In Vivo, recent data 
support this idea as a high whey protein-, leucine, and Vitamin D-enriched supplement 
preserves appendicular muscle mass in older adults during a hypocaloric diet and resistance 
exercise program compared with compared with isocaloric control (Verreijen et al., 2015). 
What is currently still unknown is whether cases of severe Vitamin D deficiency < 12 
nmol.L-1 may impact muscle function. Such concentrations are known to alter systemic Ca2+ 
homeostasis and may indeed also influence Ca2+[i] in skeletal muscle (Ceglia & Harris, 
2013). However, the prevalence of such concentrations in young healthy individuals is 
uncommon according to literature reports and thus obtaining a large enough sample to study 
the relationship between such 25[OH]D concentrations and muscle function will be a 
challenge to the researcher. The data presented here do not disprove previous findings per se 
but pose new questions as to what Vitamin D concentration is important for normal skeletal 
muscle function: 
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1. Since Vitamin D concentrations above ~20 nmol.L-1 do not associate with changes in 
skeletal muscle function, do individuals with severe deficiency (<12.5 nmol.L-1) show 
detectable changes in muscle function? 
2. As Vitamin D deficient elderly populations have demonstrated improvements in muscle 
function with supplemental Vitamin D, does this suggest Vitamin D concentration is 
only important in aged muscle when comorbidities exaggerate the loss of muscle 
function experienced with age? 
It was also demonstrated that Vitamin D might play a more important role in aspects of the 
muscle regeneration. The data presented demonstrate that increasing serum 25[OH]D 
concentrations improves the recovery from eccentric exercise and also provide novel 
insights implicating cellular aspects of the muscle regeneration process are responsive to 
Vitamin D. However, the molecular networks that orchestrate these cellular effects are yet to 
be established thus warranting further investigation. First steps were taken to characterise 
these pathways as it was shown that VDR is up regulated during myoblast fusion regardless 
of treatment although MRF expression was up regulated differentially based on treatment, 
suggesting VDR expression and activity may not be coupled. Additionally, although 
myoblast migration and fusion are important steps in muscle regeneration and regulated by 
Vitamin D, the activation and expansion of satellite cells are also steps preceding those 
investigated in the current work that should be explored in the context of Vitamin D. Taken 
together, the data suggest a causal relationship between Vitamin D and muscle regeneration, 
posing new research questions: 
1. At what serum concentration of serum 25[OH]D is muscle regeneration impaired? 
Although a 75 nmol.L-1 inclusion criteria was implemented in the study described in 
Chapter 5, basal serum 25[OH]D ranged from 16-75 nmol.L-1. 
2. At what serum 25[OH]D concentration are no further improvements in maximal torque 
recovery observed? 
3. What signalling pathways mediate the cellular remodelling response to Vitamin D? 
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4. Why does excessive Vitamin D treatment in vitro lead to impaired myoblast fusion? 
5. Is VDR expression regulated regardless of ligand availability in myogenesis and does 
ligand availability influence VDR activity? 
6. Is Vitamin D implicated in the activation and expansion of satellite cells? 
A final consideration for this field of research is whether the Vitamin D classification system 
is useful for the study of individual systems. A vibrant debate at present is what serum 
concentrations should constitute deficiency and sufficiency. As described in Chapter 2, 
Section 2.4.10., governing bodies such as the US IoM suggest the classification system 
highlighted in Table 2.3. However, the current data would suggest that for skeletal muscle 
function these classifications are not meaningful since individuals with low serum 25[OH]D 
concentrations were tested and showed no changes at the whole tissue and single fibre scale 
of analysis. Defining the individual response of different tissues to Vitamin D and the 
interaction of genetic mutations in the Vitamin D endocrine system will help to define more 
appropriate recommendations on dietary Vitamin D requirements. However, at present the 
complexities and tissue specificity of Vitamin D signalling makes gross classifications 
impossible.  
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8.4 Conclusions and Implications 
As described in the opening chapter of this thesis, low serum 25[OH]D concentrations are 
prevalent worldwide. Most tissues of the human body express the necessary components of 
the Vitamin D endocrine system to respond functionally to Vitamin D, including skeletal 
muscle. This thesis has shown that in non-pathological muscle, there are no disturbances to 
contractility in males with low serum 25[OH]D and raises new questions as to whether 
Vitamin D is implicated in contractile function. In contrast to muscle function, the data in 
this thesis have provided a systems based insight into Vitamin D and skeletal muscle 
damage demonstrating that Vitamin D is an important factor in skeletal muscle regeneration. 
Given the importance of skeletal muscle regeneration in training, performance and in ageing 
where an impaired ability to regenerate skeletal muscle is evident (Shi & Garry, 2006), it 
may be important to maintain optimal serum 25[OH]D concentration to optimise skeletal 
muscle remodelling in response to muscle damage. Screening of 25[OH]D is advisable to 
determine whether supplemental Vitamin D is required to maintain serum 25[OH]D 
concentrations of approximately 75 nmol or more. The data presented in this thesis show 
that this is easily achievable with 4,000 IU.day-1 Vitamin D3 and falls within the European 
Food Safety Authority (EFSA) safe upper limits for supplemental Vitamin D and may 
therefore be suggested as good practice to prevent impairments in the regenerative capacity 
of human skeletal muscle. 
It is now a challenge to the field to determine what precise concentrations (both low and 
high) of Vitamin D are detrimental to muscle regeneration and to identify factors of the 
Vitamin D endocrine system that introduce variability in the response to supplementation. 
The widespread prevalence of low serum 25[OH]D should not be ignored as there is now 
ample evidence providing strong support that this is detrimental to many parameters of 
human health. 
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12 (25 ± 15 nmol l−1) compared with baseline. Despite 
marked increases in total serum 25[OH]D in VItD and a 
decrease in PlB, there were no significant changes in any 
of the muscle function outcome measures at week 6 or 12 
for either group (P > 0.05).
Conclusions Elevating total serum 25[OH]D to con-
centrations > 120 nmol l−1 has no effect on skeletal 
muscle function. We postulate that skeletal muscle func-
tion is only perturbed in conditions of severe deficiency 
(<12.5 nmol l−1).
Keywords cholecalciferol · 25-Hydroxyvitamin D ·  
Supplementation · Isokinetic dynamometry · 
Electromyostimulation · Fatigue
Abbreviations
25[OH]D  25-Hydroxyvitamin D
1,25[OH]D  1,25-Dihydroxyvitamin
ca2+   calcium, Ionized
EclIA   Enzyme-linked chemiluminescent 
immunosorbent assay
EMS   Electromyostimulation
FDA   Food and Drug Agency
iPtH   Intact parathyroid hormone
IU   International units
IKD   Isokinetic dynamometry
lc–MS/MS  liquid chromatography tandem mass 
spectrometry
llOQ   lower limit of quantification
n    newtons
nm   newton metres
nmol l−1  nanomoles per litre
PAr-Q  Physical activity readiness Questionnaire
Pmol l−1  Picomoles per litre
rad s−1   radians per second
Abstract 
Purpose Vitamin D may be a regulator of skeletal muscle 
function, although human trials investigating this hypoth-
esis are limited to predominantly elderly populations. We 
aimed to assess the effect of oral vitamin D3 in healthy 
young males upon skeletal muscle function.
Methods Participants (n = 29) received an oral dose of 
10,000 IU day−1 vitamin D3 (VItD) or a visually identical 
placebo (PlB) for 3 months. Serum 25[OH]D and intact 
parathyroid hormone (iPtH) were measured at baseline 
and at week 4, 8 and 12. Muscle function was assessed in 
n = 22 participants by isokinetic dynamometry and percu-
taneous isometric electromyostimulation at baseline and at 
week 6 and 12.
Results Baseline mean total serum 25[OH]D was 
40 ± 17 and 41 ± 20 nmol l−1 for PlB and VItD, respec-
tively. VItD showed a significant improvement in total 
25[OH]D at week 4 (150 ± 31 nmol l−1) that remained 
elevated throughout the trial (P < 0.005). contrastingly, 
PlB showed a significant decrease in 25[OH]D at week 
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rDI    recommended daily intake
US IoM    United States Institute of Medicine
UVB    Ultraviolet B
Introduction
Vitamin D is classically regarded as a vital endocrine regu-
lator of bone health via its role in calcium and phosphate 
homeostasis (Anderson et al. 2012). However, a myriad of 
non-skeletal effects of the steroid hormone are now known 
and are predominantly attributable to the identification of 
the vitamin D receptor in virtually all tissues (rosen et al. 
2012) including skeletal muscle (Srikuea et al. 2012). 
genome-wide analyses suggest that any improvement in 
vitamin D status significantly affects the expression of a 
large number of genes that have many biological func-
tions (Hossein-nezhad et al. 2013). Specifically regarding 
skeletal muscle, it has long been understood that patients 
with osteomalacia resultant from inadequate dietary vita-
min D intake often display an accompanying skeletal mus-
cle myopathy presenting as a proximal muscle weakness 
that is responsive to vitamin D supplementation (Ziam-
baras and Dagogo-Jack 1997; Irani 1976; Smith and Stern 
1967; Al-Said et al. 2009). Emerging data now suggest at 
a cellular level that skeletal muscle is indeed a tissue that 
responds functionally to vitamin D. recent data have dem-
onstrated in vivo improvements in mitochondrial oxidative 
function when severe vitamin D deficiency is corrected 
in humans (Sinha et al. 2013). Moreover, studies in chick 
embryo myoblast cultures have provided robust evidence 
that vitamin D is a regulator of intracellular ca2+ concen-
tration (capiati et al. 2000; Morelli et al. 1993), which 
has also been observed in vivo in chicks (Vazquez et al. 
1995) and in vitro in fully differentiated soleus muscle (de 
Boland et al. 1988). Vitamin D may therefore be impli-
cated in skeletal muscle contractility, which early reports 
from vitamin D depleted rats have alluded to (rodman 
and Baker 1978). Aside from these observations, reports 
suggest a role for the bioactive vitamin D compound 
1,25-dihydroxyvitamin D (or 1,25[OH]D) in signalling 
pathways which involved myoblast proliferation and dif-
ferentiation indicating a key role for vitamin D in muscle 
cell development and survival (garcia et al. 2013; Srikuea 
et al. 2012; Stratos et al. 2013). Despite such evidence, 
vitamin D deficiency is still widespread around the globe 
(van Schoor and lips 2011). We have previously shown 
that this observation is consistent in sub-populations of 
professional athletes and healthy, young athletic cohorts 
(Morton et al. 2012; close et al. 2013a, b).
A number of trials have sought to assess the effect of 
vitamin D status on muscle function at a macroscopic scale. 
Insights from these investigations have established a link 
between vitamin D status and falls and various other physi-
cal performance measures such as handgrip, lower limb 
strength, balance and gait speed (Bischoff-Ferrari et al. 
2004; gerdhem et al. 2005; Houston et al. 2007; Marantes 
et al. 2011). However, such trials are limited to predomi-
nantly geriatric or clinical populations, and it is difficult 
to generalise such findings to young healthy populations, 
due to age-related skeletal muscle disease (i.e. sarcopenia). 
the few trials that have been conducted in young otherwise 
healthy cohorts have resulted in equivocal findings, with 
some investigations reporting beneficial effects of vitamin 
D supplementation in muscle (Sinha et al. 2013; close 
et al. 2013b) and others observing no perceptible changes 
following supplementation (close et al. 2013a). Hamper-
ing such findings further is large heterogeneity in outcome 
measures implemented to assess muscle function, low par-
ticipant numbers, heterogeneity in supplementation proto-
cols and varying baseline vitamin D status of the sample 
population making the cross comparison between findings 
difficult.
Adding further complexity to this issue is that the daily 
requirement for vitamin D needed to elevate total serum 
vitamin D concentrations to a level necessary for optimal 
physiological function is a point of debate. With regard 
to dose, the United States Institute of Medicine (US IoM) 
has set the rDI for vitamin D at 600 IU day−1 for young 
adults and tolerable upper intake at 4,000 IU day−1 (IoM 
2011), although the US IoM set the ‘no observed adverse 
effect limit’ (nOAEl) at 10,000 IU day−1 (IoM 2011). In 
relation to total serum 25-hydroxyvitamin D (or 25[OH]
D) concentration, the US IoM suggest >50 nmol l−1 as 
adequate whilst suggesting that concentrations exceeding 
125 nmol l−1 may be detrimental to health. Others have 
suggested that these guidelines are too conservative and 
claim values exhibited in those living outdoors in sun-rich 
climates (~100 nmol l−1) to be adequate, since they reflect 
the values present when the human genome evolved in such 
rich environments around equatorial Africa (Vieth 2011; 
Heaney 2011). An ‘optimal’ 25[OH]D concentration for 
muscle function is currently still elusive and no study till 
date has tested the hypothesis that elevating serum 25[OH]
D concentrations to >120 nmol l−1 is optimal for muscle 
function in healthy recreationally active individuals, as 
previously suggested (Heaney 2011). Our group has previ-
ously implemented doses of 20,000 and 40,000 IU week−1 
oral vitamin D3, but failed to elevate serum concentrations 
>100 nmol l−1 (close et al. 2013a). thus higher doses may 
be necessary to achieve a total serum 25[OH]D concentra-
tion >100 nmol l−1.
given the available evidence and a clear lack of data 
in the area, we sought to investigate the impact of vita-
min D status on lower limb muscle function using valid 
macroscopic techniques including percutaneous isometric 
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myostimulation (IMS) and isokinetic dynamometry (IKD) 
in healthy, recreationally active young men. We hypoth-
esized that supplementing with high dose oral vitamin 
D3 (cholecalciferol) to elevate total serum 25[OH]D con-
centrations > 100 nmol l−1 (suggested optimal Zitter-
mann 2003; Heaney 2011; Vieth 2011) would have a ben-
eficial effect on our chosen outcome measures of muscle 
function.
Methodology
Participants
twenty-nine male participants (age = 22.7 ± 3 years; 
height = 179.3 ± 5.9 cm; weight = 76.1 ± 16.2 kg) vol-
unteered to partake in the current trial. Participants received 
detailed information regarding the study procedures and 
were required to complete a PAr-Q, a medical history 
questionnaire and provide written informed consent before 
inclusion in the trial. Strict exclusion criteria were imple-
mented for participant safety and validity of the investi-
gation. Participants were excluded if they had underlying 
health problems as identified by completion of the medical 
history questionnaire, were sunbed users or taking vitamin 
D supplementation, standard oral multivitamins or, cur-
rently unfit to perform physical exercise, currently taking 
prescribed medication and those who expected a drastic 
change in their physical activity/training routine during 
the trial. After meeting these initial inclusion criteria, par-
ticipants provided a venous blood sample that was analysed 
for total 25-hydroxyvitamin D (25[OH]D) concentration. 
those presenting with total serum 25[OH]D concentra-
tions ≥100 nmol l−1 were excluded from the trial. Ethical 
approval was granted by the local ethics committee of liv-
erpool John Moores University, and all data were collected 
in accordance with the Declaration of Helsinki.
Participants were block randomized based on their 
baseline 25[OH]D concentration and electrically evoked 
20 Hz isometric knee extensor force into two experimental 
groups. Of the 29 initial participants, 22 completed all test 
procedures whilst the remaining 6 only took part in supple-
mentation and blood sampling and one dropped out. this 
was due to an inability on the participants’ behalf to com-
mit sufficient time for each testing point. Fourteen partici-
pants were assigned to an oral vitamin D treatment group 
(VItD) and 15 participants were initially assigned to a vis-
ually identical placebo control group (PlB) (see table 1).
Vitamin D supplementation
Participants allocated to VItD received 10,000 IU day−1 
of vitamin D3 (Bio-tech Pharmacal. Arkansas, USA) taken 
as two 5,000 IU gelatin capsules. those allocated to PlB 
received two visually identical placebo capsules each 
containing 90 mg cellulose (Bio-tech Pharmacal. Arkan-
sas, USA). the supplementation period lasted 12 weeks 
between the months of January and April to achieve a pla-
teau in serum 25[OH]D response, as previously shown in a 
dose response trial with 10,000 IU day−1 vitamin D3 chole-
calciferol (Heaney et al. 2003). Both researcher and partici-
pant were blinded until completion of the study procedures.
Blood sampling
For the analysis of vitamin D metabolites and iPtH, par-
ticipants provided a fasted venous blood sample collected 
from the antecubital vein into two K2EDtA plasma (10 ml) 
vacutainers and two serum separator [(SSt) 8.5 ml] vacu-
tainers (Beckton Dickinson. Oxford, UK) prior to supple-
mentation and then at 4, 8 and 12 weeks post-supplemen-
tation. SSt samples were allowed to clot for 1 h at room 
temperature whilst K2EDtA samples were immediately 
stored on ice, following which all samples were centrifuged 
for 15 min at 1,500 rcf at 4 °c. Serum and plasma were 
extracted and stored at −80 °c until required for analysis.
Analysis of vitamin D metabolites and intact parathyroid 
hormone (iPtH) concentration
For the analysis of vitamin D concentration 25(OH)D2, 
25(OH)D3 were extracted from serum samples, follow-
ing zinc sulphate protein precipitation, using Isolute c18 
solid phase extraction cartridges. Potential interfering 
compounds were removed by initial elution with 50 % 
methanol followed by elution of the vitamins using 10 % 
tetrahydrofuran in acetonitrile. Dried extracts were recon-
stituted prior to injection into a high performance liquid 
chromatography tandem mass spectrometer (lc–MS/
MS) in the multiple reaction mode. the multiple reac-
tion mode transitions (m/z) used were 413.2 > 395.3, 
401.1 > 383.3 and, 407.5 > 107.2 for 25(OH)D2, 25(OH)
D3, and hexa-deuterated [OH]D3, respectively. the assay 
Table 1  Block randomization data including mean total serum 
25[OH]D concentration presented as nmol l−1 and mean isometric 
force from a single stimulation at a frequency of 20 Hz and stimula-
tion intensity of 130 mA
PlB VItD
Mean total 25[OH]D (nmol l−1) 40 41
 ±SD 17 21
 t test t = 0.867, P = 0.876
Mean isometric force (n) 267 307
 ±SD 69 67
 t test t = −1.086, P = 0.303
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was validated against published acceptance criteria (FDA 
2001). Assay sensitivity was determined by the lower limit 
of quantification (llOQ): 25[OH]D3 = 2.5 nmol l−1 
and 25[OH]D2 = 2.5 nmol l−1. coefficients of variation 
(cVs) for the assay were 10 % across a working range of 
2.5–625 nmol l−1 for both 25[OH)D2 and 25(OH)D3. Data 
regarding assay precision, detection and recovery are pro-
vided in table 2A, B. table 2A demonstrates imprecision 
of the assay and 2B shows recovery efficiency. Intra-assay 
precision was assessed by running quality control materi-
als (chromsystems Instruments and chemicals. gräfelfing, 
germany) and commercially bought material (calf serum) 
ten times (n = 10) within a single run, and separately over 
15 runs (n = 15) for inter-assay assessment. Values used to 
determine assay variation are expressed as SD and %cV. 
Acceptance criteria define that %cV should not exceed 
10 % in both intra- and inter-assay (table 2A). Extrac-
tion recovery was assessed by determining the amount of 
vitamin D3/D2 recovered from the amount spiked prior to 
extraction. the percentage recovery was calculated by the 
measured value against the sum of endogenous value and 
spiking concentration. Spiked recovery is determined by 
adding known quantity of 25[OH]D3/D2 to serum samples 
with different levels of endogenous 25[OH]D (table 2B). 
the data demonstrate good assay recovery, indicating 
that the procedure was able to efficiently extract vitamin 
D from matrix and the method was able to determine the 
amount recovered accurately. Masscheck calibration mate-
rials and controls are traceable against nISt 972 reference 
material. Furthermore, the lc–MS/MS method of analysis 
has previously been validated against other commercially 
available assays and is regarded as the most valid and reli-
able technique for the assessment of vitamin D metabolites 
(Snellman et al. 2010).
classification of vitamin D status was based upon the 
US IoM (2011) guidelines (see table 3).
For the analysis of iPtH, an Elecsys electrochemilumi-
nescent immunoassay (EclIA) by cobas (roche Diag-
nostics. Indianapolis, USA) was implemented. Fifty μl 
of plasma, a biotinylated monoclonal PtH-specific anti-
body and monoclonal PtH-specific antibody labelled with 
a ruthenium complex were formed into a sandwich com-
plex. After addition of streptavidin-coated microparticles, 
the complex became bound to the solid phase via interac-
tion of biotin and streptavidin. the reaction mixture was 
aspirated into the measuring cell where the microparticles 
Table 2  (A) Imprecision of the lc–MS/MS assay and (B) recovery efficiency of the assay
Intra precision was assessed by running quality control materials (chromsystems) and commercially bought material (calf serum) ten times 
(n = 10) within a single run, and separately over 15 runs (n = 15) for inter-assay assessment. Variation is expressed as standard deviation (SD) 
and percentage of coefficient of variation (%cV)
A
nmol l−1 chromsystem 1 chromsystem 2 calf serum
Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2 Vitamin D3 Vitamin D2
Intra-assay precision
 Mean 42.9 43.4 80.2 81.1 6.9 7.8
 SD 4.1 3.4 7.8 8.6 0.7 0.8
 %cV 9.5 7.8 9.7 10.6 10.1 10.2
Inter-assay precision
 Mean 40.4 32.4 76.8 95.3 7.7 7.8
 SD 2.4 3.3 7.2 8.3 0.7 0.9
 %cV 6 10 9.3 8.7 9.1 10.8
B
Endogenous 25[OH]D3 (nmol l−1) Spiked (nmol l−1) Measured value (nmol l−1) %recovery
Sample 1 5.5 50 53.7 96.4
Sample 2 10.2 100 103.4 93.8
Blank 0 500 491 98.2
Endogenous 25[OH]D2 (nmol l−1) Spiked (nmol l−1) Measured value (nmol l−1) %recovery
Sample 1 37.0 50 84 96.5
Sample 2 80.2 100 171.3 95
Blank 0 500 479 95.8
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were magnetically captured onto the surface of the elec-
trode. Unbound substances were then removed with Pro-
cell. Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a pho-
tomultiplier. results were determined via a calibration 
curve which is instrument-specifically generated by two-
point calibration and a five-point master curve provided 
via the reagent barcode. the measuring range of the assay 
was 0.127–530 pmol l−1 (defined by the lower detection 
limit and the maximum of the master curve). the Elecsys 
EclIA has previously been validated by multicentre evalu-
ation as a valid and reliable measure of iPtH concentration 
(Hermsen et al. 2002).
Assessment of lower limb muscle function
A number of outcome measures were employed to validly 
assess muscle function of the lower limb. Participants com-
pleted both an IKD protocol and EMS protocol. All tests 
were completed at baseline, week 6 and week 12 of sup-
plementation apart from IKD, which was only completed at 
baseline and week 12.
Isokinetic dynamometry
Isokinetic torque was assessed on a Biodex isokinetic 
dynamometer (Biodex Medical Systems Inc. Shirley, nY, 
USA), previously validated for its use in reliable assess-
ment of muscle function variables related to force produc-
tion (Drouin et al. 2004). Participants were seated as per 
the manufacturer’s guidelines with a 90° flexion of the hip 
and non-extendable straps crossing the chest and abdo-
men and across the quadriceps to maximise isolation of the 
target muscle groups. the test protocol consisted of four 
consecutive maximal extension and flexion movements 
(Baltzopoulos and Brodie 1989) of the right quadriceps 
and hamstrings at two different fixed angular velocities, 
1.05 rad s−1 (60 deg s−1) and 3.14 rad s−1 (180 deg s−1) 
from which peak torque (nm) was generated, separated 
by a 5-min rest to allow full recovery of the high energy 
phosphate pool (Soderlund and Hultman 1991). testing at 
two angular velocities produces valuable information as 
to how peak torque is produced by during different activa-
tion patterns (Baltzopoulos and Brodie 1989) as it is under-
stood that neurological activation patterns of motor units 
changes as the angular velocity increases e.g. from 60 to 
180 deg s−1 (lesmes et al. 1978) thus replicating differ-
ent locomotive activities. All participants were familiar-
ized with the protocol until the coefficient of variation for 
each participant was <10 % (Atkinson and nevill 1998) 
(table 4).
Percutaneous isometric electromyostimulation
Stimulation was applied through surface electrodes, deliv-
ered via a BIOPAc systems MP100 stimulator (BIOPAc 
systems inc, Santa Barbara, cA, USA) and knee extension 
forces were recorded with a tension compression load cell 
(tedea-Huntleigh, Vishay Precision group Inc. Malvern, 
PA, USA) connected to a non-extendable strap attached to 
the participants’ lower leg approximately 2–3 inches from 
the malleolus. Information collected from the force trans-
ducer was visualized and analysed using AcqKnowledge 
v.3.7.2 software (BIOPAc systems inc. Santa Barbara, cA, 
USA). Muscles were stimulated at an intensity of 130 mA 
for each test procedure as described previously (gerrits 
et al. 2002). For the determination of muscle contractile 
properties, contraction was evoked by a 1-Hz twitch. For 
the determination of fatigue resistance, contractions were 
evoked by 20 Hz, 200-ms square wave pulses, previously 
defined to be representative of normal voluntary human 
motor neurone firing rates (Bigland-ritchie et al. 1979), 
and thus physiologically valid when used to assess the 
fatigue resistance of human skeletal muscle.
For every session, the position of the participant in the 
isometric chair (lido Active, loredan, Davis, cA, USA) 
was standardized in accordance with guidelines previ-
ously published (Morton et al. 2005). two 3 × 5 inch 
(8 × 13 cm) oval self-adhesive stimulating electrodes 
(chattanooga, DJO global, cA, USA) were placed approx-
imately 2 inches above the knee joint across the vastus 
medialis (VM) and proximal to the acetabulofemoral joint 
across the vastus lateralis (Vl). Participants were required 
to fully extend and contract the quadriceps to make the 
muscle body more apparent prior to electrode placement 
Table 3  the US IoM (2011) guidelines for vitamin D status and 
suggested optimal concentrations (Zittermann 2003)
Serum 25[OH]D (nmol l−1) Status
<12 Severely deficient
12 to <30 Deficient
30 to 50 Inadequate
>50 Adequate
>100 to 250 Suggested optimal (Zittermann 2003)
>120 to 225 Suggested optimal (Heaney 2011)
Table 4  co-efficient of variation for each isokinetic dynamometry 
variable
Data are presented as group means from familiarization trials. 
1.05 rad s−1  = 60 deg s−1; 3.14 rad s−1 = 180 deg s−1
Measurement 
variable
Flexion 
1.05 rad s−1
Extension 
1.05 rad s−1
Flexion 
3.14 rad s−1
Extension 
3.14 rad s−1
cV% 3.9 3.7 4.9 4.1
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to minimise antagonist coactivation, although this was not 
monitored with electromyography during stimulation.
to determine time to peak twitch and half relaxation 
time, a 1-Hz, 200-ms square wave pulse was administered. 
time to peak twitch was determined as the time taken to 
reach peak isometric force from the onset of stimulation. 
Half relaxation time was determined as the time from peak 
stimulated force to reach half peak stimulated force. test–
retest reliability data revealed that the cV % for time to 
peak twitch and for ½ relaxation time as determined by a 
1-Hz twitch at 130 mA was 4.5 and 5.7 %, respectively. 
Fatigue resistance was determined from 2 min repeated 
stimulation with 20 Hz, 200-ms square wave pulses every 
750 ms (total of 160 evoked contractions equating to 32 s 
of total stimulation). Fatigue index was calculated as abso-
lute force loss from the first stimulated contraction to the 
final stimulated contraction.
Statistical methods
A power calculation was performed by a priori using 
Minitab software (v.16) to allow for any dropouts based 
on detecting a significant change in serum 25[OH]D and 
increased peak torque in response to vitamin D supplemen-
tation. Pilot work from our laboratories during the winter 
months suggested that the standard deviation for test–retest 
serum 25[OH]D concentrations (taken 6 weeks apart) in 
young athletes is ∼12 nmol l−1. Furthermore, previous 
work from our laboratory demonstrated that standard devi-
ation in isokinetic force at 1.04 rad s−1 (60 deg s−1) is ~35 
nm. to enable the detection of a 50 nmol l−1 increase in 
total serum 25[OH]D concentration between pre-supple-
mentation and post-supplementation with 80 % power, 
n = 3 participants per group was required. to enable a 
10 % (21 nm) increase in peak torque between pre-sup-
plementation and post-supplementation with 80 % power, 
n = 12 per experimental group was required. therefore, we 
initially recruited 30 participants to allow for dropouts and 
maintain statistical power.
For determination of test–retest reliability in familiariza-
tion trials, a paired sample t test was used. For the analy-
ses of total serum 25[OH]D, PtH and all muscle function 
measurement variables, a two-way mixed design AnOVA 
was implemented. Where an interaction between inde-
pendent variables was detected, simple main effects were 
explored with a one-way AnOVA. Significant main effects 
were explored using the Bonferroni post-hoc procedure and 
α was set at 0.05. In addition, a linear regression was plot-
ted using Pearson’s correlation to assess whether baseline 
25[OH]D concentration was a predictor of Δ 25[OH]D in 
response to supplementation. All analyses were performed 
using SPSS (Predictive Analytics Software v.20, IBM cor-
poration, nY, USA). Data are presented as mean ± SD.
Results
total serum 25[OH]D and iPtH
there was a significant interaction between group and 
time for total serum 25[OH]D (P < 0.005). Serum 25[OH]
D concentration showed a significant main effect for time 
(P < 0.005) and treatment group (P < 0.005). Participants 
in VItD demonstrated significantly elevated total serum 
25[OH]D concentrations at week 4 compared with base-
line that remained elevated throughout the trial. contrast-
ingly, participants in PlB displayed total serum 25[OH]
D concentrations significantly lower at week 12 compared 
with baseline (see Fig. 1a). In addition, regression analysis 
revealed that pre-treatment vitamin D concentration was a 
strong predictor of 25[OH]D response to supplementation 
in VItD, where 83 % of the variation in response to sup-
plementation was attributable to baseline concentration 
(see Fig. 1b). VItD showed no significant change in iPtH 
concentration throughout the trial (P = 0.322), whereas 
PlB showed a significant increase in iPtH concentration 
at week 4 (P < 0.005), which remained elevated throughout 
the trial (see Fig. 1c) showing an inverse relationship with 
serum 25[OH]D.
Maximum voluntary contraction
there were no differences between experimental groups 
in peak torque production at either of the fixed movement 
velocities or for flexion/extension (P = 0.610). Further-
more there was no effect of experimental treatment as no 
changes were observed in peak torque production for either 
of the movement velocities or for flexion/extension fol-
lowing supplementation with 10,000 IU day−1 vitamin D3 
(P = 0.345, see Fig. 2).
Fatigue resistance
the effects of vitamin D supplementation on fatigue resist-
ance of the Vl and VM muscles can be seen in Fig. 3. 
Data are presented as absolute maximal force (Fig. 3a) and 
percentage of maximal force (Fig. 3b), although statisti-
cal analysis was performed on the fatigue ratio of absolute 
data only. no significant interaction was detected between 
treatment group and time i.e. baseline, week 6 and week 12 
(P = 0.134). However, approaching significant main effect 
was also not observed for experimental group (P = 0.063).
time to peak twitch and half relaxation time
no significant differences were detected between treat-
ment groups for time taken to reach peak isometric twitch 
force (P = 0.968) or half relaxation time (P = 0.924). 
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Furthermore, there was no significant effect of time for 
either time to peak twitch (P = 0.861) or half relaxation 
time (P = 0.293) indicating that a treatment effect was not 
observed (see Fig. 4).
Discussion
the aim of the current study was to investigate the impact 
of vitamin D status on muscle function in healthy, recrea-
tionally active young men. We hypothesized that supple-
menting with oral vitamin D3 (cholecalciferol) to elevate 
total serum 25[OH]D concentrations > 100 nmol l−1 (sug-
gested optimal Zittermann 2003; Heaney 2011; Vieth 2011) 
would have a beneficial effect on muscle function. How-
ever, we demonstrate that in a population of predominantly 
vitamin D inadequate young men, supplementation with 
10,000 IU day−1 effectively elevated total serum 25[OH]D 
Fig. 1  a response of total serum 25[OH]D to 12-week supplementa-
tion with 10,000 IU day−1 vitamin D3 or placebo. b linear regression 
describing the relationship between baseline vitamin D status and 
response to supplementation. Baseline total 25[OH]D concentration 
is the predictor variable whilst change in total 25[OH]D at 12 weeks 
is the response variable. c response of intact parathyroid hormone to 
12-week supplementation with 10,000 IU day−1 vitamin D3 or pla-
cebo. (Asterisk) Denotes significance to baseline (P < 0.05)
Fig. 2  Peak torque data from maximal extension (ext) and flexion 
(flex) of the right lower limb at two fixed velocities of 1.05 rad s−1 
(60o s−1) and 3.14 rad s−1 (180o s−1) prior to and following 12-week 
supplementation with 10,000 IU day−1 or placebo
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concentration to values >100 nmol l−1; this had no effect 
(positive or negative) on muscle force, muscle fatigue or 
muscle contractile properties.
Our primary findings are in agreement with other ran-
domized interventional trials assessing the impact of vita-
min D supplementation on skeletal muscle function. Pre-
vious data from our group has demonstrated in a sample 
of 30 club level athletes with a mean 25[OH]D concen-
tration of 51 nmol l−1 (SD ± 24 nmol l−1) that neither 
20,000 or 40,000 IU week−1 of vitamin D3 for 12 weeks 
were effective in improving 1-rM bench press, leg press 
or vertical jump height, although both doses achieved a 
significant elevation of total serum 25[OH]D (20,000 and 
40,000 IU day−1 vitamin D3 = 85 ± 10 nmol l−1 and 
91 ± 24 nmol l−1, respectively) after 12 weeks (close 
et al. 2013a). Similarly, other studies predominantly under-
taken in elderly cohorts have failed to detect improvements 
in strength parameters following supplementation (Kukul-
jan et al. 2011; Kenny et al. 2003). As highlighted in a sys-
tematic review and meta-analysis, trials in which the sam-
ple population display serum concentrations >25 nmol l−1 
have failed to show improvements in muscle strength 
parameters following supplementation (Stockton et al. 
2011).
We also report that elevating serum 25[OH]
D > 100 nmol l−1 does not negate the force producing 
capacity, fatigue resistance or contractile properties of 
skeletal muscle in humans, an idea that has previously 
Fig. 3  a Absolute isometric 
force and b percentage force 
loss during 120 s of repeated 
unilateral lower limb stimu-
lation from an electrically 
evoked square wave pulse of 
200 ms, 20 Hz and a stimula-
tion intensity of 130 mA, every 
750 ms. Data presented prior to 
supplementation (baseline) and 
then at week 6 and 12 of sup-
plementation
Author's personal copy
1317Eur J Appl Physiol (2014) 114:1309–1320 
1 3
been suggested; One randomized controlled trial has 
previously reported that annual high dose vitamin D3 
(500,000 IU) effectively elevated serum concentrations of 
25[OH]D to approximately 120 nmol l−1 in community 
dwelling older women (Sanders et al. 2010). However, 
this resulted in an increased risk of falls and fractures 
compared with a placebo control group. this observation 
could be attributable to the dosing strategy implemented, 
as smaller but more frequent doses in other rct’s do not 
show comparable findings. Furthermore, although Sand-
ers et al. state that baseline prevalence of risk factors for 
falls and fractures was similar in both the supplemented 
and placebo groups, the physical activity profile of the 
two experimental groups is not reported. this is a con-
founding factor given that physical activity is a valuable 
counter measure for sarcopenia (Forbes et al. 2012), thus 
disparity in the physical activity profile of the two experi-
mental groups is of importance when interpreting this 
data.
We also report that measurement of iPtH displayed an 
inverse relationship with serum 25[OH]D, in line with pre-
vious data (Sai et al. 2011). PlB showed elevated iPtH 
concentration whereas the opposite was observed for 
VItD, which may be explained by the understanding that 
1,25-dihydroxyvitamin D represses the transcription of 
the PtH gene and also indirectly regulates PtH secretion 
by regulating the expression of calcium sensing receptors 
(Kumar and thompson 2011). thus, in addition to provid-
ing evidence that our findings produce no negative effect 
of high serum 25[OH]D concentrations (>100 nmol l−1) 
on skeletal muscle function, we further demonstrate that 
our supplementation protocol offers a positive effect on 
the maintenance of iPtH concentrations. It is reported 
that high serum 25[OH]D concentrations (>100 nmol l−1) 
may be necessary for disease prevention (Heaney 2011; 
Vieth 2011), thus we demonstrate that such concentrations 
needed to optimise other biological functions are unlikely 
to be detrimental to the normal function of skeletal muscle.
It is important to also consider the available evidence 
that suggests vitamin D supplementation has a beneficial 
impact on muscle function. case studies have previously 
described a proximal muscle weakness associated with 
nutritional osteomalacia that is responsive to supplemen-
tation with vitamin D (Ziambaras and Dagogo-Jack 1997; 
Irani 1976; Smith and Stern 1967; Al-Said et al. 2009). 
recently, in contrast to our current findings, we have 
observed an improvement in 10-m sprint times and verti-
cal jump height following supplementation in a group of 
vitamin D deficient young athletes (close et al. 2013b). A 
recent trial has also demonstrated in a sample of severely 
deficient individuals (all <15 nmol l−1) that supplemen-
tation with 20,000 IU of vitamin D3 on alternate days 
for 10–12 weeks significantly elevated serum 25[OH]
D (>100 nmol l−1) and resulted in significant improve-
ments in phosphocreatine recovery half-time (τ½ Pcr) of 
the soleus muscle, indicative of improved mitochondrial 
oxidative function as measured by 31P-magnetic resonance 
spectroscopy (Sinha et al. 2013). Furthermore, in a system-
atic review previously mentioned (Stockton et al. 2011), 
the authors also discuss that though participants with base-
line 25[OH]D >25 nmol l−1 show no change in muscle 
strength with vitamin D supplementation, a limited num-
ber of trials demonstrate an increase in proximal muscle 
strength in adults with vitamin D deficiency. A common 
underlying feature of these positive outcome trials is that 
a large portion of the sample population exhibited severe 
vitamin D deficiency (<12 nmol l−1) at baseline that was 
corrected with vitamin D3 supplementation. It is reasona-
ble to postulate based on such findings that skeletal muscle 
function only displays perceptible perturbations in function 
when vitamin D status of the sample population reaches 
concentrations <12 nmol l−1.
Fig. 4  Muscle contractile properties from an electrically evoked 
1-Hz twitch and a stimulation intensity of 130 mA. Data are dis-
played from baseline, 6 and 12 weeks of supplementation with 
10,000 IU day−1 vitamin D3 or placebo
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taking the available evidence into account, we propose a 
possible reason that an improvement in muscle function was 
not detected in the current study, because muscle function 
was not impaired to begin with as no participants had serum 
25[OH]D concentrations in the range <12 nmol l−1. If one 
assumes a sigmoidal physiological response of skeletal 
muscle to vitamin D, it may be difficult to detect a response 
when nutrient status is already on the ascending limb or pla-
teau of the response curve (lappe and Heaney 2012). thus 
skeletal muscle may only display sharp decrements in func-
tion at serum 25[OH]D concentrations <12 nmol l−1, but 
thereafter shows no perceptible added benefit of the increas-
ing concentrations. this could be due to a disturbance of 
systemic and intracellular calcium concentrations that occur 
in severe deficiency, affecting both contractile activity and 
intracellular signalling, and a notion previously put for-
ward (girgis et al. 2012). Although speculative, this would 
explain much of the human data available on vitamin D sta-
tus and muscle function.
We acknowledge that there were limitations in the 
current study design regarding supplemental dose and 
response. We did not measure markers of vitamin D tox-
icity thus compromising the efficacy of our supplemen-
tation protocol. An early indication of adverse effects 
to vitamin D supplementation is hypercalciuria (Vieth 
2007); however, this was not monitored in the current trial. 
Symptoms of vitamin D toxicity are wholly attributable 
to hypercalcemia/hypercalciuria, including nausea, dehy-
dration and lethargy. no participants reported any of the 
associated symptoms. the dose of 10,000 IU day−1 was 
selected as previous trials including our own (close et al. 
2013a) have failed to achieve the desired serum 25[OH]D 
concentrations >100 nmol l−1 with lower doses. In addi-
tion, data have demonstrated that oral vitamin D intakes 
of 9,600 IU day−1 are needed to obtain serum 25[OH]
D concentrations above 100 nmol l−1 in 97 % of a large 
cohort of 3,667 participants (garland et al. 2011). clinical 
trial evidence and dermal photosynthesis of vitamin D fol-
lowing UVB exposure supports our assumption that a pro-
longed daily dose of 10,000 IU•day−1 is unlikely to cause 
adverse effects in otherwise healthy persons (Vieth 2007). 
the authors are, however, in support of toxicity monitor-
ing in future trials that employ high daily doses of vitamin 
D. Further, our sample size calculation determined that to 
enable a 10 % (21 nm) increase in peak torque between 
pre-supplementation and post-supplementation with 80 % 
power, n = 24 was required. Although 29 participants 
completed supplementation and blood sampling, only 22 
completed all muscle function trials. this is a potential 
confounding factor, however, it may be argued given that 
no trends were observed, and P-values were strongly non-
significant that it is unlikely a two-participant deficit that 
significantly affected our findings.
Conclusions
In summary, the current investigation has added to a body 
of evidence that suggests young healthy adults present with 
inadequate and deficient vitamin D concentrations in the 
winter months. We have demonstrated that elevating serum 
25[OH]D concentrations in a predominantly insufficient 
group to concentrations >100 nmol l−1 may be effectively 
achieved by daily supplementation with 10,000 IU vitamin 
D3 (cholecalciferol); however, this does not improve or 
negate skeletal muscle function. We propose that muscle 
function of healthy young adults is likely only aberrant in 
a state of severe vitamin D deficiency (<12 nmol l−1) and 
thus future work should assess this. Due to the inter-indi-
vidual variation in baseline vitamin D status and response 
to supplementation, it is crucial that the baseline vitamin D 
concentration of the sample population being tested is con-
sidered in any interventional trial as this may have a signifi-
cant impact upon the outcome of the trial.
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Abstract
Interest in Vitamin D has risen considerably recently with many athletes now advised to take daily vitamin D supplements.
The reason for this interest is partly not only attributed to the resurgence of the Vitamin D-deficient disease rickets but also
due to the discovery of a Vitamin D receptor in many tissues suggesting a more global role for Vitamin D than previously
considered. Unlike the other vitamins that are obtained through the diet, Vitamin D is unique since endogenous synthesis
following ultraviolet B (UVB) exposure is the predominant route of entry into systemic circulation. Moreover, Vitamin D
could be better classed as a seco-steroid, given that its structure is similar to that of a steroid, and its production is derived
from a cholesterol precursor (7-dehydrocholesteol) in the skin. The classification of Vitamin D status is currently subject to
considerable debate with many authors opposing governing body recommendations. Regardless of the suggested optimal
concentration, there is now growing evidence to suggest that many athletes are in fact Vitamin D deficient, especially in the
winter months largely as a consequence of inadequate sun exposure, combined with poor dietary practices, although the
consequences of such deficiencies are still unclear in athletic populations. Impaired muscle function and reduced
regenerative capacity, impaired immune function, poor bone health and even impaired cardiovascular function have all been
associated with low Vitamin D in athletes, however, to date, the majority of studies on Vitamin D have described
associations and much more research is now needed examining causation.
Keywords: 25-hydroxyvitamin D, 1α,25-dihydroxyvitamin D, muscle, bone, supplementation, ultraviolet B radiation
1. Introduction
There are numerous examples that provide evidence
that many of the great civilisations heralded the sun for
its apparent benefit to human health. In ancient
Greece, Herodotus was said to have recommended
‘solaria’ as a cure for weak and flabby muscles, and
thus the ancient Greek Olympians were told to train
and lie under the sun’s rays (Mercola, 2008). Such
observations weremade long before the realisation that
sunlight was essential for Vitamin D synthesis. In the
past decade, we have witnessed a considerable increase
in research attention towards the ‘sunlight vitamin’
(Vitamin D), which is in part due to the re-emergence
of the preventable bone disorder rickets. In recent
years, there have been a number of key findings which
have advanced the field considerably, particularly the
identification of the Vitamin D receptor (VDR) in
many tissues through which Vitamin D exerts many of
its effects (reviewed by Demay, 2006). Moreover, the
generation of the VDR knockout mouse (Li et al.,
1997) has provided great insight into the multiplicity
of roles for Vitamin D. It is now understood that
aspects of innate and acquired immunity (Chun, Liu,
Modlin, Adams, & Hewison, 2014), bone health
(Ebeling, 2014), cardiovascular health (Lavie, Dinico-
lantonio, Milani, & O’Keefe, 2013) and biological
processes within skeletal muscle are just some of the
physiological features thought to be regulated by
Vitamin D. This review will explore Vitamin D
synthesis, considerations when assessing and inter-
preting measurement of Vitamin D status, the biolo-
gical actions of Vitamin D relevant to the athlete and
protocols for supplementation with Vitamin D.
2. Vitamin D synthesis
The human genome has developed the mechanism
for Vitamin D synthesis in the skins’ dermis that is
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activated by sunlight, or more specifically, ultraviolet
B (UVB) radiation (Holick, 1995). During this
photosynthetic reaction, the B-ring of 7-dehydrocho-
lesterol (precursor to cholesterol and previtamin D3)
is cleaved and resultantly, the thermodynamically
unstable previtamin D3 (pre-cholecalciferol) is
formed. Thermal isomerisation following this cleav-
age yields Vitamin D3, a seco-steroid hormone. In
human skin, the thermal isomerisation process con-
verts ∼80% of previtamin D3 to Vitamin D3 within 8
hours of exposure to UVB (Tian, Chen, Matsuoka,
Wortsman, & Holick, 1993).
There are many factors that can affect the dermal
synthesis of Vitamin D. For example, the amount of
radiation that actually reaches the biosphere (thus
available for cutaneous Vitamin D photosynthesis) is
a product of wavelength and the amount of ozone that
solar radiation must pass, which itself is a function of
the solar zenith angle dependent on latitude, season
and time of day (Chen, Chimeh et al., 2007). If UVB
reaches the skin, another influential factor impacting
the subsequent photosynthetic reaction is skin pig-
mentation as melanin competes with 7-dehydrocho-
leterol for UVB radiation. Resultantly, those with
darker skin require exposure to a stronger source of
UVB or more prolonged exposure time to elicit
comparable changes in circulating Vitamin D con-
centration seen in lighter skinned persons (Chen,
Chimeh et al., 2007; Clemens, Henderson, Adams, &
Holick, 1982).
An obvious alternative route for obtaining vital
nutrients not naturally synthesised (such as the other
vitamins) is through dietary intake. Indeed, there are
some, but very few, dietary sources of Vitamin D,
although as will become evident, it is unlikely that
humans obtain enough Vitamin D from such sources
to compensate for a lack of sun exposure. Unlike
dermal synthesis that solely produces Vitamin D3,
dietary intake provides both Vitamin D2 and D3.
Dietary sources of Vitamin D include oily fish, eggs,
fortified breakfast cereals, shitake mushrooms and
powdered milk. However, intake of these foods
appears to be poor in developed countries (Depart-
ment of Health National Diet and Nutrition Survey,
2011; Hill, O’Brien, Cashman, Flynn, & Kiely,
2004; Moore, Murphy, Keast, & Holick, 2004;
Tylavsky, Cheng, Lyytikainen, Viljakainen, & Lam-
berg-Allardt, 2006). Large-scale investigations have
identified that <2% of individuals studied meet the
recommended daily allowance (RDA) for Vitamin D
intake from foods (Hill, Jonnalagadda, Albertson,
Joshi, & Weaver, 2012). Worryingly, Chen, Chimeh
et al. (2007) provide evidence that many foods
stating fortification with Vitamin D may in fact
contain <80% of the Vitamin D claimed on the
label, whilst 14% of samples tested contained no
detectable Vitamin D.
3. Vitamin D metabolism
Regardless of how Vitamin D is obtained (through
dermal synthesis or obtained from dietary sources),
both forms will travel in the circulation bound to the
Vitamin D-binding protein (DBP) (Cooke & Had-
dad, 1989). It is of importance to note that Vitamin
D2 (ergocalciferol) which enters systemic circulation
from dietary food sources undergoes the same hydro-
xylation steps as Vitamin D3; however, D3 has a
relative potency to Vitamin D2 of 9.5:1 (Armas,
Hollis, & Heaney, 2004).
Once circulating bound to DBP, Vitamin D will
undergo two important hydroxylation steps occurring
in the liver (via 25-hydroxylase) and in the kidney (via
1α-hydroxylase) or tissues directly expressing 1α,
25-hydroxylase. The resultant seco-steroid, 1α,25-
dihydroxyvitamin D (1,25[OH]2D), is metabolically
active, and it is this form of Vitamin D that exerts its
biological effects. The efficacy of tissues expressing
1α,25-hydroxylase to convert DBP-bound 25[OH]D
will be dependent upon the ability of the cell to
internalise the 25[OH]D-DBP complex. In skeletal
muscle, this is likely to be achieved by the expression
of membrane-bound megalin that has recently been
identified (Abboud et al., 2013).
Specifically relating to skeletal muscle, following
this final activating hydroxylation step, 1α,25[OH]2D
will bind to the VDR and exert genomic and non-
genomic effects. Non-genomic effects appear to be
rapid and research focus has pointed to a prominent
role for 1α,25[OH]2D in stimulating signalling path-
ways including the PI3/Akt and mitogen-activated
protein kinase/extracellular signal related kinase
(MAPK/ERK) pathways (Buitrago, Pardo, & Boland,
2013). Genomic effects rely on heterodimerisation of
the 1α,25[OH]2D-VDR complex with retinoic x
receptor (RXR) acting on Vitamin D response ele-
ments (VDREs). The VDR-RXR complex interacts
with transcription machinery and recruits specific
coactivators with chromatin modifying enzymatic
activity that consequently recruit transcription factors
to gene promoter regions. The complex may also
recruit corepressors allowing regulation of target gene
expression related to the function of the cell. In this
way, cellular demand may be translated to cellular
action (Ingraham, Bragdon, & Nohe, 2008). The
pathway from vitamin D synthesis to cellular effect is
summarised in Figure 1.
4. Assessing Vitamin D status
4.1. What, why and how to measure it
Over 40 metabolites of Vitamin D have been identi-
fied (Bouillon, Okamura, & Norman, 1995), but
most of these have a very short half-life in the
circulation and so are currently of minimal interest.
2 D. J. Owens et al.
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Although the parent sterol Vitamin D has a half-life
close to 24 h (Clemens, Actams, Nolan, & Holick,
1982), this is relatively short compared to 25[OH]D
with a half-life of 21–30 days (Zehnder et al., 2001).
The measurement of circulating 25[OH]D is a better
indicator of Vitamin D stores whether obtained from
UVB exposure (contributing 80–90% of 25[OH]D)
or dietary sources (contributing 10–20%). The most
potent physiologically active, circulating metabolite
produced by humans is 1α,25 dihydroxyvitamin D
(1α,25[OH]2D), which has a half-life of 4–15 h, while
25[OH]D circulates in nmol.L−1 concentrations,
1α,25[OH]2D is present in much lower concentra-
tions (pmol.L−1).
Supplementation of foods and health products or
physician treatment with either Vitamin D2 (ergo-
calciferol) or D3 (cholecalciferol) can increase the
percentage derived from exogenous sources, and so
assay technology needs to be able to measure both
D2 and D3 metabolites. The main rate-limiting step
in the pathway of Vitamin D metabolism is the
25 hydroxylation that takes place in the liver.
This step is primarily dependent on the substrate
concentration (Vitamin D) and is the reason why
seasonal variability exists related to UVB exposure.
1-hydroxylation mainly takes place in the kidney but
can also happen in bone, skin, placenta and granu-
loma tissue (sarcoid and tuberculosis) (Zehnder et al.,
2001) and requires 25OHD2/D3 as the substrate. The
rate of 1α,25[OH]2D production by the kidney can be
influenced by the prevailing calcium (Ca) and para-
thyroid hormone (PTH) concentration. For these
reasons, as well as the short half-life, measurement
of total 1,25[OH]2D is a poor indicator of overall
Vitamin D status as total 25[OH]D needs to decrease
to around 10 nmol.L−1 for total 1,25[OH]2D to
decrease significantly (Need et al., 2008).
Isotope dilution liquid chromatography–mass spec-
trometry (LC-MS/MS) is considered the gold stand-
ard method for measuring serum total 25[OH]D and
can simultaneously quantitate 25[OH]D2 and 25
[OH]D3 with summation of the two values, resulting
Figure 1. Schematic representation of the Vitamin D synthetic and metabolic pathways. Vitamin D is obtained via dermal synthesis, a self-
regulated process that produces vitamin D3 or inert photoproducts when sufﬁcient production is achieved. Vitamin D is also obtained in
both D2 and D3 forms from the diet. Both endogenous production and exogenous intake elevate serum concentrations of vitamin D, which
undergoes two hydroxylation steps (via hepatic 25-hydroxylase and renal 1α-hydroxylase or target tissues expressing CYP27B1) to
activation. The active 1α-25[OH]2D exerts its effects via the VDR and stimulates rapid non-genomic and genomic effects. Inactivation of
the active 1α-25[OH]2D occurs via hydroxylation at C-24 catalysed by the 24-hydroxylase enzyme.
Vitamin D and the athlete 3
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in an accurate and precise measure of total 25[OH]D.
All immunoassays evaluated appropriately have a
problem with the recognition of 25[OH]D2 and
under-recover this molecule whether added in the
natural/synthetic form or estimated in the circulation
following ingestion. Detailed comparison of
the performance of commercially available assays
inclusive of assay data can be found in Snellman et al.
(2010).
4.2. What do the numbers mean?
The two most commonly reported units of measure-
ment for 25[OH]D are ng.ml−1 and nmol.L−1,
where 1 ng.ml−1 = 2.496 nmol.L−1. The SI unit for
Vitamin D is nmol.L−1 and will be used herein.
Following quantification by the assay of choice, data
are produced giving an indication of circulating
Vitamin D in the sample tested. 25[OH]D2 and
25[OH]D3 may both be analysed and referred
together as total serum 25[OH]D. At present, there
is disparity as to what serum 25[OH]D concentra-
tions constitute deficiency, adequacy and an
‘optimal’ status. The US Institute of Medicine (US
IoM) at present provide guidelines that should be
accepted until revision (<12 nmol.L−1 severely defi-
cient; 12–<30 nmol.L−1 deficient; 30–50 nmol.L−1
inadequate; >50 nmol.L−1 adequate). However, it is
noteworthy that numerous scientific researchers dis-
agree with such guidelines and propose that they are
too conservative and outdated.
4.3. Supplementation efficacy and dose
As with the measurement units used for circulating
metabolites of Vitamin D, there is more than one
unit of measurement for supplemental Vitamin D. It
is extremely important to distinguish between inter-
national units (IU) and µg (100 IU = 2.5 µg Vitamin
D2/D3). Clearly, confusing these two units could
result in extremely large or very low and ineffective
doses of Vitamin D. A further consideration before
supplementation is whether Vitamin D2 or D3 is
more effective. Quite simply, Vitamin D3 is approxi-
mately 87% more potent in raising and maintaining
serum 25[OH]D concentrations and produces two-
to three-fold greater storage of Vitamin D than does
equimolar D2 (Heaney, Recker, Grote, Horst, &
Armas, 2011). This is intuitive, given that the
primary route of obtaining Vitamin D is via dermal
synthesis, a process that produces Vitamin D3.
A further consideration to the efficacy of supple-
mentation is that there exists great inter-individual
differences in baseline 25[OH]D concentration, and
this can have a profound impact upon the response
to supplementation. For example, baseline Vitamin
D concentration is a strong predictor of the response
to supplementation, i.e. those with low basal serum
25[OH]D show the greatest response to supple-
mentation (see Figure 2, redrawn from Close,
Leckey, et al., 2013; Owens et al., 2014). Moreover,
individuals with similar baseline 25[OH]D may not
respond to supplementation in a comparable way,
given that genetic variation in the Vitamin DBP gene
also appears to influence responsiveness to supple-
mentation (Nimitphong, Saetung, Chanprasertyotin,
Chailurkit, & Ongphiphadhanakul, 2013).
Serum 25[OH]D responds to supplementation in
a dose-dependent manner (Heaney, Davies, Chen,
Holick, & Barger-Lux, 2003). However, along with
basal 25[OH]D, the desired 25[OH]D concentra-
tion will influence the supplementation dose. This
remains a topic of hot debate, and a universal serum
concentration for optimisation of all physiological
functions affected by Vitamin D is far from being
established. However, it is becoming more com-
monly accepted that the health of many biological
systems and processes including the immune system,
cardiovascular system, the nervous system and the
cell cycle is better at serum 25[OH]D concentrations
>75 nmol.L−1 (Heaney, 2013). To achieve serum
concentrations >75 nmol.L−1, we have previously
demonstrated that supplementation with oral Vit-
amin D3 at a dose of 5000 IU.day
−1 for 8 weeks can
effectively achieve this (Close, Russell, et al., 2013).
Other authors suggest that estimated serum concen-
trations needed for other health benefits are above
100 nmol.L−1 and that a daily requirement of 9600
IU.day−1 is needed to maintain such serum concen-
trations (Garland, French, Baggerly, & Heaney,
2011). In support, Holick and colleagues have
demonstrated that adults in a bathing suit exposed
Figure 2. Relationship between baseline serum 25[OH]D con-
centrations and the magnitude of change in serum 25[OH]D in
response to Vitamin D3 supplementation. Data presented are an
amalgamation of Close, Russell, et al. (2013) and unpublished
data from our laboratory. Oral Vitamin D3 administered was
between 2000 and 10,000 IU per day.
4 D. J. Owens et al.
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to 1 minimal erythemal dose tanning bed (UVB)
radiation raises blood levels of Vitamin D to levels
equivalent to those achieved by ingesting between
10,000 and 25,000 of Vitamin D (Holick, 2002).
Notably, these supplemental doses would be con-
sidered ∼8× and ∼16× of the recommended daily
intake (RDI), respectively, as the US Institute of
Medicine (US IoM) has set the RDI for Vitamin D
at 600 IU.day−1 (for young adults) and tolerable
upper intake (TUI) at 4000 IU.day−1 (IoM, 2011)
which is in accordance with recent guidance by the
European Food Safety Authority (EFSA, 2012).
Thus scientific opinion of numerous research groups
is in contrast to that of governing bodies.
When interpreting such opinions, it is vitally
important to consider that dermal synthesis of
Vitamin D via UVB exposure is self-regulated with
previtamin D being converted to inactive photopro-
ducts when synthesis is no longer required (Holick,
MacLaughlin, & Doppelt, 1981). Such a biological
mechanism is not available for oral ingestion, thus it
is prudent to adhere to the current TUI of 4000 IU.
day−1 suggested by both the IoM and the EFSA until
further evidence is generated.
5. Vitamin D status of athletes
From the available literature and our own findings, it
is evident that there is great inter-individual variation
in basal Vitamin D concentration in participants
tested at the same point of the year. As an example,
Figure 3 demonstrates cumulative findings from a
trial conducted in our laboratory during the winter
months across a range of athletic disciplines.
A notable observation from the data is that many
tested athletes present with Vitamin D concentra-
tions which are considered deficient by the US IoM.
Furthermore, other reports from around the world
have shown similar findings to our own, supporting
the notion that Vitamin D deficiency and insuffi-
ciency is widespread among athletic communities
(Allison et al., 2014; Bescos Garcia & Rodriguez
Guisado, 2011; Magee et al., 2013; Wolman et al.,
2013). This may have numerous adverse effects that
may ultimately attenuate normal physiological func-
tion, as will be described. It must be stressed that
due to the ‘mega-dose’ supplementation culture in
professional and amateur sport, it is also important
to consider that although supplementation guide-
lines exist, athletes do indeed take doses of vitamin
D well above the TUI level. It is, therefore, vital to
be aware of the adverse effects of extreme vitamin D
supplementation, which will be discussed later in
Section 7.
6. Physiological roles of Vitamin D relevant to
the athlete
6.1. Vitamin D and muscle
It has long been understood that a proximal muscle
weakness (myopathy) associates with nutritional
osteomalacia (caused by severe Vitamin D deficiency)
and is responsive to supplementation with Vitamin D
(Al-Said, Al-Rached, Al-Qahtani, & Jan, 2009; Irani,
1976; Smith & Stern, 1967; Ziambaras & Dagogo-
Jack, 1997). Recently, our group has observed an
improvement in 10-m sprint times and vertical jump
height following supplementation with 5000 IU day−1
in a group of Vitamin D-deficient young athletes
(Close, Russell, et al., 2013). Others have also
demonstrated in a sample of severely deficient indivi-
duals (<15 nmol·L−1) that supplementation with
20,000 IU of Vitamin D3 on alternate days for
10–12 weeks significantly elevated serum 25[OH]D
(> 100 nmol·L−1) and resulted in significant improve-
ments in phosphocreatine recovery half-time (τ½
PCr) of the soleus muscle, indicative of improved
mitochondrial oxidative function as measured by 31P-
magnetic resonance spectroscopy (Sinha, Hollings-
worth, Ball, & Cheetham, 2013). A feature underly-
ing all of these positive outcome trials is a large
portion of the sample population exhibit severe Vit-
amin D deficiency (<12.5 nmol.L−1) at baseline that
is corrected with Vitamin D3 supplementation.
Some investigations have failed to detect improve-
ments in muscle function following supplementation
with Vitamin D. Systematic review and meta-ana-
lysis of the current literature show that participants
with baseline 25[OH]D > 25 nmol.L−1 show no
change in muscle strength following Vitamin D
supplementation including our own recently pub-
lished observations (Owens et al., 2014) in which we
Figure 3. Serum 25[OH]D concentration of a variety of athletes
(and age-matched controls) in relation to current classiﬁcation
guidelines; dark grey area represents deﬁciency (<30 nmol.L−1),
lighter grey area insufﬁciency (<50 nmol.L−1) and lightest grey
area sufﬁciency (>50 nmol.L−1). (Data redrawn from Close
et al., 2012).
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have sensitively assessed skeletal muscle contractile
properties and peak torque production.
At the cellular and molecular level, positive find-
ings have been consistently reported for Vitamin D-
related investigations. Specifically, control of intra-
cellular Ca2+ (Vazquez, de Boland, & Boland, 1997,
1998), enhanced stimulatory effect of Leucine
(Salles et al., 2013), stimulation of mitogen-activated
protein kinases (MAPKs; (Buitrago et al., 2013;
Buitrago, Ronda, de Boland, & Boland, 2006) and
promotion of promyogenic and angiogenic growth
factors (Garcia, Ferrini, Norris, & Artaza, 2013;
Garcia, King, Ferrini, Norris, & Artaza, 2011) have
all been reported. If these findings are translated in
vivo, improvements in muscle contraction, growth
and regeneration following damage may be observed
when vitamin D status is optimal; however, such
work is lacking considerably at present.
6.2. Vitamin D and muscle regeneration
A fascinating feature of human skeletal muscle is its
ability to respond to positive and negative stimuli, a
characteristic that is vital in adaptation to a training
bout or in recovery from damaging exercise. This
regenerative process relies on the resident muscle
stem cells termed ‘satellite cells’, wedged between the
sarcolemma and basal lamina (Mauro, 1961). Briefly,
in response to appropriate cues satellite cells will exit
quiescence, proliferate and differentiate to regenerate
areas of damaged muscle. An exciting novel role
emerging for Vitamin D is related to this process of
skeletal muscle regeneration as the seco-steroid
appears to display an ability to mediate myoblast
proliferation and differentiation (Buitrago et al., 2013;
Garcia et al., 2011, 2013; Srikuea, Zhang, Park-
Sarge, & Esser, 2012). Findings have demonstrated
that in the absence of 25[OH]D, 1α,25[OH]2D or the
VDR, signalling of pathways necessary for growth and
survival such as MAPKs, Src and Akt (PKB) are
reduced and muscle cell development is impaired
(Buitrago et al., 2013; Garcia et al., 2011).
Aside from the ability to proliferate and differen-
tiate in response to appropriate stimuli, migration of
myoblasts to and within the site of damage is also a
key step in the regenerative process of adult skeletal
muscle (Saini, Faulkner, Al-Shanti, & Stewart,
2009). Following muscle damage, myoblasts have
the capability to migrate towards the site of repair
(Watt, Karasinski, Moss, & England, 1994). Fur-
thermore, the ability to migrate is necessary for
proper alignment and fusion of myoblasts to form
multinucleated myotubes (Leloup, Mazeres, Daury,
Cottin, & Brustis, 2006; Vaz, Martins, Thorsteins-
dottir, & Rodrigues, 2012). Recently, insights into
the signals involved in myoblast migration have
alluded to an important role for PI3/Akt and
MAPK/ERK pathways in myoblast migration (Dim-
chev, Al-Shanti, & Stewart, 2013). As described,
these pathways are indeed mediated by Vitamin D,
at least in C2C12 myoblast models. Figure 4 provides
a graphical interpretation highlighting the potential
points at which Vitamin D may influence skeletal
muscle regeneration.
Recently, one group has demonstrated that a high-
dose Vitamin D treatment in rats improves the
cellular turnover and recovery of soleus muscle
crushed in vivo (Stratos et al., 2013). Muscle sam-
pling in this study revealed Vitamin D enhanced cell
proliferation and attenuated apoptosis when com-
pared with rats treated with a vehicle solution. Ad-
ditionally, the expression of prolyl-4-hydroxylase-β
was increased in Vitamin D-treated rats, evidence of
increased extracellular matrix proteins. In another
study employing a rat model, investigators observed a
decline in rotator cuff healing in diet-induced Vitamin
D-deficient rats (Angeline et al., 2014). Angeline and
colleagues demonstrated significant decreases in load
to failure and in collagen matrix proteins in deficient
rats. Indeed, the skeletal muscle extracellular matrix
is comprised of such matrix proteins and is crucial in
signalling events that occur in skeletal muscle regen-
eration (Lund & Cornelison, 2013).
In humans, data on the role of Vitamin D in muscle
recovery are still lacking. However, promising pre-
liminary observations suggest that basal Vitamin D
concentration predicts immediate and persistent
muscle weakness after damaging exercise. In particu-
lar, correlative data suggest that serum concentrations
>75nmol.L−1 may be necessary for optimal force
recovery following damage (Barker et al., 2013).
Given the available evidence, this area of research
warrants further attention as it may have direct
implications for monitoring the Vitamin D status of
athletes to promote optimal muscle recovery.
6.3. Vitamin D and bone health
Vitamin D is essential for skeletal health as it
promotes calcium absorption from the bowel and
enables mineralisation of newly formed osteoid
tissue in bone (Francis, Anderson, Patel, Sahota, &
van Staa, 2006). The major manifestation of Vitamin
D deficiency is osteomalacia in adults and rickets in
children, which the Department of Health (DoH)
suggests are generally associated with a serum total
25[OH]D concentration of <20 nmol.L−1 (DoH,
1991). Vitamin D insufficiency may lead to second-
ary hyperparathyroidism, bone loss and fragility
fractures in older people (Bischoff-Ferrari, Giovan-
nucci, Willett, Dietrich, & Dawson-Hughes, 2006;
Lips, 2001; Sahota, Gaynor, Harwood, & Hosking,
2001; Sahota et al., 2004), although data in young
otherwise healthy individuals is less documented.
6 D. J. Owens et al.
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The Institute of Medicine (IoM) Report on Dietary
Reference Intakes for Calcium and Vitamin D inves-
tigated the relationship between Vitamin D
status and bone health (IoM, 2011) using evidence
from two systematic reviews commissioned by the
Agency for Healthcare Research and Quality
(AHRQ), from theUniversity of Ottawa (Chung et al.,
2009) and the Tufts Evidence-Based Practice Centre
(Cranney et al., 2007). These examined the relation-
ship between serum total 25[OH]D as a marker of
Vitamin D exposure and PTH concentration, calcium
absorption, calcium balance, bone mineral density
(BMD), fracture risk and rickets/osteomalacia as
potential indicators of bone health. From these ana-
lyses, the IoM highlighted the inconsistency that exists
with different threshold serum total 25[OH]D con-
centrations above which PTH reaches a plateau,
ranging from <30 nmol.L−1 to 100–125 nmol.L−1.
The IoM also suggested that most people with a serum
total 25[OH]D between 30 and 50 nmol.L−1 have
adequate calcium absorption.
Meta-analyses of randomised controlled trials
(RCTs) investigating the effect of Vitamin D supple-
mentation on fractures indicate that combined cal-
cium and Vitamin D supplementation modestly
decrease the risk of hip and other non-vertebral
fractures, whilst Vitamin D alone is ineffective
(DipartGroup, 2010; Hathcock, Shao, Vieth, &
Heaney, 2007). AHRQ-Tufts concluded that com-
bined Vitamin D and calcium supplementation
decreased fracture risk in institutionalised older
people, but the effect in community-dwelling older
people was inconsistent. They suggested that a serum
25[OH]D of 40 nmol.L−1 is sufficient to meet the
Vitamin D requirement for bone health in 50% of the
population, whilst 50 nmol.L−1 would be sufficient
for 97.5% of the population. They, therefore, con-
cluded that people are at risk of deficiency when
serum 25[OH]D is <30 nmol.L−1 but suggest that
some people are potentially at risk of inadequacy
when serum 25[OH]D is 30–50 nmol.L−1. Although
some authors recommend much higher values for
serum total 25[OH]D (>75 nmol.L−1) for optimal
bone health, there is significant debate regarding the
data and the analysis that leads to these conclusions.
No randomised placebo controlled trial has con-
firmed the optimal target for circulating serum total
25[OH]D to be above 75 nmol.L−1 when the outlook
is bone health. It should, however, be noted that
many athletes do present with serum 25[OH]D
<50 nmol.L−1 with some <10 nmol.L−1 and may,
therefore, benefit from targeted interventions to
improve bone health. Notably, we have recently
demonstrated that professional flat and national
hunt jockeys often present with serum 25[OH]D
concentrations of 37.6 ± 28 and 35.1 ± 14 nmol.L−1,
respectively, along with poor markers of bone health
such as elevated C-terminal telopeptide (β-CTX)
concentrations and negative Dual Energy X-ray
Absorptiometry (DXA) T scores (Wilson et al., 2013).
6.4. Vitamin D and immune function
The VDR and Vitamin D metabolising enzymes are
present in many cells of the immune system. Indeed,
one of the most established roles for Vitamin D is its
Figure 4. Schematic representation of the proposed roles of Vitamin D in skeletal muscle regeneration. (1) Quiescent satellite cell (2)
activated satellite cell (3) proliferating myoblasts, known to be mediated by Vitamin D (Garcia et al., 2011; Srikuea et al., 2012) (4)
migrating myoblast that requires PI3/Akt and MAPK/ERK pathways, both mediated by Vitamin D (Buitrago et al., 2013) (5) differentiating
myoblasts, known to be mediated by Vitamin D (Garcia et al., 2011) (6) formation of ECM proteins, which Vitamin D has been implicated
in (Angeline et al., 2014; Stratos et al., 2013).
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ability to regulate aspects of innate and adaptive
immunity. Therefore, Vitamin D deficiency is likely
to directly compromise optimal functioning of aspects
of the immune system causing increased infection
frequency.
Immune cells from the adaptive arm of the immune
system (T and B cells) express the VDR as well as the
Vitamin D metabolising enzymes. In particular upon
activation, the VDR is up-regulated in these cells,
leading to profound modulation of Vitamin D
responsive genes implicated in proliferation and
in differentiation (Chen, Sims et al., 2007). In
accordance, data have demonstrated that the immu-
nomodulatory effects of Vitamin D on the adaptive
immune system appear to be directed through the
control of proliferation and differentiation of B cells
and various T cell subtypes (Baeke, Takiishi, Korf,
Gysemans, & Mathieu, 2010). This has important
implications for normal antibody production and
prevention of an exaggerated immune response
(Prietl, Treiber, Pieber, & Amrein, 2013).
In relation to innate immunity, Vitamin D appears
to enhance chemotaxis and the phagocytic capability
of macrophages and monocytes (Baeke et al., 2010).
Additionally, 1,25[OH]2D up-regulates the transcrip-
tion of antimicrobial peptides (AMPs), acting as a key
link between toll-like receptor (TLR) activation and
the antimicrobial response. AMPs are produced by
epithelial cells and macrophages and essentially act as
broad spectrum antibiotics, thus are an important
first line of defence against invading microbes.
Accordingly, data have demonstrated that Vitamin
D-deficient persons exhibit lower concentrations of
AMPs such as cathelicidin (Jeng et al., 2009) and low
Vitamin D status associates with an increased fre-
quency of upper respiratory tract infections (URTI)
(Ginde, Mansbach, & Camargo, 2009; Laaksi et al.,
2007). Aside from directly influencing antimicrobial
activity, Vitamin D targets antigen-presenting cells
such as monocytes and dendritic cells; 1,25[OH]2D
may alter the morphology of such cells to a more
tolerogenic state (Baeke et al., 2010). These effects
are likely to induce T regulatory cells (Treg) which are
pivotal in controlling normal immune responses
(Lemire, Adams, Sakai, & Jordan, 1984).
In relation to the athlete, it is well known that regular
moderate exercise is associated with reduced infection
frequency when compared with sedentary individuals.
In contrast, prolonged bouts of strenuous exercise can
lead to transient depression of aspects of immune
function, lasting from 3 to 24 hours after exercise.
Further, periods of overreaching may compound this
immunosuppressive response (see Gleeson, 2007 for
comprehensive review). This, therefore, potentially
places Vitamin D-deficient athletes in a heightened
immunocompromised state at greater infection risk.
Recently, Mike Gleeson’s laboratory has provided the
first evidence that confirms such a hypothesis. The
group found that in a cohort of 267 athletes (He et al.,
2013), significantly more participants who presented
with Vitamin D deficiency (<30 nmol.L−1) experi-
enced URTI symptoms compared with participants
with concentrations >120 nmol.L−1, and immune
function markers also showed improvement in indivi-
duals with higher Vitamin D concentrations.
In summary, Vitamin D deficiency is likely to
directly compromise optimal functioning of aspects
of the immune system causing increased infection
frequency. Given the available data, this appears to
hold true for athletic performers, putting periodised
training programmes at risk of disturbance and
increases the probability of suboptimal adaptation to
training stimuli. The discussed findings provide
robust evidence to support the maintenance of
adequate Vitamin D concentrations, particularly dur-
ing the winter months when sunlight exposure is low
and infection frequency is high.
7. Vitamin D toxicity: When is too much a
problem?
Most investigators believe that Vitamin D toxicity
manifests through hypercalcaemia. This is rarely
seen unless the Vitamin D dose is very high as a
result of inappropriate high-dose treatment or acci-
dental overdosing (Hathcock et al., 2007). The high
serum calcium leads eventually to soft tissue calci-
fication and resultant renal and cardiovascular dam-
age. An IoM report summarised the evidence from a
number of supplementation studies of Vitamin
D (IoM, 2011), which covered a range of doses
(800–300,000 IU.day−1) and duration (months–
years) and concluded that Vitamin D below 10,000
IU.day−1 is not usually associated with toxicity,
whereas doses equal to or above 50,000 IU.day−1
for several weeks or months are frequently associated
with toxicity with documented hypercalcaemia. Not-
ably, however, both the IoM and the EFSA declare
4000 IU.day−1 as the TUI as a preventative measure
to avoid rare cases of toxicity occurring with vitamin
D intakes <10,000 IU.day−1.
Studies that report a reverse J-shape curve for the
relationship between mortality and 25[OH]D, show
a beneficial effect as serum total 25[OH]D concen-
trations increase to 30 nmol.L−1, with lowest mor-
tality at 50 nmol.L−1 and then increased risk above
75 nmol.L−1 (Durup et al., 2012). However, like
many Vitamin D studies, the paper by Durup et al.
was not able to assign cause and effect, and there-
fore, caution must be taken when interpreting these
data. Studies in post-menopausal women have also
raised concerns regarding high-dose replacement
therapy. The use of a 500,000 IU Vitamin D dose
resulted in an increase in falls and fractures in the
8 D. J. Owens et al.
D
ow
nl
oa
de
d 
by
 [L
ive
rp
oo
l J
oh
n M
oo
res
 U
niv
ers
ity
] a
t 0
7:5
1 2
0 A
ug
us
t 2
01
4 
group receiving Vitamin D and in a further study of
300,000 IU single dose of Vitamin D an increase in
falls was observed. Therefore, whilst toxicity does
appear to be rare, there is a genuine risk, and athletes
should certainly be discouraged from unmonitored
mega dose supplements and encouraged to follow
evidence-based guidelines provided by the US IoM
and the EFSA.
8. Summary and future directions
Despite the resurgence in interest into the effects of
Vitamin D on athletic performance, due to a lack of
high-quality research studies, particularly those trying
to establish cause and effect, it is still difficult to give
definitive advice to the athlete. What is clear is that
many athletes tested in the winter months would
appear to be Vitamin D deficient, and this does not
exclude athletes that live in sun-rich environ‐
ments such as Western Asia (Hamilton, Grantham,
Racinais, & Chalabi, 2010). It would, therefore, appear
sensible to supplement these athletes with Vitamin D3
to correct such deficiencies, which in turn has the
potential to improve muscle function, bone health,
immune health and preliminary data suggest even
cardiac structure (Allison et al., 2014). Whilst at
present it is not possible to give an ideal serum
concentration of 25[OH]D that athletes should strive
to achieve, there are data to suggest that values
>75 nmol.L−1 have the potential to improve immune
health and skeletal muscle regeneration following
muscle injury (Barker et al., 2013; He et al., 2013).
What is clear, however, is that extreme deficiencies (i.e.
<25 nmol.L−1) could impair skeletal muscle function,
and it is therefore sensible to test all athletes and
recommend supplementation as appropriate. As far as
a dose is concerned, we have demonstrated that doses
of 2000–5000 IUper day for 8 weeks increase serum 25
[OH]D > 75 nmol.L−1. Considering current guidance
provided by the US IoM and the EFSA and given the
fact that our doses are well within the safe upper limit
suggested by the IoM (i.e. <10,000 IU), daily dosing
with 4000 IU may be a sensible dose for supplementa-
tion. Future research must now focus on establishing if
Vitamin D deficiencies are having detrimental physio-
logical effects or are simply correlated with such events.
High-quality mechanistic studies are now clearly war-
ranted adopting a systems biology approach to answer
such questions. Only then will it be possible to under-
stand the role of VitaminD in athletic performance and
begin to identify if there is such a thing as an ‘optimal
Vitamin D concentration’ for athletes.
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First published October 27, 2015; doi:10.1152/ajpendo.00375.2015.—Skel-
etal muscle is a direct target for vitamin D. Observational studies
suggest that low 25[OH]D correlates with functional recovery of
skeletal muscle following eccentric contractions in humans and crush
injury in rats. However, a definitive association is yet to be estab-
lished. To address this gap in knowledge in relation to damage repair,
a randomised, placebo-controlled trial was performed in 20 males
with insufficient concentrations of serum 25(OH)D (45  25 nmol/l).
Prior to and following 6 wk of supplemental vitamin D3 (4,000
IU/day) or placebo (50 mg of cellulose), participants performed 20 
10 damaging eccentric contractions of the knee extensors, with peak
torque measured over the following 7 days of recovery. Parallel
experimentation using isolated human skeletal muscle-derived myo-
blast cells from biopsies of 14 males with low serum 25(OH)D (37 
11 nmol/l) were subjected to mechanical wound injury, which enabled
corresponding in vitro studies of muscle repair, regeneration, and
hypertrophy in the presence and absence of 10 or 100 nmol
1,25(OH)2D3. Supplemental vitamin D3 increased serum 25(OH)D
and improved recovery of peak torque at 48 h and 7 days postexercise.
In vitro, 10 nmol 1,25(OH)2D3 improved muscle cell migration
dynamics and resulted in improved myotube fusion/differentiation at
the biochemical, morphological, and molecular level together with
increased myotube hypertrophy at 7 and 10 days postdamage. To-
gether, these preliminary data are the first to characterize a role for
vitamin D in human skeletal muscle regeneration and suggest that
maintaining serum 25(OH)D may be beneficial for enhancing repar-
ative processes and potentially for facilitating subsequent hypertro-
phy.
muscle damage; regeneration; vitamin D
ECCENTRIC CONTRACTION, CONTUSIONS, AND TOXIC INSULTS cause
skeletal muscle damage that leads to decrements in functional
capacity. Yet skeletal muscle is uniquely equipped to regener-
ate via the activation, proliferation, migration, and differenti-
ation of resident muscle stem cells known as satellite cells (43);
indeed, muscle regeneration is significantly compromised
when satellite cells are ablated. Effective repair usually leads to
full functional recovery of the damaged tissue, whereas inef-
fective repair leads to fibrosis and suboptimal rescue of func-
tion, such as in severe muscular dystrophies (32).
Many intrinsic, local, and systemic factors interact to or-
chestrate the muscle repair process, and thus identifying and
targeting modifiable risk factors that compromise any step of
this process can augment functional recovery. Recent insights
from human trials have reported that vitamin D3, a member of
a group of pleiotropic prosteroid hormones, is implicated in
numerous biological processes. Vitamin D is synthesized pri-
marily in the skins dermis following exposure to ultraviolet B
radiation (sunlight exposure), which results in the conversion
of 7-dehydrocholesterol to pre-vitamin D3 and subsequently to
vitamin D3. Nutritionally, both vitamin D2 and D3 can be
obtained from dietary sources, albeit in far less quantity than
can be synthesized following sunlight exposure. It is important
to consider that presently, little biological significance can be
attributed to vitamin D2, and therefore Vitamin D3 is thought to
be the main contributor to vitamin D status (reviewed in Ref.
34). Whether vitamin D3 is obtained from dietary sources or
via ultraviolet B exposure, the metabolite will undergo hy-
droxylation at the liver to form 25-hydroxyvitamin D
[25(OH)D], the main marker of vitamin D status, and a further
hydroxylation step in the kidney to form the biologically active
1-dihydroxyvitamin D3 [1,25(OH)2D3]. The bioactive me-
tabolite can interact with the vitamin D receptor (VDR) to
modulate genomic and nongenomic processes that function to
control biological events in the cell (25). Classically, vitamin D
is understood to be a major regulator of calcium and phosphate
homeostasis, being required for normal bone mineralization.
Indeed, the bone disorder rickets is caused by insufficient
vitamin D3 exposure and is reversible with supplemental vita-
min D (27). Research evidence from the past decade, however,
is now indicative that many tissues of the human body are
responsive to vitamin D and function suboptimally when
exposure to vitamin D is limited (26). Despite the understand-
ing of the importance of vitamin D in human health, low
circulating vitamin D concentrations [measured as total serum
25(OH)D] prevail in humans and are indeed associated with
numerous preventable disease states. One such tissue that may
be affected by low vitamin D concentrations is skeletal muscle.
Recently, it has been suggested that the sterol is implicated in
skeletal muscle regeneration and remodeling (reviewed in Ref.
34), and indeed, sufficient 25(OH)D positively correlates with
muscle force recovery from damaging eccentric exercise (6, 7).
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These studies, while promising, are compromised by the ob-
servational nature of their design and raise the question of the
potential cause-effect mechanisms between vitamin D and
muscle repair and remodeling.
Fragments of evidence from animal and cellular models
have provided supporting preliminary data for the observa-
tional insights in humans. In in vivo crush injury rat models,
vitamin D sufficiency culminates in significant increases in
bromodeoxyuridine-positive proliferating myoblasts, de-
creased apoptosis via staining tissue for DNA damage, and
subsequent improvements in maximal force recovery com-
pared with deficient rats (51). In addition, vitamin D supple-
mentation, following BaCl2 damage of murine tibilais anterior,
culminates in improved regeneration and increased expression
of the VDR (25), highlighting the potential of the vitamin D
pathway in controlling aspects of the regeneration process (50).
Complementing these in vivo rodent studies, in vitro studies
using C2C12 murine myoblasts also indicate that myoblast
proliferation, differentiation, myotube hypertrophy, and sur-
vival are mechanisms facilitated by vitamin D; however,
similar human muscle cell studies remain to be performed
(21, 45, 50). This is particularly relevant given that circu-
lating 25(OH)D and 1,25(OH)2D are undetectable in many
rodent species.
Taken together, a definitive cause-effect relationship be-
tween vitamin D and skeletal muscle repair and remodeling is
yet to be established in humans by well-controlled, transla-
tional investigations. Therefore, the aim of the current work
was to implement a systems-based trial to delineate the role of
vitamin D in humans using an in vivo and in vitro design, and
our aims were with twofold objectives: 1) to investigate the
effect of low serum 25(OH)D on functional recovery from
eccentric exercise, implementing a randomized controlled trial
(RCT), and 2) to identify aspects of muscle cell regeneration
that are responsive to supplemental vitamin D, using human
primary muscle-derived cells, from deficient male participants
in an in vitro model of muscle damage, repair, and regeneration
in the presence or absence of vitamin D3. This in vivo/in vitro
model allowed us to identify the impact of vitamin D on whole
tissue muscle recovery of function and the cellular adaptations
that vitamin D may modulate during functional repair of
skeletal muscle following a damaging event.
It was hypothesized that 1) raising serum 25(OH)D from a
low level with supplemental vitamin D3 could improve the
functional recovery from eccentric exercise and 2) treatment of
isolated muscle cells from humans with the active vitamin D
metabolite 1,25(OH)2D3 would improve migration, the ca-
pacity for differentiation/fusion, and myotube hypertrophy fol-
lowing damage in vitro.
MATERIALS AND METHODS
Inclusion Criteria and Ethical Approval
Strict inclusion criteria were implemented for both trials. Inclusion
was limited to males aged 18–30 with no underlying medical ailments
as identified by a medical history questionnaire, physical activity
readiness questionnaire, and screening by a trained physician. Those
taking fish oils, multivitamins, or vitamin D supplements or using sun
beds were excluded from the trials. Finally, only individuals under-
taking 3 h/wk of physical activity above daily tasks were included
in the trial. Following informed consent and the meeting of the initial
inclusion criteria, participants provided a venous blood sample that
was analyzed for total serum 25(OH)D (nmol/l) and were excluded if
serum concentration was 75 nmol/l, suggestive of adequate vitamin
D concentration (26, 31).
Ethical approval for study 1 (in vivo) was granted by the Liverpool
John Moores University Research Ethics Committee and for study 2
(in vitro) by the NHS West Midlands National Research Ethics
Committee (NREC approval no. WM/09/13). All data were collected
and stored in line with the Declaration of Helsinki and the Human
Tissues Act.
Blood Sampling and Analysis of Vitamin D Metabolites
For the analysis of vitamin D metabolites (D2 and D3) in both study
1 and study 2, following informed consent, serum was harvested from
fasted venous blood samples collected from the antecubital vein.
Serum was stored at 80°C until it was required for analysis.
For the analysis of total serum 25(OH)D concentration (sum of D2
and D3 metabolites), high-pressure liquid chromatography tandem
mass spectrometry (LC-MS/MS) was implemented. The LC-MS/MS
method of analysis has been validated against other commercially
available assays and is regarded as the gold standard for the assess-
ment of vitamin D metabolites (48). Analyses were performed in a
Vitamin D External Quality Assurance Scheme-accredited laboratory.
Assay procedures were conducted as previously described (35).
Randomized Controlled Trial Methods
Twenty volunteers (21  1 yr, 179  4 cm, 84  13 kg) met the
inclusion criteria for study 1 and were allocated to the RCT. Partici-
pants were first block randomized based on their basal serum
25(OH)D and maximal isokinetic torque of the right knee extensors at
60°/s (1.05 rad/s). On the day of muscle damage, participants were
instructed to produce a maximal voluntary contraction (MVC) prior to
and following the bout of eccentric exercise. MVC torque was
subsequently measured at 24 h, 48 h, and 7 days following the
exercise bout to monitor functional recovery. Participants then re-
ceived either an oral vitamin D3 supplement [VITD; 4,000 IU/day
European Food Safety Authority standard safe upper limit (18)] or a
visually identical placebo capsule (PLB; 50 mg of cellulose) for 6 wk,
following which a second blood sample was drawn for analysis of
vitamin D metabolites and the eccentric exercise bout and MVC
protocol were repeated (Figure 1).
MVC torque was assessed on a Biodex isokinetic dynamometer
(Biodex Medical Systems, Shirley, NY) that was previously validated
for its use in reliable assessment of muscle function variables related
to torque production (17). Participants were seated as per the manu-
facturers’ guidelines with a 90° flexion of the hip and nonextendable
straps crossing the chest and abdomen and across the quadriceps to
maximize isolation of the target muscle group. The test protocol
consisted of four consecutive maximal extension movements of the
right quadriceps at two different fixed movement velocities, 60 (1.05
rad/s) and 180°/s (3.14 rad/s), separated by a 5-min rest period to
allow full recovery of the high-energy phosphate pool, from which
peak torque (Nm) was calculated (49). All participants were familiar-
ized with the protocol until the coefficient of variation for each
participant was 10% (5).
The eccentric exercise bout was a modified version of that de-
scribed previously and known to cause muscle damage (36). Further-
more, similar eccentric exercise protocols with a smaller volume of
work have been shown to result in the activation and proliferation of
satellite cells (30), an important consideration to allow for the transfer
of findings between our in vitro and in vivo models. Exercise was
performed on a Cybex isokinetic dynamometer and consisted of 200
unilateral eccentric contractions at 30°/s (0.52 rad/s) executed as 20
sets of 10 contractions interspersed by 30-s rest intervals. Exercise
was performed through the participants’ full range of motion and thus
was specific to each participant. Muscle soreness was measured at the
same time points as MVC measurements and was determined via
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pressure algometry. The distance from the inguinal crease to the tip of
the patella was measured, and muscle soreness readings were then
obtained 5 cm from the patella and at the midpoint of the quadriceps.
Participants indicated the point at which pressure from the algometer
became painful, and the reading indicated by the algometer was noted
(in kg).
Methods for the In Vitro Model of Muscle Regeneration
Reagents, chemicals, and solvents. Growth media (GM) used for
the expansion of human muscle-derived cell populations consisted of
Hams F-10 nutrient mix (Lonza, Basel, Switzerland) with added
L-glutamine (2.5 mM), 10% heat-inactivated fetal bovine serum
(hiFBS; Gibco, Thermo Fisher Scientific, Altincham, UK), 10%
newborn calf serum (NBCS; Gibco), 1% penicillin-streptomycin (PS;
50 units of penicillin-50 g of streptomycin; Life Technologies,
Warrington, UK), and 1% amphotericin B (2.5 g/ml; Gibco). Dif-
ferentiation media (DM) consisted of -MEM (Lonza), 1% hiFBS,
1% NBCS, 1% PS, and 1% amphotericin B (2.5 g/ml). Quiescent
media (QM) used in human skeletal muscle cell pretreatments con-
sisted of the same components as DM; however, hiFBS and NBCS
were added at a concentration of 0.1% each (0.2% serum total).
Phosphate-buffered saline (PBS; Sigma-Aldrich) was used to wash
cell monolayers. The active vitamin D metabolite 1,25-dihydroxyvi-
tamin D3 was purchased from Sigma-Aldrich and reconstituted as per
the manufacturers guidelines in 100% ethanol (40 l/well in DM, final
volume for highest 1,25(OH)2D3 treatment). Desmin polyclonal
rabbit anti-human antibody (Ab 15200) was purchased from Abcam
(Abcam, Cambridge, UK), and TE7 monoclonal mouse anti-human
antibody (Ab CBL271) was purchased from Merck Millipore. Sec-
ondary fluorophore (TRITC goat anti-rabbit) and nuclear counterstain
(DAPI) were purchased from Life Technologies.
Muscle biopsy procedure. Fourteen volunteers (age  25  3 yr,
height  181  5 cm, weight  81  10 kg) were included in study
2 and provided a skeletal muscle biopsy. The average total serum
25(OH)D concentration for the group was 37  11 nmol/l. Partici-
pants were instructed to avoid exercise training 48 h preceding the
biopsy procedure. On arrival at the laboratory, participants were asked
to relax in a supine position on a hospital bed while the biopsy site
was prepared. Briefly, the incision site (vastus lateralis) was shaved to
maximize sterility and washed with an alcohol swab and Hydrex
surgical scrub (ECOLAB Leeds, UK), following which a sterile sheet
was used to maintain sterility. To anesthetize the biopsy site, 1.5 ml
of bupivacaine hydrochloride (Astra Zenica, Luton, UK) was admin-
istered at a concentration of 5 mg/ml. A sterile single-use scalpel was
used to penetrate the skin and deep muscle fascia and a Bard
disposable core biopsy instrument (12 g  10 cm; CR Bard, Crawley,
UK) to retrieve a biopsy of muscle (	20–30 mg tissue).
Isolation and Characterization of Human Muscle-Derived Cells
Mixed populations of myoblasts and fibroblasts were harvested
from all 14 biopsy specimens by implementing a modified method of
that described previously (9) and characterized by immunofluorescent
staining (described in detail below) for the detection of specific
proteins expressed by myoblasts (desmin) and fibroblasts (TE7).
Myogenic proportion ranged from 25 to 65% (median 45%), and all
populations were included for analysis. Pilot data revealed that the
proportion of myoblasts to fibroblasts does not affect the ability of
either cell type to migrate or the ability of myoblasts to fuse (data not
shown). Thus, cell populations were not sorted into pure populations
due to the importance of the presence of fibroblasts in myogenesis (33,
41). Biopsy samples were transferred in precooled transfer media
(TM; containing Hams F-10, 2% hiFBS, 1% PS, and 1% amphoter-
icin-B) to the laboratory (maximum 30 min). To dissociate the tissue,
biopsy samples were carefully dissected with a sterile scalpel in petri
dishes to remove visible connective and adipose tissue while still in
Hams F-10 TM. Following three washes with ice-cold PBS (0.01 M
phosphate buffer, 0.0027 M KCl, and 0.137 M NaCl, pH 7.4, in
dH2O) and antibiotics (1% PS and 1% amphotericin-B), 5 ml of
trypsin-EDTA was added, and the samples were scissor minced to
fragments 1 mm3. The dissected sample was triturated on a mag-
netic stirring platform at 37°C. The trypsinization process was re-
peated two times in succession, and the supernatant derived following
each treatment was collected and pooled with horse serum at a
concentration of 10% of the total volume to inhibit further protease
activity. Once trypsin treatments were complete, pooled cell superna-
tant was centrifuged at 1,300 rpm for 5 min to produce a cell pellet.
The supernatant was discarded and the cell pellet resuspended in GM
and plated on a T25 cm2 culture flask for cell population expansion.
Following	10 days in culture, T25 cm2 culture flasks reached	80%
confluence and were passaged via trypsinization. Cells were counted
using Trypan Blue exclusion and frozen in GM with 10% dimethyl
sulfoxide (DMSO) as a cryopreservant or replated to expand the
population. All experiments were performed on cells between pas-
sages 3 and 5 to avoid issues of senescence (3).
Cell Culture
All cell culture experiments were performed under a Kojair Bio-
wizard Silverline class II hood (Kojair, Vippula, Finland). Cells were
incubated in a HERAcell 150i CO2 Incubator (Thermo Scientific,
Cheshire, UK). Cell populations were cultured on T75- (Nunc, Rosk-
ilde, Denmark) and T25-cm2 (Corning, Life Sciences) culture flasks,
and experiments were performed in sterile six-well plates (Nunc).
Culture flasks and six-well plates were coated with a 2 mg/l porcine
gelatin solution (	90–110 g, Bloom; Sigma-Aldrich, Dorset, UK) to
allow cell adhesion.
Cell Treatments
For the expansion of cell populations, cells were grown in GM,
which was changed every 48 h following two brief washes with 1
PBS. Once cell monolayers reached a confluent state, GM was
removed, monolayers were washed twice with PBS, and GM was
replaced with QM for 20 h, following which QM was exchanged for
Fig. 1. Schematic representation of experi-
mental procedures. *Peak torque and muscle
soreness measurement, which were per-
formed immediately prior to, immediately
after (post), and then at 24 h, 48 h, and 7
days following an eccentric exercise proto-
col consisting of 20 sets of 10 eccentric
contractions performed at 30°/s and sepa-
rated by 30-s rest intervals between sets.
Blood was collected presupplementation and
then again following the 6-wk supplementa-
tion period for measurement of total serum
25-hydroxyvitamin D [25(OH)D].
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QM 
 mitomycin C (10 g/ml) for 3 h to allow replication arrest, as
determined by pilot experimentation and by previous work (15). This
method was implemented to study migration in the absence of inter-
fering proliferation. Subsequent to 3 h of treatment with QM 

mitomycin C, cells were damaged by a vertical scrape with a 1-ml
pipette tip. The mitomycin C pretreatment media was aspirated, and
damaged cell monolayers were washed three times with 1 PBS to
remove cell debris and residual pretreatment media. Each six-well
culture plate was subjected to a low dose of exogenous 1,25(OH)2D3
(10 nmol in DM; Lo), a high dose (100 nmol in DM; Hi), or control
vehicle (20 l/ml 100% EtOH; Veh) in DM; n  2 wells per dose per
experiment (experiments performed on n  14). The doses of vitamin
D selected were based on previously published research (11, 22, 23,
50) and were used to determine whether potential responses in cell
migration, fusion, and hypertrophy were dose dependent. Immediately
following the addition of treatments, monolayers were placed in a
controlled live imaging microscopy environment (Leica DMB 6000
equipped with PeCon incubation system and gas control system) of
37°C with 5% CO2 and images, were captured every 30 min for 48 h
for the analysis of cell migration dynamics (migration distance,
velocity, and directionality; see below).
Wound-Healing Assay and Migration Analysis
TIF files captured over the 48-h filming period were exported from
Leica Application Suite and loaded as TIF image stacks in ImageJ
with a cell counter plug-in. Cells in the outer (segment 1) and inner
(segment 2) wound spaces were counted (see Fig. 2). TIF files were
also exported as TIF image stacks into ImageJ with a manual tracking
tool plug-in (IBIDI, Munich, Germany). The individual trajectory of
each cell was tracked in the x- and y-axes and derived raw coordinate
data exported in an ImageJ chemotaxis and migration tool plug-in
(IBIDI) for analysis. The chemotaxis tool analyzed raw data from the
manual tracking tool and provided quantitative data on the migration
of individual and grouped cell trajectories, including migration veloc-
ity (V; in m/min), accumulated migration distance (DAcc; in m),
Euclidean migration distance (DEuc; in m) and directionality (Dir; in
arbitrary units, with 0 being random migration and 1 being a straight
line).
Creatine Kinase Activity
At 0 and 48 h and 7 and 10 days following the mechanical scrape
insult, creatine kinase (CK) activity was analyzed as a marker of
muscle cell differentiation/fusion into myotubes, as described previ-
ously (2, 20, 44, 47). Cell monolayers were first lysed with 300
l/well of 50 M Tris-mes and 1% Triton-X 100, pH 7.8 (TMT). Ten
microliters of TMT cell lysate was loaded in duplicate wells on a
96-well UV plate and used for quantification of CK activity. The CK
reaction reagent and diluent (Catachem) were prepared as per the
manufacturer’s instructions and heated for 2 min at 37°C. When
reconstituted, the reagent contained the following active ingredients:
30 mmol/l PCr, 2 mmol/l ADP, 5 mmol/l AMP, 2 mmol/l NAD, 20
mmol/l N-acetyl-L-cystine, 3,000 U/l hexokinase, 2,000 U/l G-6-PDH,
10 mmol/l1 Mg2
, 20 mmol/l D-glucose, 10 mol/l di(adenosine 5=)
pentaphosphate, and 2 mmol/l EDTA. The reagent mixture was then
added to the samples and the change in absorbance monitored con-
tinuously over 10 min in a spectrophotometer (Thermo Multiskan
Spectrum plate reader) at a wavelength of 340 nm. Final concentra-
tions were relativized to total protein are reported as mU·mg1·ml1.
For the quantification of total protein, a bicinchoninc acid (BCA)
assay was also performed on lysed samples. BSA protein standards
were prepared at 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, and 0 mg/ml. The
BCA reaction materials were purchased as part of a Pierce BCA
protein assay kit (Rockford, IL) and prepared as per the manufactur-
er’s guidelines. Two hundred microliters of the working reagent was
added to all wells containing 10 l of sample using a multichannel
pipette (excluding the blank, which was TMT alone), and the plate
was incubated at 37°C for 60 min. Following background subtraction,
the absorbance was recorded at 30 and 60 min at 595 nM using a
Thermo Multiskan Spectrum plate reader. The standard curve was
generated by plotting the average blank-corrected 595-nM measure-
ment of each BSA standard against its preprogrammed known con-
centration in milligrams per milliliter. Sample concentrations were
calculated from the standard curve.
Morphology and Immunocytochemistry
To determine myotube formation at 7 and 10 days, damaged
monolayers were imaged at four sites per well in the wound site
immediately postdamage (0 h). These image coordinates were then
saved to allow monitoring of a consistent wound site to avoid
experimental bias. Images were captured at 7 and 10 days, exported as
TIFF image files, and analyzed in ImageJ. Morphology for assessment
of muscle cell fusion/differentiation was assessed by myotubes per
field of view and myotube hypertrophy via the assessment of myotube
diameter and myotube area. Myotubes were counted via ImageJ cell
counter plug-in, and only myotubes for which the entire length of the
tube was visible in the field of view were considered. Myotubes were
determined as cells containing three or more nuclei. Myotube area was
determined by manually drawing a line around the sarcolemma of
each myotube. By normalizing the pixel scale to the micron scale of
each image, a value expressed as m2 is obtained. To calculate
myotube diameter, three equidistant diameters along the length of the
myotube (left center, center, and right center) were measured and
averaged. A total of three images per well per treatment were ana-
lyzed, treatments were performed in duplicate, and experiments were
performed on 14 cell populations from 14 different individuals.
Therefore, 84 images per condition were assessed.
Experiments above were repeated for immunocytochemical stain-
ing to visualize nuclei for the accurate determination of myonuclear
fusion index and myonuclear domain size. Monolayers were fixed at
10 days postinsult via 5-min graded methanol incubations [25, 50, and
100% vol/vol methanol in 1 Tris-buffered saline (TBS)] and stored
wet in 1 TBS until they were required for staining. Monolayers were
permabilized and blocked for 2 h prior to staining with 5% goat serum
and 0.2% Triton X-100 in 1 TBS. Cells were incubated overnight at
5°C with 1° Desmin antibody (1:200). After overnight incubation, 1°
Fig. 2. Representative image of a scrape wound inflicted with a 1-ml pipette
tip. The wound area is 900 m in width and split into 3  300-m
segments. Magnification is 10.5, and scale bar is 100 m. The outmost
segments are referred to as segment 1 and the single inner segment is
referred to as segment 2.
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antibody was removed, and the cells were washed three times with 1
TBS. Secondary antibody TRITC antibody (1:200) was then applied
and left for 2 h at 5°C. Finally, following removal of 2° antibody and
three TBS washes, a nuclear counterstain (Sytox-Green; 1:5,000) was
applied, and monolayers were incubated for 1 h before a final three
TBS washes. Fluorescent images were then captured at 10 days
postdamage and nuclei counted via ImageJ cell counter plug-in. A
total of three images per well were analyzed per treatment, and
treatments were performed in duplicate (n  2/condition/sample).
This immunostaining procedure was also used in the characterization
of the cell populations described above in which cells were stained
with desmin (1:200) and TE7 (1:200) to determine the relative
proportion of myoblasts to fibroblasts.
Gene Expression: RNA Isolation, Primer Design, and RT-
Quantitative PCR
Total RNA was isolated at 0 h post mechanical damage via wound
infliction and then at 48 h and 7 and 10 days postdamage. Monolayers
were washed with 1 PBS (1 ml/well), and RNA was extracted using
300 l/well TRI Reagent (Sigma-Aldrich, Dorset, UK). RNA was
isolated via guanidium thyocyanate phenol cholorform extraction.
Concentration and purity were assessed via UV spectroscopy using a
Nanodrop spectrophotometer 3000 (Fisher Scientfic, Rosklide, Den-
mark). Only samples with a purity ratio between 1.9 and 2.2 were used
for the downstream application of RT-quantitative PCR (qPCR).
Purified RNA was diluted to 7.3 ng/ml in 9.5 l of DNase
RNase-free H2O (Sigma-Aldrich) to create a final reaction concentra-
tion of 70 ng. RNA was reverse transcribed and amplified with
specific primer sequences in a rotor-gene Q (Qiagen, Manchester,
UK) PCR machine using a one-step SYBR Green I RT-qPCR kit
(Qiagen). Briefly, double-stranded cDNA was first synthesized at
50°C for 10 min with the use of dTP oligonucleotides and reverse
transcriptase. cDNA was denatured to single-stranded DNA at 95°C
for 10 s, and combined primer annealing and extension were initiated
at 60°C for 30 s. Primers sequences were designed using National
Centre of Biotechnology Primer-BLAST software and RTprimerDB
(http://www.rtprimerdb.org/), and highly purified salt free primer for
each sequence was purchased from Sigma-Aldrich. Detailed primer
information can be found in Table 1. A relative method of mRNA
expression was used as described previously with a stable reference
gene (RPL13a; %coefficient of variation  1.8%) and a 0-h untreated
control sample (CT method; see Ref. 38). Melt curve analysis was
performed to confirm all PCR products demonstrated a clear single
peak (same) melt temperature showing that only one gene target had
been amplified and that primer-dimer issues were not present.
Additionally, amplified PCR products were electrophoretically sep-
arated to ensure correct end product length of amplified genes. Eight
microliters of Norgen FullRanger 100-bp DNA ladder and 8 l of
sample were loaded after preparation with a DNA loading dye
(Geneflow, Staffordshire, UK) into an agarose gel [2% agarose (Bio-
line Reagents, London, UK) in 1 Tris-acetate-EDTA buffer (Invit-
rogen, Life Technologies Paisley, UK)] prepared with Midori Green
nucleic acid stain (Nippon Genetics Europe, Düren, Germany) at a
dilution of 1:200. Samples were electrophoretically separated at 50 V
for 20 min, followed by 70 V for an additional 20 min. Following
electrophoretic separation, gels were placed on a UV transilluminator
for visualization and analysis.
Statistical Analysis
All statistical analyses were performed using SPSS Predictive
Analytics Software (version 20; IBM). For the comparison of two
group means a t-test was used, and where comparison of multiple
groups of means was required, an analysis of variance (ANOVA) was
used. Data sets were first checked for normal distribution, and
where data violated the assumption of normality, an appropriate
correction factor was used. If data violated the assumption of
sphericity, Greenhouse-Geiser or Huyn-Feldt correction factors
were used. Where significant main effect and interactions were
present, the Bonferroni post hoc pairwise comparisons test was
used to detect where significances lay between paired comparisons,
an analysis that includes correction for an ANOVA’s multiple
comparisons. Significance was assumed when  reached 0.05.
All data are presented as mean  SD.
RESULTS
Randomized Controlled Trial
At baseline, no significant differences were detected be-
tween experimental groups for total serum 25(OH)D (P 
0.05), with mean serum concentrations of 45 15 and 45 25
nmol/l for PLB and VITD, respectively. Following 6 wk of
supplementation with 4,000 IU/day vitamin D3, a significant
interaction effect was observed between treatment group and
time (P  0.005). Post hoc analysis revealed that the VITD
group showed a significant increase in total serum 25(OH)D at
week 6 compared with presupplementation (pre  45  25 vs.
post  115  31 nmol/l, P  0.005) and a significant
difference when compared with PLB (P  0.005). Conversely,
the PLB group demonstrated a significant decline in serum
25(OH)D at week 6 compared with presupplementation (pre 
45  25 vs. post  33  13 nmol/l, P  0.013; see Fig. 3E).
At both pre- and postsupplementation test points, VITD and
PLB demonstrated comparable, significant losses of peak
torque immediately postexercise at both 60 and 180°/s (all at
P  0.005), indicating that the eccentric exercise protocol
effectively caused skeletal muscle damage. At the presupple-
mentation time point, no interaction effect was detected be-
tween treatment group and maximal torque recovery over 7
days for either 60 (P 0.281) or 180°/s (P 0.310). However,
following supplementation, a significant interaction effect be-
tween recovery time point, test week (pre/postsupplementa-
Table 1. Gene primer sequences for human MDC samples and amplicon lengths
Gene Accession No. Primer Sequence Amplicon Length, bp Exon Junction
VDR NM_001017536 GACCTGTGGCAACCAAGACT (forward) 174 Reverse: 1,575/1,576
GGACGATCTGGGGAGACGA (reverse)
MYOG NM_002479.5 TCCCAGATGAAACCATGCCC (forward) 103 None
AGGCCCCTGCTACAGAAGTA (reverse)
MRF4 NM_002469.2 ACCCTTCCTGGCCTAATCCT (forward) 198 None
ACCCTTCCTGGCCTAATCCT (reverse)
RPL13A NM_012423 GGCTAAACAGGTACTGCTGGG (forward) 105 Reverse: 230/231
AGGAAAGCCAGGTACTTCAACTT (reverse)
MDC, muscle-derived cell; VDR, vitamin D receptor; MYOG, myogenin; MRF4, myogenic regulatory factor 4; RPL13A, ribosomal protein L13a. All primers
were used in the same PCR cycling conditions.
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tion), and treatment group at 60°/s (P  0.049) was detected.
Exploration of this interaction identified a significant improve-
ment in torque recovery in the supplemental VITD group
following supplementation at 48 h (14% improvement, P 
0.042) and 7 days post-eccentric exercise (13.7% improve-
ment, P  0.001) compared with presupplementation. Al-
though a slight improvement was observed for VITD postsupple-
mentation at 180°/s (48 h  5.6% improvement, 7 days  9.9%
improvement), this result failed to meet statistical significance
(Fig. 3). We then also plotted the change in peak torque
recovery at 7 days against the change in total serum 25(OH)D
as a linear regression to determine whether a relationship
existed (Fig. 3F). Interestingly, 88% of the variation in peak
torque recovery could be explained by the change in serum
25(OH)D (r2  0.88). Despite improvements in functional
capacity, there was no interaction between treatment group and
time for measurements of muscle soreness at either midquad-
riceps (P  0.71) or 5-cm patella (P  0.418), which was due
possibly to the highly subjective nature of the sensation of pain
and a disconnect between the mechanisms regulated by vitamin
D in the repair process and those that regulate the sensation of
pain.
In Vitro Model of Muscle Damage to Assess Repair and
Regeneration
Having ascertained a beneficial impact on strength recovery
after eccentric exercise induced damage in the presence of
vitamin D, we next wished to establish the influence of vitamin
D on muscle-derived cell migration, a key initial event in
muscle repair. Cell monolayers were treated with 10 and 100
nmol 1,25(OH)2D3 or vehicle (EtOH) following a damaging
mechanical scrape insult and live-imaged for 48 h. A signifi-
cant treatment group effect was detected for V, Dacc, DEuc and
Dir (P  0.005). Both Hi- and Lo-dose 1,25(OH)2D3 signif-
icantly enhanced cell migration V compared with vehicle, with
1.37- and 1.43-fold increases observed, respectively (P 
0.0005), vs. control. Hi dose was also superior to Lo dose
A                                                  B
C                                                  D
E                                                  F
Fig. 3. A–D: recovery profile of peak isoki-
netic torque at 60 and 180°/s following 6-wk
supplementation with 4,000 IU/day vitamin
D3 (A and B) or visually identical placebo (C
and D). #Significance to presupplementation
torque at the highlighted time point; sig-
nificance for the loss of both pre- and post-
supplementation torque immediately follow-
ing eccentric exercise (post ex) when com-
pared with preexercise (pre ex) values.
E: total serum 25(OH)D response to either
4,000 IU/day vitamin D3 or placebo. **Sig-
nificance to presupplementation and placebo;
*significance to baseline. F: linear regression
describing the relationship between total
serum 25(OH)D (nmol/l) between pre- and
postsupplementation and the peak torque
(Nm) recovery at 7 days postexercise be-
tween pre- and postsupplementation.
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(0.331  0.11 vs. 0.318  0.1 m/min, respectively, P 
0.033). A similar observation was made in DAcc, as Hi treat-
ment promoted greater migration (953  305 m) distances
than Lo (909  281 m, P  0.009) whereas both Hi and Lo
were superior to Veh (666  288 m, P  0.0005). However,
although both Lo and Hi treatment improved DEuc when
compared with Veh, there were no differences between the two
doses (P  0.193), which would imply a loss of directionality
in the Hi-dose treatment. Indeed, analysis revealed that Hi-
dose-treated skeletal muscle cells demonstrated a loss of di-
rectionality [0.498 0.21 arbitrary units (AU)] compared with
Lo-dose- (0.546  0.2 AU) and Veh-treated (0.547  0.23
AU) cells (P  0.005), whereas Lo and Veh showed no
differences. Taken together, both Lo and Hi resulted in more
cells at the inner wound space (Lo  20  9, Hi  21  8
cells) vs. Veh at 48 h (16  7 cells) as a consequence of
improved migration speed and distance. No significant differ-
ences were evident in wound size between conditions, indicat-
ing that this is unlikely to have affected results (Lo  949 
146 vs. Hi  927  103 vs. Veh  925  108 m, P 
0.810). Data are presented in Fig. 4.
Treatment of cultures with 10 or 100 nmol 1,25(OH)2D3
resulted in superior migration dynamics compared with vehicle
alone; however, the same dosing strategy led to differential
effects on myoblast fusion at 7 and 10 days following the
damaging event in the current investigation. Morphological
data analysis revealed that myoblast fusion was significantly
inhibited, as fewer myotubes were observed per field with 100
nmol 1,25(OH)2D3 vs. 10 nmol and vehicle at 7 days post-
damage (Hi  2  2 vs. Lo  6  4 vs. Veh  3  1
myotubes/field, P  0.0005). In contrast, Lo treatment led to
significant improvements in myotube number compared with
100 nmol and Veh at both 7 (as above) and 10 days (Lo 
10  3 vs. Hi  6  2 vs. Veh  6  2 myotubes/field, P 
0.005). This observation was also similar for myotube area
with Lo treatment, resulting in significantly greater myotube
area vs. Hi and Veh at 7 (Lo  4,984  2,776 vs. Hi 
4,603 1,697 vs. 4,227 1,768 m2, P 0.003) and 10 days
(Lo  5,488  2,853 vs. Hi  4,671  2,932 vs. Veh 
4,388  2,312 m2, P  0.0005). Myotube diameter was
significantly greater at 7 days in both Lo- and Hi-dose treat-
ments vs. Veh (Lo 14.13 4 vs. Hi 13.7 4.5 vs. Veh
12.12  3.8 m, P  0.005); however, this effect was lost at
10 days (Lo 13.6 4 vs. Hi 12.6 4.1 vs. Veh 12.1
3.7 m, P  0.256).
Findings from biochemical analyses and fluorescent imaging
were in agreement with morphological findings. Creatine ki-
nase (CK) activity data were analyzed via a mixed-design
ANOVA. Results show that CK activity was elevated above
Veh with Lo treatment and repressed with Hi compared with
both Lo and Veh at 7 days (Lo  302.5  173 vs. Hi  186.7
 132 vs. Veh  290  160.5 mU·mg1·ml1), although this
effect did not reach statistical significance. At 10 days, Lo
treatment cells demonstrated significantly higher CK activity
compared with both Hi and Veh (Lo  340.4  183 vs. Hi 
258.4  188 vs. Veh  229.4  139.5 mU·mg1·ml1, P 
0.017). Myonuclei and myonuclear domain size were analyzed
by one-way ANOVA. The CK observations correlated with a
significantly greater accretion of myonuclei in Lo-treated cells
vs. Hi and Veh at 10 days postdamage (Lo  5.9  2.3 vs. Hi
 3.5  1.4 vs. Veh  3.4  1.2 nuclei per myotube per field,
P 0.0005); however, myonuclear domain size was smaller at
10 days with Lo treatment (Lo  986.5  439.4 vs. Hi 
1,460  726.3 vs. Veh 1,257.3  584 m2, P  0.0005; see
Figs. 5
and 6).
To determine the impact of treatment on myogenic gene
expression, CT analyses were performed by comparing the
fold change in target gene expression against both a nontreated
0-h control and a stable reference gene (RPL13a). Results
demonstrated that on average Lo-treated cells upregulated
myogenic regulatory factor 4 (MRF4) expression to a greater
extent at both 7 and 10 days (3.2  2.7- and 3.7  1.5-fold)
than Hi- (0.5  0.3- and 0  0.2- fold) and Veh-treated cells
(2.4  2.8- and 2.8  2.4-fold). Similarly, Lo-treated cells
showed an increased myogenin expression at 10 days (84 
95-fold) compared with Hi (64  79-fold) and Veh (62- 
70-fold); however, these data failed to meet statistical signifi-
cance (P  0.05), which was likely due to very large variation
in basal expression of the MRFs. VDR expression showed no
discernible difference between groups at any time point; how-
ever, all significantly increased expression in a similar trend
with myogenin between 48 h and 7 days as a main effect for
time was detected (P  0.022). Interestingly, Hi-treated cells
also showed an impairment (albeit not a statistically significant
one) in the ability induce both MRFs at 7 days postinsult vs.
control and Lo-treated cells, which correlates with biochemical
observations demonstrating lower CK activity in Hi-treated
cells at 7 days (Fig. 7).
DISCUSSION
The aims of the current investigation were twofold. First, we
looked to identify the effect of increasing serum 25(OH)D
from a level of insufficiency on the functional recovery of
skeletal muscle following eccentric work. Second, we aimed to
establish cellular aspects of muscle regeneration and remodel-
ing that may be responsive to vitamin D, providing a novel
mechanistic underpinning for in vivo observations. It was
hypothesized that increasing total serum 25(OH)D with sup-
plemental vitamin D3 would lead to an improvement in peak
torque recovery following eccentric exercise. Furthermore, we
postulated that myogenic progenitor migration, fusion, and
myotube hypertrophy would be improved in the presence of
exogenous 1,25(OH)2D3.
The data presented provide novel insights that point toward
an important role for vitamin D in muscle recovery in vivo and
repair, regeneration, and hypertrophy in vitro. The main find-
ings from this work demonstrate that elevating serum 25(OH)D
from 	40 to 75 nmol/l with supplemental vitamin D3 (4,000
IU/day) results in improved functional recovery from eccentric
exercise at 48 h and 7 days postexercise vs. a placebo control
group, which showed no changes in recovery rate. In an
attempt to provide initial insights into the mechanisms respon-
sible, we also uncovered novel roles for vitamin D3 in muscle
progenitor migration, fusion, and myotube hypertrophy follow-
ing an artificial wound injury in vitro. Both the migration
velocity and distance traveled into the wound site were signif-
icantly enhanced with both 10 and 100 nmol 1,25(OH)2D3
treatments, implying that vitamin D3 may function to stimulate
cell migration in a positive manner when considered in the
context of muscle repair. Furthermore, the 10-nmol treatment
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also led to elevated CK activity above that of 100 nmol and
vehicle at all time points, reaching significance at 10 days
postinsult. In accord with these data, myotube number and size
were both significantly elevated in the 10-nmol treatment at 10
days vs. 100 nmol and vehicle, which was likely attributable to
an increased ability to accrete myonuclei, which was further
supported by a reduction in myonucelar domain that suggests
there were more nuclei in longer/larger myotubes with less
domain to serve per myotube. Interestingly, the 100-nmol dose
of vitamin D3 suppressed this effect, and fusion capability only
A
B
                                         C                                         D
E                                        F                                        G
Fig. 4. Muscle-derived cell (MDC) migration dynamics following a mechanical scrape injury in the presence of low-dose (Lo; 10 nmol) or high-dose (Hi; 100
nmol) 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] or vehicle solution (Veh; 100% EtOH). A: representative phase contrast microscope images captured at 48
h postwounding. Scale bar, 100 m; n  14. B: representative migration tracking plots produced via ImageJ chemotaxis tool. Trajectories are mapped in m.
C: average no. of cells migrated into segments 1 and 2 at 48 h postdamage. D: directionality (Dir; 0–1). E: migration velocity (V; m/min). F: Euclidean
migration distance (DEuc). G: accumulated migration distance (DAcc; m); *Significance to Veh; **significance to all other treatments.
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reached the level of the vehicle control by day 10. Together,
these data imply that enhanced cellular characteristics of the
muscle regeneration process may partly explain improved
functional recovery of skeletal muscle with higher serum
25(OH)D in vivo and may also point toward a positive role for
vitamin D in muscle remodeling given the increases in myo-
tube size and nuclear accretion.
The positive influence of 10 nmol of 1,25(OH)2D3
administration on cell migration is analogous to effects
observed in other cell types. For example, exogenous treat-
ment of vascular smooth muscle cells with 1,25(OH)2D3
induced migration following activation of phosphatidylino-
sitol 3-kinase (PI3K), with the observed effects being abol-
ished by the addition of the PI3K inhibitor LY-294002 (42).
Indeed, the importance of PI3K in myoblast migration has
been characterized previously (15), and stimulation of this
pathway by 1,25(OH)2D3 has been reported previously in
skeletal myoblasts (11), pointing toward stimulation of
PI3K activity as a potential mediator of improved muscle-
derived cell (MDC) migration dynamics observed in the
current trial. Activation of PI3Ks and their lipid product
PI(3,4,5)P3 leads to increases in GTP-bound Rac, which is
an important small GTPase along with Rho involved in the
control of downstream signaling that generates filamentous
actin branching and lamellipodia formation (40). Therefore,
it could be postulated based on available evidence that
vitamin D may function to stimulate MDC migration
through the activation of PI3K and increased downstream
activity of small Rho GTPases resultantly altering actin
cytoskeletal dynamics. Taken together, vitamin D possesses
the capability to improve the velocity of which skeletal
muscle progenitors can reach a site of damage to permit
repair and remodeling of the area. Future research should
aim to investigate this pathway in the context of vitamin D
A                                                    D
B
C
Fig. 5. Effect of Lo or Hi 1,25(OH)2D3 vs. Veh
on myotube morphology following 7 and 10 days
of mechanical scrape wounding in DM. A: aver-
age myotubes per field of view. B: average myo-
tube diameter (m). C and D: average myotube
area (m2; C) and representative phase contrast
microscope images (D) captured at 10 days in the
wound space of each condition. Scale bar, 100
m. *Significance to all other treatments at that
time point.
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and examine cytoskeletal dynamics. Furthermore, the rele-
vance of enhanced muscle cell migration in vivo should also
be investigated.
The finding that 1,25(OH)2D3 improved myoblast fusion
is perhaps not surprising since vitamin D is a closely related
hormone system with some of the characteristics of true
steroids as receptor ligands, such as testosterone. Indeed,
testosterone has repeatedly been demonstrated to enhance
myoblast differentiation in vitro (14, 46). In a similar
observation to the current study, these investigations also
detected significant increases in hyperplasia and hypertro-
phy in the presence of the steroid. Interestingly, reports
suggest that the significant myonuclear accretion observed
during overload-induced hypertrophy is not lost during a
3-mo period of severe disuse atrophy (10). Furthermore,
treatment of mice with testosterone propionate was demon-
strated to induce nuclear accretion and hypertrophy that,
following a period of testosterone withdrawal, led to atrophy
but a sustained elevated myonuclear number that enhanced
retraining-induced fiber hypertrophy (19).
Together, these data imply that steroid exposure stimulates
adaptive remodeling that primes the muscle for adaptation in
subsequent bouts of mechanical stimuli. Therefore, the finding
that vitamin D increased nuclear accretion, accounting for a
hypertrophic effect in vitro, is particularly interesting and
raises new questions as to whether the sterol may also function
similarly to testosterone treatment. Mechanisms accounting for
the hypertrophic response elicited by vitamin D are yet to be
established, although recent trials have provided evidence that
vitamin D treatment improves breast meat yield in male broiler
chickens through the mTOR pathway (52), a known major
regulator of mechanical overload-induced muscle growth (24).
A                                                          D
B
C
Fig. 6. Effect of Lo or Hi 1,25(OH)2D3 vs.
Veh on biochemical aspects of myotube for-
mation and immuncytochemical analysis of
nuclear accretion. A: average creatine kinase
(CK) activity (mU·mg1·ml1) at 48 h and 7
and 10 days following damage. *Significance
to other conditions at a time point. B and C:
average nuclei per myotube per field of view
(B) and myonuclear domain size (C) at 10
days following damage. *Significance to all
other conditions. D: representative fluores-
cent microscopy images taken at 10 days
following damage. Scale bar, 100 m.
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Furthermore, proteasomal enzyme activities, expression of the
E2 ubiquitin-conjugating enzyme, and ubiquitin conjugates are
increased in vitamin D-deficient vs. replete rats (8). Recently,
an in vivo report also demonstrated that type IIa skeletal
muscle fibers are increased in number and that myostatin
mRNA is downregulated with vitamin D supplementation in
human males during a resistance training program (1), provid-
ing preliminary support for the adaptive remodeling observa-
tions made in vitro in the current work.
Our in vitro findings also show similarities and disparities
with other models of myogenesis in the context of vitamin D.
As a contrasting example, increases in myotube diameter and
MHC type II have been detected following 100-nmol treatment
of C2C12 myoblasts, which is indicative of a positive myogenic
effect (22). In another trial, following serum depletion of 100
nmol of 1,25(OH)2D3 was shown to suppress myotube for-
mation, which was analogous to the current study. However,
the treatment led to a 1.8-fold increase in cross-sectional size
of individual myotubes associated with slightly decreased
myostatin expression (23). The inconsistency between the
current work and previous findings may lie in fundamental
differences in the metabolism of vitamin D in humans and
rodents. Although both species express the same components
of the vitamin D endocrine system, rodents typically obtain all
vitamin D from dietary sources, which are minimal amounts
(29). As a result, many rodent species show negligible quan-
tities of the major circulating vitamin D metabolites despite
showing no typical symptoms of vitamin D deficiency, such as
hypercalcemia, hypercalciuria, and elevated PTH concentra-
tion. Moreover, these species show discrimination of the D2
metabolite over the D3 form, which is the reverse in humans
(28). An additional difference is that the current work imple-
mented a coculture model in which fibroblasts were also
present with myoblasts. Indeed, fibroblasts are known to pos-
itively regulate alignment and fusion of skeletal myoblasts
(41), and therefore, it may be argued that our data present a
more physiologically relevant insight into the regulation of
myogenesis by vitamin D.
It is important to postulate whether our in vitro observations
could be attributable for the improved resolution of MVC
torque seen in vivo. Indeed, the activation and increased
activity of satellite cells is evident within 24 h following
eccentric work in humans (12, 16, 30). Moreover, increases in
embryonic MHC content have been observed from 2 days,
peaking at 7 days following eccentric work indicative of the
incorporation of committed myoblasts into myofibers, which
also shows a strong trend with functional recovery of peak
torque that starts to recover at 24 h and peaks at 7 days (37). To
confirm such a link, analysis of biopsy specimens in parallel to
torque recovery is necessary.
It must be considered that myoblast migration, fusion, and
hypertrophy are only some of the cellular mechanisms that
underlie the resolution of damaged skeletal muscle as a result
of eccentric work. Satellite cell activation and expansion, an
immune response, reinnervation, recapillarization, and extra-
cellular matrix remodeling are also important events that result
in full function recovery of damage muscle tissue. It is well
characterized that both innate and acquired immunity are
potently regulated by vitamin D (39), nerve recovery and
remyelination are improved in the presence of vitamin D (13),
proangiogenic growth factors are upregulated in regenerating
A
B
C
Fig. 7. Time course effects of 1,25(OH)2D3 on CT mRNA expression
levels of myogenic regulatory factor 4 (MRF4; A), myogenin (MYOG; B), and
vitamin D receptor (VDR; C). Fold changes were calculated against a stable
reference gene (RPL13a) and an internal calibrator (0-h sample).
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vitamin D-treated myoblasts in vitro (21), and increased secre-
tion of extracellular matrix components have been reported in
vitamin D-deficient rats using a rotator cuff repair model (4).
Taken together, it is possible that vitamin D had the profound
effect observed in vivo as a result of interaction with a number
of events that orchestrate muscle repair and remodeling. Thus
work is now warranted to investigate these processes collec-
tively in the presence and absence of vitamin D to fully
characterize how regenerating human skeletal muscle is af-
fected by the availability of the sterol.
Although the present study provides a promising concept of
a relationship between vitamin D and muscle repair and re-
modeling, there are some limitations to be considered. First,
the sample size of the RCT is indeed small, and larger scale
studies will be needed to firmly establish the findings made in
the current trial. This will also allow for subgroup analysis and
perhaps the detection of subtle functional changes that could
not be detected in the supplemental vitamin D group for peak
torque recovery at 180°/s. Moreover, the chosen model of
exercise is highly specific, with movements performed at two
fixed velocities. Although this is ideal for experimental repeat-
ability, such regimens are not common in everyday life and
training. Thus, future experimental designs should expand on
the current work and employ “real world” protocols resulting
in muscle damage, such as downhill running or resistance
training, employing negative repetitions of common strength
training exercises. Serial biopsies alongside functional mea-
surements of muscle recovery following eccentric work will
also help to solidify the link between the in vivo and in vitro
findings described in the current work. Finally, relating to our
in vitro model, we utilized commonly implemented supra-
physiological doses of 1,25(OH)2D3; however, we now
beleive that estimation of the concentration of 1,25(OH)2D3
that skeletal muscle is exposed to is the next step toward
further optimizing studies of vitamin D and skeletal muscle in
vitro.
To conclude, this study is the first to identify a novel role for
vitamin D in human skeletal muscle regeneration. In vivo
observations made here demonstrate that low serum 25(OH)D
is easily elevated with supplemental vitamin D3 and may
benefit skeletal muscle recovery, regeneration, and hypertro-
phy. A challenge to the field is to now expand these prelimi-
nary findings by employing larger sample sizes and aiming to
characterize all aspects of muscle regeneration that are respon-
sive to vitamin D. Furthermore, new questions are raised as to
whether “at risk” populations susceptible to muscle damage
and/or vitamin D inadequacy, such as the elderly, who are
known to exhibit low serum 25(OH)D, experience aggravated
declines in regenerative capacity and remodeling when serum
25(OH)D is low.
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